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AA: arachidonic acid 
AC: Adenylyl cyclase 
ACE: Angiotensin converting enzyme 
ACEI: ACE inhibitors 
AngI: Angiotensin I 
AngII: Angiotensin II 
AP-1: Activator protein-1 
ApoE: Apolipoprotein E 
ARB: AngII receptor blockers 
AREs: Adenylate- and uridylate-rich elements 
AT1R: Angiotensin II type 1 receptor 
AT2R: Angiotensin II type 2 receptor 
BH4: Tetrahydrobiopterin 
Ca2+: Calcium 
CaM: Calmodulin 
cAMP: Cyclic adenine 3’, 5’- monophosphate 
Cdk: Cyclin-dependent kinase 
Chk2: Checkpoint kinase 2 
COX-1: Cyclooxygenase 1 
COX-2: Cyclooxygenase 2 
CREB: cyclic AMP-responsive binding protein 
cPGES: Cytosolic prostaglandin E2 synthase 
DAG: Diacylglycerol 
DP: PGD2 receptor 
ECM: Extracellular matrix 
EGFR: Epidermal growth factor receptor 
Egr-1: Early growth response protein 1 
ELAV1: Embryonic Lethal, Abnormal Vision, Drosophila-like 1 
Elf-3: E74-like factor 3 
Elk-1: ETS domain-containing protein 1 
eNOS: Endothelial nitric oxide synthase 
EP: PGE2 receptor 
ER: Endoplasmic reticulum 
ERK1/2: Extracellular signal-regulated kinase 1/2  
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ETS-1: Erythroblast transformation-specific 1 
FP: PGF2α receptor 
GPCRs: G protein-coupled receptors 
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IL-1R: IL-1 receptor 
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IP: PGI2 receptor 
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p38 MAPK: p38 Mitogen activated protein kinase 
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pCaMKII: Ca2+/CaM-dependent protein kinase II 
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PGE2: Prostaglandin E2 
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Prostanoids and reactive oxygen species (ROS) are implicated in the 
vascular structural and functional alterations associated with cardiovascular 
diseases. Angiotensin II (AngII) induces vascular inflammation through 
increased production of cytokines such as interleukin 1β (IL-1β). Both AngII and 
IL-1β stimulate the expression of pro-inflammatory enzymes including 
cyclooxygenase 2 (COX-2) and NADPH oxidases increasing the production of 
prostanoids and ROS. Among the NADPH oxidase isoforms, NOX-1 and NOX-4 
appear to be particularly important in vascular smooth muscle cells (VSMC). 
Human antigen R (HuR), a RNA binding protein, is able to stabilize different 
mRNAs favoring the pro-inflammatory status in pathological conditions. 
However, to our knowledge, no studies have evaluated whether post-
transcriptional mechanisms mediated by HuR participate in the control of COX-
2 or NOX expression in VSMC. 
The aim of this PhD Thesis was to investigate transcriptional and post-
transcriptional mechanisms implicated in the regulation of COX-2, NOX-1 and 
NOX-4 expression in VSMC stimulated with AngII and IL-1β. In addition, the 
role of this regulation in vascular remodeling was evaluated. In line with this 
general aim, the PhD Thesis was divided into two specific aims that provided 
the following results and conclusions: 
1. HuR is involved in the stabilization of COX-2 mRNA in cancer cells and 
AngII is able to increase COX-2 mRNA stability in vascular cells. In the 
first part of the PhD Thesis, we investigated the contribution of HuR upon 
COX-2 expression induced by AngII and IL-1β and its consequences on 
VSMC migration and vascular remodeling. The main findings were: 1) In 
VSMC, AngII potentiated COX-2 and tenascin-C (TN-C) expressions and 
cell migration induced by IL-1β. 2) The effect of AngII on IL-1β-induced 
COX-2 expression was accompanied by increased COX-2 3’UTR 
reporter activity and mRNA stability occurring through cytoplasmic HuR 
translocation and COX-2 mRNA binding. These effects were blocked by 
ERK1/2 and HuR inhibitors. 3) VSMC migration induced by AngII+IL-1β 
was reduced by blockade of COX-2, TXAS, ERK1/2, HuR, TP and EP 
receptors and was stimulated by PGE2 and TXA2. 4) COX-2, mPGES-1, 
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TXAS and HuR expressions were increased in the aorta from AngII-
infused mice and in carotid-ligated arteries. 5) TN-C expression and 
vascular remodeling induced by AngII infusion were abolished by a COX-
2 inhibitor and by mPGES-1 deletion. These results demonstrate that the 
synergistic induction of COX-2 by AngII and IL-1β in VSMC involves HuR 
through an ERK1/2-dependent mechanism. Moreover, we demonstrate 
that the HuR/COX-2 axis participates in cell migration and vascular 
damage. 
 
2. HuR-dependent post-transcriptional mechanisms are implicated in gene 
expression in inflammation; however, its involvement regulating NOX 
expression has not been studied yet. In the second part of the PhD 
Thesis, we explored transcriptional and post-transcriptional mechanisms 
involved in the effects of AngII and IL-1β on NOX-1 and NOX-4 
expressions in VSMC and their implications in cell migration. The main 
findings were: 1) IL-1β increased NOX-1 expression, NADPH oxidase 
activity and ROS production, effects potentiated by AngII. Conversely, IL-
1β decreased NOX-4 expression and H2O2 production that were 
unaffected by AngII. 2) AngII+IL-1β interfered with the decay of NOX-1 
mRNA and promoted HuR binding to NOX-1 mRNA. Moreover, HuR 
blockade reduced AngII+IL-1β-induced NOX-1 mRNA stability and 
levels. 3) NOX-1 and HuR blockade reduced the AngII+IL-1β-induced 
NADPH oxidase activity and ROS production. 4) The decreased NOX-4 
expression induced by IL-1β was blocked by a protein synthesis inhibitor 
and was accompanied by a decrease in 200 bp proximal promoter 
activity. 5) AngII and/or IL-1β increased VSMC migration that were 
prevented by NOX-1 and HuR blockade and were augmented by NOX-4 
overexpression. Thus, HuR-mediated NOX-1 mRNA stabilization is 
partially responsible for AngII+IL-1β-dependent NOX-1 expression and 
ROS production in VSMC whereas transcriptional mechanisms are 
involved in decreased NOX-4 expression induced by IL-1β. Regulation of 
NOX-1/4 contributes to VSMC migration, important process in 
inflammatory conditions. 
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In summary, in this PhD Thesis we present evidences that the combination 
of AngII and IL-1β, two inflammatory stimuli important for cardiovascular 
diseases, synergistically induce the expression of two major pro-inflammatory 
proteins COX-2 and NOX-1 that in turn participate in VSMC migration and 
vascular remodeling. We also demonstrate for the first time that the RNA 
binding protein HuR is key to increase the mRNA stability of both genes, thus 
participating in cell migration induced by inflammatory stimuli. We believe that 
HuR/COX-2/NOX-1 pathways might be novel pharmacological targets to 
prevent or regress vascular remodeling associated to cardiovascular diseases. 
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Los prostanoides y las especies reactivas de oxígeno están implicadas en 
las alteraciones vasculares estructurales y funcionales asociadas a 
enfermedades cardiovasculares. Angiotensina II (AngII) induce inflamación 
vascular a través de un aumento en la producción de citoquinas como 
interleuquina 1β (IL-1β). AngII e IL-1β estimulan la expresión de enzimas pro-
inflamatorias como ciclooxigenasa 2 (COX-2) y NADPH oxidasas, aumentando 
así la producción de prostanoides y especies reactivas de oxígeno. Entre las 
isoformas de NADPH oxidasa, NOX-1 y NOX-4 parecen ser particularmente 
importantes en células musculares lisas vasculares (CMLV). El antígeno 
humano R (HuR), una proteína de unión a RNA, es capaz de estabilizar 
diferentes mRNAs favoreciendo el estado pro-inflamatorio en situaciones 
patológicas. Sin embargo, hasta donde conocemos, ningún estudio ha 
evaluado si mecanismos post-transcripcionales mediados por HuR participan 
en el control de la expresión de COX-2 o NOX en CMLV. 
El objetivo de esta Tesis Doctoral ha sido investigar los mecanismos 
transcripcionales y post-transcripcionales implicados en la regulación de la 
expresión de COX-2, NOX-1 y NOX-4 en CMLV estimuladas con AngII e IL-1β. 
Adicionalmente, se evaluó el papel de esta regulación en el remodelado 
vascular. De acuerdo con este objetivo general, la Tesis Doctoral se dividió en 
dos objetivos específicos que dieron lugar a los siguientes resultados y 
conclusiones: 
1. HuR está implicada en la estabilización del mRNA de COX-2 en células 
cancerosas y AngII es capaz de estabilizar el mRNA de COX-2 en 
células vasculares. En la primera parte de esta Tesis Doctoral, 
analizamos la contribución de HuR en la expresión de COX-2 inducida 
por AngII e IL-1β y sus consecuencias sobre la migración de CMLV y el 
remodelado vascular. Los resultados principales fueron: 1) En CMLV, 
AngII potenció la expresión de COX-2 y tenascina-C (TN-C) y la 
migración celular inducida por IL-1β. 2) El efecto de AngII sobre la 
expresión de COX-2 inducida por IL-1β se acompañó de un incremento 
en la actividad reportera de la 3’UTR y de la estabilidad del mRNA de 
COX-2 a través de la translocación citoplásmica de HuR y de su unión al 
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mRNA de COX-2. Estos efectos se bloquearon por inhibidores de 
ERK1/2 y HuR. 3) La migración de CMLV inducida por AngII+IL-1β se 
redujo por el bloqueo de COX-2, TXAS, ERK1/2, HuR y los receptores 
TP y EP y se estimuló por PGE2 and TXA2. 4) La expresión de COX-2, 
mPGES-1, TXAS y HuR estaba aumentada en aorta de ratones 
infundidos con AngII y arterias carótidas ligadas. 5) La expresión de TN-
C y el remodelado vascular inducido por la infusión de AngII se abolieron 
por un inhibidor de COX-2 y por la deleción de mPGES-1. Estos 
resultados demuestran que la inducción sinérgica de COX-2 producida 
por AngII+IL-1β en CMLV implica a HuR a través de un mecanismo 
dependiente de ERK1/2. Nuestros resultados demuestran además, que 
el eje HuR/COX-2 participa en la migración celular y en el daño vascular. 
 
2. Mecanismos post-transcripcionales dependientes de HuR están 
implicados en la expresión génica en inflamación; sin embargo, su 
participación regulando la expresión de NOX no se ha estudiado todavía. 
En la segunda parte de esta Tesis Doctoral, exploramos los mecanismos 
transcripcionales y post-transcripcionales implicados en los efectos de 
AngII e IL-1β en la expresión de NOX-1 y NOX-4 en CMLV y sus 
implicaciones en la migración celular. Los resultados principales fueron: 
1) IL-1β incrementó la expresion de NOX-1, la actividad NADPH oxidasa 
y la producción de especies reactivas de oxígeno. En cambio, IL-1β 
disminuyó la expression de NOX-4 y la producción de H2O2, las cuales 
no se afectaron por AngII. 2) AngII+IL-1β interfirió con la disminución del 
mRNA de NOX-1 y promovió la unión de HuR al mRNA de NOX-1. 
Además, el bloqueo de HuR redujo la estabilidad y los niveles del mRNA 
de NOX-1 inducidos por AngII+IL-1β. 3) El bloqueo de NOX-1 y de HuR 
redujo la actividad NADPH oxidasa y la producción de especies 
reactivas de oxígeno inducidas por AngII+IL-1β. 4) La disminución de la 
expresión de NOX-4 inducida por IL-1β se bloqueó por un inhibidor de la 
síntesis proteica y se acompañó de una disminución en la actividad del 
promotor proximal de 200 bp. 5) AngII y/o IL-1β aumentaron la migración 
de VSMC que se previno por el bloqueo de NOX-1 y HuR y se aumentó 
por la sobreexpresión de NOX-4. Así, la estabilización del mRNA de 
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NOX-1 mediada por HuR es parcialmente responsable de la expresión 
de NOX-1 y de la producción de especies reactivas de oxígeno en 
respuesta a AngII+IL-1β en CMLV. Asimismo,  mecanismos 
transcripcionales están implicados en la disminución de la  expresión de 
NOX-4 inducida por IL-1β. La regulación de NOX-1/4 contribuye a la 
migración de CMLV, proceso importante en condiciones inflamatorias. 
En resumen, en esta Tesis Doctoral presentamos evidencias de que la 
combinación de AngII e IL-1β, dos estímulos inflamatorios importantes en 
enfermedades cardiovasculares, inducen sinérgicamente la expresión de dos 
de las principales proteínas pro-inflamatorias COX-2 y NOX-1, las cuales a su 
vez, participan en la migración de CMLV y en el remodelado vascular. También 
demostramos por primera vez, que la proteína de unión a RNA HuR es clave 
en el aumento de la estabilidad del mRNA de ambos genes. Creemos que las 
rutas HuR/COX-2/NOX-1 serían unas nuevas dianas farmacológicas para 
prevenir o revertir el remodelado vascular asociado a enfermedades 
cardiovasculares. 
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Inflammation is the response of the body to injury or infection in order to 
restore the physiological function and the structure of a tissue. Inflammation has 
been implicated in the pathogenesis of different diseases such as arthritis, 
cancer and stroke. In addition, in the last years, it has become evident that 
inflammation is a key player in cardiovascular disease (Ricciotti and FitzGerald, 
2011). During inflammation, the synthesis of different cytokines modulates the 
expression of adhesion molecules, chemokines and different pro-inflammatory 
enzymes such as cyclooxygenase-2 (COX-2) or NADPH oxidases (Sprague 
and Khalil, 2009). These cytokines can act in conjunction with humoral or 
hormonal mediators important for cardiovascular diseases, such as angiotensin 
II (AngII), to enhance inflammatory damage (Tummala et al., 1999). COX-2-
derived prostanoids or NADPH oxidase-derived reactive oxygen species (ROS) 
contribute to vascular diseases not only by their direct effects in the vessels but 
also by enhancing the inflammatory response (Harrison et al., 2011; Ricciotti 
and FitzGerald, 2011).  
In this Introduction, we will review different aspects of the inflammatory 
process in the context of cardiovascular disease. AngII and interleukin-1β (IL-
1β) will be introduced as pro-inflammatory molecules and COX-2 and NADPH 
oxidase will be presented as key pro-inflammatory enzymes. Finally, the role of 
COX-2-derived prostanoids and NADPH oxidase-derived ROS in vascular 
damage will be discussed. 
1. VASCULAR REMODELING 
1.1. ARTERY STRUCTURE 
Arteries are divided in three concentrical layers from the inside out: intima, 
media and adventitia which are organized in cellular components and 
extracellular matrix (ECM) (Figure 1). 
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Figure 1. Artery structure. Wall section showing all layers of an artery wall. From 
Giannoukos and Min, 2013.  
• Intima: it is in the inner part of the vessel and comprises a monolayer of 
endothelial cells which lay in the basement membrane. This layer of 
endothelial cells is separated from the media layer by the internal elastic 
lamina which is a fenestrated lamina of elastic fibers. The intima layer is 
important in the control of vascular function and structure because 
endothelial cells are an important source of vasoconstrictor/vasodilator 
and proliferative/antiproliferative factors.  
• Media: this layer includes circumferentially arranged vascular smooth 
muscle cells (VSMC) and variable amounts of ECM. The tunica media is 
separated from the tunica adventitia by a second layer of elastic fibers, 
the external elastic lamina. In response to different vasoactive factors 
and hemodynamic forces, VSMC can release a variety of substances 
which affect vascular tone and structure. 
• Adventitia: it is mainly formed by fibroblasts but it also contains 
macrophages and mast cells and different components of the ECM. In 
the last years, it has become evident that the adventitia is not only a 
mechanical support for the vessel but also an active player of the 
regulation of vascular tone and structure by releasing different factors.  
The ECM is a gel-like form which functions as a scaffolding structure for the 
vascular cells and determines the elasticity and mechanical properties of the 
vessels. Their components are synthetized by different cell types of the vascular 
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wall. The two main ECM proteins are collagen and elastin; while elastin confers 
the elastic properties to vessels, collagen provides the strength (Wagenseil et 
al., 2009). There are other ECM proteins which are in less quantity such as 
glycoproteins, proteoglycans and integrins that are involved in several cellular 
processes (Wagenseil et al., 2009). Among them, tenascin-C (TN-C) which is 
an inducible glycoprotein expressed predominantly in embryonic, remodeled 
adult tissues and in pathological conditions, is particularly interesting. 
Competitive binding of TN-C to ECM proteins and their counterpart cell-surface 
receptors mediates its ability to modulate cell-ECM interactions. The capacity of 
TN-C to interact with a wide range of ECM molecules may also enable it to 
contribute to the structural organization of the ECM. In addition, TN-C can 
promote migration and proliferation by direct activation of cell-surface growth 
factor receptors and cellular differentiation by up-regulating androgen receptor 
and endothelin type 1 receptor expression (Milwood and Orend, 2009). Thus, 
TN-C relevance relies on its implication in vascular cell differentiation, 
proliferation and migration (Milwood and Orend, 2009). 
1.2. TYPES OF VASCULAR REMODELING  
It is now accepted that the vascular wall can change its structure in order to 
maintain the appropriate lumen size to permit normal blood flow. This process is 
termed vascular remodeling (Gibbons and Dzau, 1994). This ability of the 
arteries to adapt its structure in response to physiological and pathological 
conditions is essential in situations such as pregnancy or aging but also in 
many arterial diseases. Thus, the inability of the vessels to remodel 
appropriately is considered a form of “vascular failure” that can lead to 
pathologic states such as hypertension, atherosclerosis or restenosis (Renna et 
al., 2013). This process is active and involves structural changes including cell 
growth, death, migration and the synthesis or degradation of the ECM (Renna 
et al., 2013). 
Vascular remodeling can occur with or without growth of the vessel wall (i.e. 
hypertrophic, eutrophic or hypotrophic) and with smaller, greater or similar 
lumen size (inward, outward or compensated) (Figure 2) (Mulvany et al., 1999; 
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Varik et al., 2012). Vascular remodeling differs depending on the vessel type or 
the cardiovascular disease model:  
• Hypertrophic remodeling is characterized by an increase in the media 
thickness, media/lumen and vascular cross sectional area associated 
with a more evident contribution of cell growth (Mulvany, 1999) (Figure 
2). This type of remodeling is characteristic of large arteries in ageing or 
in pathologies like hypertension (Schiffrin, 2012) or restenosis which is 
associated with proliferation and migration of different cells types (Renna 
et al., 2013). 
• Hypotrophic remodeling is associated with a decrease in the amount of 
material (i.e. diminished cross sectional area) around the vessel wall 
(Mulvany, 1999) (Figure 2). This type of remodeling may be related to 
apoptosis processes and/or to rearrangement of the material in the 
vessel wall (Intengan and Schiffrin, 2001). Hypotrophic remodeling has 
been shown in renal afferent arterioles from spontaneously hypertensive 
rats (SHR) (Nørrelund et al., 1994) and in mesenteric resistance arteries 
from ouabain-induced hypertensive animals (Briones et al., 2006). 
• Eutrophic remodeling is characterized by a decrease in the outer and 
lumen diameters and an increase in the media thickness and the 
media/lumen ratio with no change in the wall cross sectional area 
(Mulvany, 1999) (Figure 2). It has been suggested that this type of 
remodeling is due to rearrangement of the same amount of wall material 
around a smaller vessel lumen (Heagerty et al., 1993; Rizzoni and 
Agabiti-Rosei, 2012). The mechanisms leading to this type of remodeling 
are poorly known but some authors suggest that a combination of inward 
growth and peripheral apoptosis or prolonged vasoconstriction of 
vascular cells embedded in an expanded ECM can lead to eutrophic 
remodeling (Bakker et al., 2002; Schiffrin, 2012). 
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Figure 2. Types of vascular remodeling. Classification refers to changes on the 
lumen diameter (inward: upper row or outward: lower row) and vessel cross-sectional 
area (hypotrophic: left column; eutrophic: center column and hypertrophic: right 
column). Adapted from van Varik et al., 2012. 
Vascular remodeling can be induced by dynamic interactions between local 
growth factors, vasoactive substances and hemodynamic stimuli being all 
important mediators in the vascular adaptation process. The number of 
mediators involved in altered vascular structure is continuously growing; 
however, to date it is well admitted that AngII, cytokines, prostanoids and ROS 
have a key role (Renna et al., 2013). The participation of these mediators in 
vascular remodeling will be discussed in subsequent sections of this 
Introduction. 
1.3. CELL PROLIFERATION AND MIGRATION 
As mentioned, wall thickening is one of the main features of many 
cardiovascular diseases. Depending on the specific vascular bed and 
pathology, the cellular and non-cellular events leading to altered vascular 
structure might be different. Thus, hypertension causes arterial media 
thickening with or without cell growth, and ECM deposition in both humans and 
animal experimental models; however, atherosclerosis and reaction to injury 
Wall Cross Sectional Area
Lu
m
en
 D
ia
m
et
er
Introduction 
48 Andrea Aguado Martínez PhD Thesis 
such as endothelial denudation or restenosis cause intimal thickening 
associated to variable degrees of alterations in the surrounding ECM. Although 
it is known that during vascular remodeling VSMC proliferation and migration 
are processes that take place, their regulation is not exactly known (Moore, 
2013) (Figure 3). 
 
Figure 3. Pathophysiological mechanisms of arterial remodeling. Cross sectional 
schematic view of the arterial wall in (A) normal situation or (B) during arterial 
remodeling. Thickening of the wall is the main feature of arterial remodeling. Elastic 
fiber degradation, extracellular matrix calcification, collagen deposition and vascular 
smooth muscle cell migration and phenotype switching lead to adaptation of the 
vascular wall. Matrix metalloproteinase (MMP). Taken from van Varik et al. 2012. 
Intimal thickening can occur in blood vessels as a consequence of 
physiological process as occurs in ageing or in response to increased 
intraluminal pressure, or in response to injury as observed in balloon dilatation, 
stent implantation or atherosclerosis processes (Newby, 2006). Because of its 
importance, many in vivo models of VSMC growth and proliferation such as the 
carotid ligation mouse model have been developed. In this model, an intima 
lesion characterized by enrichment of VSMC occurs in response to luminal 
narrowing leading to the formation of the neointima (Newby, 2006; Moore, 
2013). Neointima is part of the reparative response to injury and its formation 
involves an important inflammatory component with infiltration of inflammatory 
cells and release of cytokines and chemokines, thrombosis, increase in the 
number of VSMC and matrix production leading to a reduction in vessel 
diameter (Kumar and Lindner, 1997; Kawasaki et al., 2001; Moore, 2013). The 
increased number of VSMC is mainly originated by migration from the 
underlying media and proliferation, although there are other processes involved 
A B
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such as transdifferentiation of endothelial cells or differentiation from circulating 
precursors (Newby, 2006; Renna et al., 2013) (Figure 3). 
The involvement of cell proliferation and/or migration in hypertensive 
vascular remodeling mainly depends of the vascular bed and the experimental 
model studied. Thus, coronary but not mesenteric vessels from SHR show 
increased VSMC number (Roque et al., 2013). In addition, administration of 
AngII, the main effector peptide of the renin-angiotensin-aldosterone system 
(RAAS) lead to a progressive increase in blood pressure and media thickening 
through migration, proliferation and hypertrophy of the VSMC, being this effect 
mediated through the AngII type 1 receptor (AT1R) (Xu and Touyz, 2006; 
Valente et al., 2012; Ozasa et al., 2013; Renna et al., 2013) (Figure 4). 
Importantly, in the last years it has become evident that vascular infiltration of 
immune inflammatory cells and pro-inflammatory mediators such as ROS are 
key contributors to the vascular remodeling observed in this pathology (Bush et 
al., 2000; De Ciuceis et al., 2005; Harrison, 2014).   
Cell proliferation and migration begin with stimulation of cell surface 
receptors that transduce the external signal to a series of coordinated 
responses inside the cell. Diverse signal transduction systems such as nuclear 
factor kappa B (NF-kB), the activator protein 1 (AP-1), the mitogen activated 
protein kinases (MAPKs) or the phosphatidylinositol-3-kinase (PI3K)/Akt 
pathways have been proposed to translate the stimulus within VSMC (Rudijanto 
et al., 2007). However, despite of the growing information regarding the 
mechanisms controlling VSMC migration and proliferation in response to stimuli 
such as AngII (Figure 4), their regulation in response to other stimuli is less 
known.  
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Figure 4. AngII induces proliferation, migration and/or hypertrophy of VSMC. 
Arrows indicate the main biological end points preceding cell proliferation, migration 
and hypertrophy in response to AngII. Adapted from Chiou et al., 2011. 
2. INFLAMMATION 
Growing evidences suggest that an imbalance between pro- and anti-
inflammatory mediators is a common pathophysiological mechanism in different 
cardiovascular diseases (Kofler et al., 2005; Vicenová et al., 2009). 
Inflammation often begins with endothelial activation through several signal 
transduction mechanisms, leading to the expression of adhesion molecules 
which attracts different immune cells (Libby, 2006). These immune cells, as well 
as the resident cells participate as donors and recipients of cytokine signals, 
amplifying the inflammatory activity (Kofler et al., 2005; Libby, 2006). It is now 
accepted that classical mediators of vascular damage such as different 
components of the RAAS including AngII and aldosterone induce pro-
PKA
AT1
AngII
MAPKs
(ERK1/2, JNK, 
p38 MAPK)Akt
ROS
NF-κB AP-1
Inmediate early genes
Hypertrophy
Fetal-type genes
Proliferation
Migration
Introduction 
Andrea Aguado Martínez PhD Thesis  51 
inflammatory actions in different cell types of the vascular wall (Sprague and 
Khalil, 2009; Brown, 2013). This inflammatory environment has deleterious 
consequences in different functions of the vasculature including 
contraction/dilation, stiffness and vascular structure (Chen et al., 2013a; 2014). 
In this section, we will focus on different molecules with potential pro-
inflammatory properties at vascular level and on two pro-inflammatory proteins, 
COX-2 and NADPH oxidase. We will also highlight findings linking these 
mediators and vascular remodeling. 
2.1. INFLAMMATORY MEDIATORS OF VASCULAR DAMAGE 
2.1.1. Cytokines 
Cytokines are a broad category of small soluble proteins including 
chemokines, interferons, ILs, lymphokines tumor necrosis factors (TNFs) and 
transforming growth factors (TGFs) which are important in cell signaling and are 
produced not only by immune cells like macrophages and B and T lymphocytes, 
but also by endothelial cells, VSMC or fibroblasts. Both anti- and pro-
inflammatory cytokines have been described. Anti-inflammatory cytokines 
include TGF-β, IL-4, IL-10 or IL-13 and the main pro-inflammatory cytokines are 
TNF-α, IL-1 or IL-6. As mentioned, the balance between anti- and pro-
inflammatory cytokines is shifted to pro-inflammatory cytokines in 
cardiovascular disease (Kofler et al., 2005; Vicenová et al., 2009) (Figure 5).  
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Figure 5. Anti- and pro-inflammatory cytokines. Implication of cytokines in 
inflammation. Granulocyte macrophage colony-stimulating factor (GM-CSF); IL-18BP 
(IL-18-binding protein); sIL-1R1 (Soluble IL-1R I); sTNF-R (Soluble TNF receptor). 
Taken from Arend, 2001.  
IL-1 family is a key player in autoimmune disorders and has been recently 
demonstrated to be involved in the development of several cardiovascular 
diseases (Vicenová et al., 2009). This family is composed by eleven members 
where IL-1α and IL-1β are the best known. IL-1β is synthesized as a precursor 
and is produced after stress or cell injury by macrophages and other immune or 
non-immune cells. The secretion of IL-1β needs two steps, the induction of its 
synthesis and a proteolytic cleavage. The main targets of IL-1β are cells of the 
immune system such as monocytes or lymphocytes, but these cytokines can 
also act on other cells such as fibroblasts, endothelial cells or VSMC to induce 
inflammatory responses (Vicenová et al., 2009). The major receptor that 
mediates the effects of IL-1β is the type I IL-1 receptor (IL-1RI) which needs IL-
1 receptor accessory protein (IL-1RAcP) as a co-receptor for signal 
transduction. After activation, IL-1RI interacts through its Toll/interleukin-1 
receptor (TIR) domains with the TIR domain of the signaling adaptor myeloid 
differentiation factor 88 (MyD88), which transduces the signal to a family of IL-
1R-associated kinases (IRAKs). Phosphorylation of IRAK by other IRAK family 
members induces cascades of signaling through TNF receptor-associated 
factor 6 (TRAF6) that will facilitate the association of TGF-β-activated protein 
kinase 1 (TAK1) with TRAF6. The activation of both IKK and MAPKs by TRAF6 
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appears to involve the TAK1 and MAPK kinase kinase (MAPKKK) respectively. 
On the other hand, PI3K activation can occur through TRAF6 and receptor 
interacting protein (RIP). The stimulation of these signaling pathways lead to 
activation of different transcription factors such as NF-κB, AP-1 which are 
involved in the synthesis of pro-inflammatory genes including COX-2 or NADPH 
oxidase-1 (NOX-1) (O’Neill and Greene, 1998; Sizemore et al., 1999; Martín et 
al., 2003; Vicenová et al., 2009; Weber et al., 2010) (Figure 6). 
 
Figure 6. Schematic illustration of IL-1 receptor signaling. In response to activation 
by IL-1, IL-1RI interacts with different proteins leading to the activation of NF-κB, 
MAPKs and PI3K/Akt leading to the synthesis of pro-inflammatory cytokines and 
enzymes. Inhibitor of nuclear factor kappa-B (IκB); Inhibitor of nuclear factor kappa-B 
kinase (IKK); MAPK kinase kinase (MAP3K); Mitogen-activated protein kinase kinase 
(MEK, MKK); Receptor interacting protein (RIP); Toll/interleukin-1 receptor (TIR) 
domain. Modified from McCulloch et al., 2006. 
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MAPKs are one of the most important signaling pathways involved in cell 
responses and are activated by IL-1β. MAPKs include different cascades being 
extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase 
(JNK) and p38 MAPK the best known. Each cascade is initiated by the 
serine/threonine phosphorylation of a MAPKKK, which phosphorylates 
tyrosine/threonine residues of MAPK kinases (MAPKK), and subsequently leads 
to phosphorylation and activation of MAPKs. The activated MAPKs then 
activate other protein kinases, nuclear proteins and transcription factors, 
leading to various cellular responses. Thus, while ERK1/2 is more related to cell 
proliferation, JNK and p38 MAPK are more involved in different processes such 
as cell cycle arrest, inflammation and apoptosis (Pearson et al., 2001) (Figure 
7). 
 
Figure 7. The three arms of the mitogen-activated protein kinase (MAPK) 
signaling pathway: ERK1/2, JNK and p38 MAPK. Each arm is initiated by the 
phosphorylation of a MAPK kinase kinase (MAPKKK), which phosphorylates a MAPK 
kinase (MAPKK) and subsequently leads to phosphorylation and activation of a MAPK 
involved in different cellular responses. Apoptosis signal-regulating kinase (ASK); 
MAPK kinase kinase (MEKK); MAPK kinase (MEK, MKK); Mixed-lineage protein kinase 
3 (MLK); V-mos Moloney murine sarcoma viral oncogene homolog (MOS); P21 protein 
(Cdc42/Rac)-activated kinase 1 (PAK); Rapidly accelerated fibrosarcoma (RAF); TGF-
β-activated kinase 1 (TAK). Adapted from Steeg, 2003. 
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PI3K is another signaling pathway activated by IL-1β which is involved in 
different cellular processes. The PI3Ks are members of a unique and conserved 
family of intracellular lipid kinases that phosphorylate phosphatidylinositol and 
phosphoinositides. There are three classes (I–III) implicated in many functions 
such as cell metabolism, survival and polarity. The activation of a receptor 
protein tyrosine kinase (RPTK) results in autophosphorylation of tyrosine 
residues. Phosphatidylinositol-3 kinase (PI3K) consisting of an adaptor subunit 
p85 and a catalytic subunit p110 is translocated to the cell membrane and binds 
to phosphotyrosine residues of the RPTK. This results in activation of PI3K 
leading to production of phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 
recruits Akt with the pleckstrin homology (PH) domain to the cell membrane, 
promoting T308 and S473 residue phosphorylation by protein serine/threonine 
kinase 3’-phosphoinositide-dependent kinases 1 and 2 (PDK1 and PDK2) 
necessary for maximal Akt activation. Activated Akt translocates to the nucleus 
and mediates the inhibition of Bcl-2-associated death promoter (Bad) and 
activation of mammalian target of rapamycin (mTOR), among others, which are 
involved in apoptosis and cell survival respectively, thus promoting cell survival, 
growth and proliferation. Phosphatase and tensin homologue deleted from 
chromosome 10 (PTEN) is a PIP3 phosphatase and negatively regulates the 
PI3K/Akt pathway (Engelman et al., 2006) (Figure 8). 
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Figure 8. Schematic representation of the PI3K/AKT signaling pathway. Activation 
of a receptor protein tyrosine kinase (RPTK) results in PI3K translocation to the cell 
membrane and activation leading to Akt activation and translocation to the nucleus 
regulating different proteins. Bcl-2-associated death promoter (Bad); Mammalian target 
of rapamycin (mTOR); Protein serine/threonine kinase 3’-phosphoinositide-dependent 
kinases (PDK); phosphatase and tensin homologue deleted from chromosome 10 
(PTEN); Phosphatidylinositol phosphate (PIP). Taken from Meier et al., 2005. 
Role of cytokines in inflammation and vascular remodeling  
The importance of cytokines on vascular diseases relies on the fact that 
they are increased systemically or locally in different cardiovascular diseases. 
Thus, serum samples from untreated hypertensive patients (Dalekos et al., 
1997) and human coronary arteries from patients suffering coronary 
atherosclerosis or cardiomyopathy (Galea et al., 1996) show elevated levels of 
IL-1β. More importantly, in some cardiovascular diseases, IL-1β levels 
correlates with disease severity (Galea et al., 1996).  
The two main mechanisms responsible for IL-1β-induced pro-inflammatory 
actions are recruitment of immune cell infiltration and synthesis of pro-
inflammatory enzymes. The role of IL-1β inducing vascular pro-inflammatory 
proteins such as COX-2 and NADPH oxidase will be reviewed in subsequent 
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sections of this Introduction. Regarding immune cell infiltration, it has been 
described that deletion of the natural inhibitor of IL-1, IL-1R antagonist (IL-1Ra), 
further impaired vascular damage induced by apolipoprotein E (ApoE) deletion 
leading to a severe form of aortic inflammation with massive infiltration of 
macrophages in the adventitia (Merhi-Soussi et al., 2005). In addition, in the 
absence of IL-1β, the severity of atherosclerosis in ApoE-/- mice decreases 
possibly through the decreased expressions of vascular cell adhesion molecule 
1 (VCAM-1) and monocyte chemotactic protein (MCP-1) in the aorta (Kirii et al., 
2003). The inflammatory reaction occurring in the vascular wall has deleterious 
functional and structural consequences. Specifically, IL-1β is directly involved in 
vascular remodeling as demonstrated by the fact that overexpression of IL-1Ra 
can inhibit the development of atherosclerotic lesions in ApoE−/− mice (Merhi-
Soussi et al., 2005). In the carotid ligation mouse model, IL-1R−/− mice show 
attenuated neointimal hyperplasia (Rectenwald et al., 2000). Accordingly, in 
vitro experiments show that IL-1β induces VSMC proliferation and migration 
(Kim et al., 2010; Wang et al., 2011a). Altogether, these results indicate that IL-
1 plays a critical role in the pathogenesis of cardiovascular disease and in 
vascular remodeling.  
2.1.2. Angiotensin II 
AngII is the main hormone peptide of the RAAS. RAAS is activated when 
blood pressure is low. First step is the renin secretion to blood mediated by 
juxtaglomerular cells. Plasma renin converts angiotensinogen released by the 
liver to AngI. Then, AngI is transformed to AngII by the angiotensin-converting 
enzyme (ACE). AngII causes constriction of blood vessels leading to a blood 
pressure increase and augments aldosterone secretion from the adrenal cortex. 
Aldosterone is a hormone that increases sodium and water reabsorption in the 
tubules of the kidneys thus increasing blood volume and therefore blood 
pressure (Mehta and Griendling, 2007) (Figure 9). 
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Figure 9. Renin-Angiotensin-Aldosterone system. Steps of the secretion of the 
renin and its conversion in AngII leading to an increase in the blood pressure. Taken 
from http://antranik.org/wp-content/uploads/2012/05/renin-angiotensin-aldosterone-
reflex-system.jpg?783ed6. 
AngII effects are mediated by different receptors, being the two major AngII 
receptors AT1 (AT1R) and AT2 (AT2R). AT1R and AT2R are G protein-coupled 
receptors (GPCRs); however, they only share 30% of homology in the amino 
acid sequence (Rüster and Wolf, 2006). AT1R is highly expressed in 
cardiovascular cells, such as VSMC and it is coupled to Gαq/11, as well as Gαi, 
Gα12/13. Apart from its effects on vascular contraction and aldosterone secretion, 
AT1R signaling lead to pro-inflammatory, proliferative and anti-apoptotic 
processes which explain at least in part, its effects in cardiovascular diseases. 
Signaling of AT1R activates mitogenic signaling pathways including MAPKs or 
PI3K, either directly or indirectly for example, through GPCR-mediated 
transactivation of the epidermal growth factor receptor (EGFR), or through other 
mechanisms including Cell division control protein 42 homolog (CDC42)/JNK or 
p38 MAPK signaling. This leads to the downstream activation of transcription 
factors, including NF-κB which is responsible for the generation of growth 
factors, cytokines, ECM and anti-apoptotic proteins (Figure 10). On the other 
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hand, AngII can promote apoptosis through AT2R by mechanisms linked to the 
inhibition of ERK1/2 signaling and the activation of cell death receptors (Nouet 
and Nahmias, 2000; George et al., 2010) (Figure 10).  
 
Figure 10. AngII signaling and implications in cell survival. AT1R signaling 
activates MAPKs or PI3K, activating transcription factors including NF-κB. In contrast 
AT2R signaling has been linked to the activation of cell death receptors, and thus, 
apoptosis. B-cell lymphoma (BCL); Bcl2 interacting protein (BID); Cell division control 
protein 42 homolog (CDC42); Inhibitor of nuclear factor kappa-B (IκB); Inhibitor of 
nuclear factor kappa-B kinase (IKK); Mitogen-activated protein kinase kinase (MEK); 
Matrix metalloproteinase (MMP); Protein kinase B (PKB); Rapidly accelerated 
fibrosarcoma (Raf); Transcription factor (TF). Taken from George et al., 2010. 
Role of angiotensin II in inflammation and vascular remodeling  
It is well accepted that chronically elevated levels of AngII play a key role in 
hypertension, atherosclerosis and restenosis (Mehta and Griendling, 2007). 
AngII is able to generate an inflammatory environment associated to the up-
regulation of adhesion molecules and production of chemokines which lead to 
monocytes/macrophages recruitment to the vascular wall (Intengan and 
Introduction 
60 Andrea Aguado Martínez PhD Thesis 
Schiffrin, 2001). This inflammatory response is observed in vivo in the AngII 
infusion model where increased expression of adhesion molecules such as 
endothelial-selectin (E-selectin), ICAM-1 and VCAM-1 is observed (Das, 2005; 
Xu et al., 2011). In this model, pro-inflammatory cytokines including TNF-α, IL-6 
and MCP-1 expressions are increased as well as macrophage infiltration in the 
arterial wall (Bush et al., 2000; Liu et al., 2003; Das, 2005; Xu et al., 2011). In 
addition, AngII stimulates the expression of key pro-inflammatory enzymes such 
as COX-2 and NADPH oxidase at vascular level (Virdis et al., 2011; Hernanz et 
al., 2014). This aspect will be reviewed in subsequent sections of this 
Introduction.  
AngII influences the architecture and integrity of the vascular wall by 
modulating cell growth and regulating ECM composition (Schiffrin, 2002; Virdis 
et al., 2013). Thus, either in vitro or in vivo, AngII induces VSMC growth, 
migration or hypertrophy, and induces changes in different ECM proteins 
(Briones et al., 2010; Mugabe et al., 2010; Lacolley et al., 2012). Proof of the 
key role of RAAS in the vascular alterations in hypertension is the fact that 
chronic administration of ACE inhibitors (ACEI) or AngII receptor blockers 
(ARBs), lowers blood pressure and improve vascular remodeling in several 
hypertensive animal models including the SHR model, which is classically 
associated with hyperactivation of the vascular RAAS (Intengan et al., 1999; 
Schiffrin, 2012; Briones et al., 2014). More importantly, hypertensive patients 
treated with ACEI, ARBs or with calcium (Ca2+) channel blockers but not with 
the β-blocker, atenolol, exhibited significant regression of vascular remodeling 
of large and small arteries independently of hemodynamic changes (Schiffrin et 
al., 2000; Schiffrin and Touyz, 2004; Briet and Schiffrin, 2013; Briones et al., 
2014). Interestingly, AngII signaling through AT1R is significantly enhanced in 
cultured VSMC from resistance arteries of hypertensive rats or patients (Touyz 
and Schiffrin, 2001; Touyz et al., 2002) which might contribute to the deleterious 
effects of AngII at vascular level in pathological conditions.  
2.2. PRO-INFLAMMATORY PROTEINS 
In this section we will discuss different aspects regarding two of the main 
pro-inflammatory proteins and their respective mediators: COX-2 and 
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prostanoids, and NADPH oxidase and ROS. Major efforts will be put on 
highlighting specific aspects of their regulation and their role in vascular 
remodeling.   
2.2.1. Cyclooxygenase-2 
Biosynthesis of prostanoids begins with the formation of PGG2/PGH2 
through the action of COXs on arachidonic acid released by phospholipases 
from the membrane phosphoglycerides. Different prostaglandin synthases 
(PGS) metabolize immediately the PGH2 into specific prostanoids (Figure 11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Prostanoid synthesis. COX-1 and COX-2 enzymes catalyze the 
biosynthesis of PGH2, which is subsequently converted into five prostanoids: the 
prostaglandins, PGE2, PGD2, PGF2α, PGI2 and thromboxane A2. These prostanoids 
bind to their own receptors: EP1-4, DP1-2, FP2, IP and TP, respectively which belong 
to the GPCRs. Taken from Rahnama’i et al., 2012. 
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COXs have two different active sites with different activities. The 
cyclooxygenase site transforms arachidonic acid into the hydroperoxy 
endoperoxide prostaglandin G2 (PGG2). The other site contains a heme group 
with a peroxidase activity which catalyzes the reduction of PGG2 into PGH2 
(Davidge, 2001; Warner and Mitchell, 2004). Three different COX isoforms have 
been described: COX-1, COX-2 and COX-3, where COX-3 is a splice variant of 
COX-1, thus, COX-3 is sometimes named as COX-1b or COX-1v (Warner and 
Mitchell, 2004). In most tissues COX-1 is constitutively expressed under 
physiological conditions. In fact, COX-1 promoter contains GC rich elements 
present in housekeeping genes (Tanabe and Tohnai, 2002). However, COX-1 
induction mediated by shear stress (Doroudi et al., 2000), IL-1β (Kirtikara et al., 
1998) or vascular endothelial growth factor (VEGF; Bryant et al., 1998) has also 
been described. 
COX-2 is an inducible isoenzyme and the dominant source of PGs in 
inflammation. COX-2 gene is approximately 8.3 kb long with 10 exons and its 
sequence contains 604 amino acids. It shares a 61% of homology with the 
human COX-1 protein and its gene structure is similar between different species 
(Tanabe and Tohnai, 2002). While COX-1 is localized in the endoplasmic 
reticulum (ER), COX-2 acts predominantly at ER and nuclear envelope (Morita 
et al., 1995). In vascular cells, COX-2 expression is induced by a wide variety of 
stimuli such as AngII, IL-1β, ROS, lipopolysaccharide (LPS) or TNF-α (Tanabe 
and Tohnai, 2002; Kuwano et al., 2004; Galán et al., 2011; Martínez-Revelles et 
al., 2013) and it is up-regulated in vascular inflammatory diseases such as 
aortic aneurysms (King et al., 2006) and balloon-injured arteries (Yang et al., 
2004a; Wang et al., 2005). In addition, arteries from hypertensive animal 
models including AngII infusion and SHR, and hypertensive patients show 
increased vascular COX-2 expression and (Hernanz et al., 2004; Adeagbo et 
al., 2005; Álvarez et al., 2005; Virdis et al., 2009; Virdis et al., 2013; Martínez-
Revelles et al., 2013) and this is normalized by treatment with ARBs (Álvarez et 
al., 2007). 
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2.2.1.1. Cyclooxygenase-2 regulation 
COX-2 is an immediate-early response gene and its expression can be 
regulated by transcriptional and post-transcriptional mechanisms such as 
mRNA stability (Tanabe and Tohnai, 2002).  
COX-2 promoter contains a TATA box and several binding sites for 
transcription factors that are responsible for its expression. Thus, NF-κB, AP-1, 
cyclic AMP-responsive binding protein (CREB) (Chun and Surh, 2004), CCAAT-
enhancer-binding proteins (C/EBP) (Iñiguez et al, 2000), V-ets avian 
erythroblastosis virus E26 oncogene homolog 1 (ETS-1) (Grall et al., 2005), T-
cell factor/lymphoid enhancer factor-response element (TCF/LEF) (Nuñez et al., 
2011) or human epidermal growth factor receptor 2 (ErbB-2) (Wang et al., 2004) 
bind to the COX-2 promoter in response to different stimuli (Figure 12). 
 
Figure 12. Structure of human COX-2 gene promoter. Binding sites for different 
transcription factors involved in COX-2 expression. CCAAT-enhancer-binding proteins 
(C/EBP); V-ets avian erythroblastosis virus E26 oncogene homolog 1 (ETS-1); T-cell 
factor/lymphoid enhancer factor-response element (TCF/LEF); human epidermal 
growth factor receptor 2 (ErbB-2). 
Depending on the stimulus and the cell type, several signaling pathways 
can participate in COX-2 expression (Tsatsanis et al., 2006). For example, 
ERK1/2 and p38 MAPK (Ohnaka et al., 2000) pathways are involved in AngII-
induced COX-2 expression in VSMC. Similarly, in vascular fibroblasts, IL-1β 
and the combination of AngII plus IL-1β stimulate COX-2 expression through 
ERK1/2 and p38 MAPK (Galán et al., 2011). 
Besides transcriptional regulation, COX-2 expression seems to be under 
the control of the post-transcriptional 3’untranslated region (3’UTR) regulation 
carried out by miRNA and RNA-binding proteins (RBPs) (Cok et al., 2003; 
Sureban et al., 2007; Young et al., 2012). A key feature present in the COX-2 
3’UTR is the adenylate and uridylate (AU)-rich element or ARE (Dixon et al., 
2000). These elements control mRNA turnover, translation and/or transport by 
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interacting with RBPs. Most of the RBPs have been associated with mRNA 
degradation [e.g., AU-rich element RNA-binding protein 1 (AUF1), RNA 
polymerase III transcription initiation factor 90 KDa subunit (BRF1) or 
tristetraprolin (TTP)] and/or suppression of translation (e.g., T-cell intracellular 
antigen 1 (TIA-1), TIA-1 related protein (TIAR)] (Meisner and Filipowicz, 2011). 
In contrast, the RBPs which belong to Hu family induce ARE-mediated mRNA 
stabilization. One of these members is the HuR protein (Hu antigen R; ELAVL1) 
that can stabilize different mRNAs, including COX-2 mRNA (Dixon et al., 2001; 
Young et al., 2012) (Figure 13).  
 
Figure 13. Schematic COX-2 transcript. COX-2 mRNA with its coding sequence (in 
orange) and its 3’UTR (in black). In the COX-2 3’UTR, the AREs are shown (triangles 
in the low panel). Different post-transcriptional regulators of COX-2 expression are also 
shown (in the upper panel).  
HuR is primarily nuclear localized and contributes to the mRNA stabilization 
of many genes when exported to the cytoplasm (Figure 14). In the nucleus, 
HuR associates with the pre-mRNA introns and affects splicing and likely other 
nuclear processing events. HuR is exported to the cytoplasm with the mature 
mRNA where HuR stabilizes mRNAs, may help with transient mRNA storage 
(as in stress granules) and modulates the recruitment of the mRNA with the 
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translation machinery (polysomes) (Figure 14). Thus, HuR is implicated in a 
wide variety of physiological and pathological processes such as cell growth, 
differentiation and inﬂammation (Guhaniyogi and Brewer, 2001; Misquitta et al., 
2001; Eberhardt et al., 2007; Meisner and Filipowicz, 2011). 
 
Figure 14. HuR shuttling and functions. In the nucleus, HuR associates with the pre-
mRNA introns (thin black lines) HuR is exported to the cytoplasm with the mature 
mRNA where HuR stabilizes mRNAs, may help with transient mRNA storage and 
modulates the recruitment of the mRNA with the translation machinery. Taken from 
Srikantan and Gorospe, 2011. 
HuR contains three RNA-recognition motif (RRM) domains. The third RRM 
domain (RRM3) is separated of the other two domains by a hinge region where 
the HuR-nucleo-cytoplasmic shuttling sequence (HNS) is located. RRM3 
contributes to interactions with the poly-A tail of target mRNA and the two N-
terminal tandem RRM domains can selectively bind AREs (Figure 15). 
Furthermore, RRM1 and RRM2 are involved in HuR dimerization, necessary for 
its binding to the AREs of mRNA targets. Some low-molecular-weight drugs, 
such as MS-444, bind to this region inhibiting the dimerization of the protein and 
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thus, HuR binding to the mRNAs (Meisner and Filipowicz, 2007; Meisner and 
Filipowicz, 2011). 
 
Figure 15. Schematic overview of HuR domain organization. HuR domain 
organization and functional annotation. Modified from Meisner and Filipowicz, 2011. 
HuR can undergo different post-translational modifications which are involved in 
HuR subcellular location (Meisner and Filipowicz, 2011). These modifications 
include phosphorylation and methylation of serine and threonine residues and 
they are responsible for HuR nuclear-cytoplasmic shuttling (Meisner and 
Filipowicz, 2011) and activity (Yang et al., 2004b). Many proteins have been 
described to phosphorylate HuR such as checkpoint kinase 2 (Chk2) and 
protein kinase C (PKC) α or δ (Meisner and Filipowicz, 2011) (Figure 16). 
Moreover, in different pathologies including cancer, HuR cytoplasmic 
translocation is accompanied by an increase in HuR expression (Wang et al., 
2013), thus HuR activity can be regulated by its expression or by post-
translational modifications. 
 
Figure 16. Positions of post-translational modifications of HuR. Phosphorylation of 
S88, S100 and T118 is catalyzed by Chk2. S158 and S221 are phosphorylated by 
PKCα and S221 and S318 by PKCδ. S202 is a substrate for Cdk1. Arg217 is 
methylated by CARM-1. Finally, caspase 3 can cleave HuR at S226. Coactivator-
associated arginine methyltransferase 1 (CARM-1). Modified from Meisner and 
Filipowicz, 2011. 
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We have previously mentioned that HuR is involved in a number of 
physiological and pathological processes such as cell growth, differentiation 
and inﬂammation. However, data available in vascular cells are scarce. In 
human umbilical vein endothelial cells, HuR regulates stress-sensitive genes 
and HuR siRNA inhibits inflammatory responses including up-regulation of 
ICAM-1 and VCAM-1, NF-κB phosphorylation and adhesion of monocytes 
(Rhee et al., 2010). Moreover, in VSMC, HuR is translocated to the cytoplasm 
after PDGF stimulation and stabilizes different genes implicated in cell 
proliferation such as cyclin-dependent kinase 2 (Cdk2) (Pullmann et al., 2005). 
Although the ability of HuR to stabilize COX-2 mRNA in different cell types such 
as intestinal cancer cells, myeloid leukocytes or human mesangial cells has 
been described (Dixon et al., 2001; Dixon et al., 2006; Doller et al., 2008; 
Young et al., 2012), the ability of HuR to influence COX-2 expression in 
vascular cells is not yet explored. More importantly, whether HuR-dependent 
COX-2 stabilization has a role in VSMC migration is still unknown. 
2.2.1.2. Prostanoids 
As mentioned, prostanoids are metabolites of the arachidonic acid and play 
an important role in inflammation, platelet aggregation, 
vasoconstriction/relaxation and vascular remodeling. After the initial synthesis of 
the short-lived but biologically active PGH2, the production of the different 
prostanoids (the prostaglandins PGE2, PGD2, PGF2α, PGI2 and TXA2) depends 
on the activity of specific synthases; thus, prostanoid production depends on 
both COX and PGS activities (Figure 17). Prostanoids have different vascular 
effects depending on the activation of specific receptors. Prostanoids receptors 
are GPCRs and their nomenclature is based on the ligand bound by the 
receptor (Bos et al., 2004). Each prostaglandin receptor is coupled with a Gα 
subunit triggering G-protein-dependent cAMP and/or Ca2+ signaling that 
modulate a variety of transcription factors and intracellular signaling pathways 
involved in multiple cellular processes (Figure 17). We will now focus on the 
specific signaling pathways activated by each prostanoid receptor. 
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Figure 17. Signal transduction mechanisms of prostaglandin receptors. 
Prostaglandin receptors with their Gα-coupled subunit trigger G-protein-dependent 
cAMP and/or Ca2+ signaling. Taken from Mohan et al., 2012. 
Prostaglandin E2 (PGE2) 
PGE2 is a pro-inﬂammatory molecule produced by PGE2 synthases (PGES) 
that has an important role in the control of vascular tone (Audoly et al., 2001) 
and structure (Wang et al., 2011b). There are three PGES isoenzymes, two 
microsomal isoforms (mPGES-1 and mPGES-2) and one cytosolic isoform 
(cPGES) all of them coded by different genes. In most tissues, cPGES is 
constitutively expressed and coupling between cPGES and COX-1 has been 
proposed suggesting that cPGES might be involved in cellular homeostasis 
(Helliwell et al., 2004). On the other hand, mPGES-1 is induced by inflammatory 
stimuli and is the principal source of PGE2 (Cheng et al., 2006). Different stimuli 
are able to increase mPGES-1 expression and/or activity at vascular level. For 
example, in cultured VSMC and fibroblasts, LPS or IL-1β, but not AngII, induce 
mPGES-1 expression (Wang et al., 2006; Galán et al., 2011). On the other 
hand, Wang et al. (2008) showed that in the AngII-infused mouse model, 
mPGES-1 vascular expression is increased. Because of the synchronized 
induction in the presence of some pro-inflammatory stimuli, a coupling between 
COX-2 and mPGES-1 has been suggested (Murakami et al., 2000; Stichtenoth 
et al., 2001); however, this issue is still under debate (de Oliveira et al., 2008).  
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mPGES-1 promoter contains GC boxes which are binding sites for Sp1 and 
early growth response factor-1 (Egr-1) which are responsible for basal 
transcription of the mPGES-1 (Ekstrom et al., 2003).  In addition, the promoter 
sequence was found to contain consensus binding sites for C/EBPα and -β, AP-
1 and the CACCC-binding factor, as well as putative progesterone or 
glucocorticoid response elements. Moreover, NF-κB (Catley et al., 2003) and 
the interaction between Egr-1 and C/EBPβ, a novel distal enhancer element, 
are necessary for regulating IL-1β-induced mPGES-1 expression (Walters et 
al., 2012).  
As mentioned, PGE2 has diverse functions depending on the activation of 
specific receptors. PGE2 receptors include EP1, EP2, EP3, and EP4, which are 
encoded by distinct genes. The four EP receptors bind PGE2 with higher affinity 
than others prostanoids. Moreover, each EP receptor is coupled to different G-
proteins (Bos et al., 2004) (Figure 18). The EP1 receptor seems to activate Gq 
and leads to a PLC-dependent Ca2+ release and PKC activity, activating 
MAPKs. The EP2 and EP4 receptors activate Gs, which leads to the activation of 
cAMP/PKA/CREB pathway and at the same time impair MAPK activation. The 
EP3 receptor activation leads to activation of Gi, and then PLC/PKC and MAPKs 
due also to a decrease in cAMP levels (Bos et al., 2004) (Figure 18). It has also 
been suggested that the activation of EP3 can activate Gs and Gq (Liebmann et 
al., 2000; Yamaoka et al., 2009).  
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Figure 18. Activation of distinct EPs by PGE2 induces several signaling 
pathways. PGE2 binds to distinct EPs to induce either activation of the MAPK pathway 
via Gq or Gi, or to induce up-regulation of cAMP and subsequently activation of PKA 
which leads to decreased MAPK activation. Mitogen-activated protein kinase kinase 
(MEK); Rapidly accelerated fibrosarcoma (Raf); Modified from Bos et al., 2004. 
EP1 and EP3 have been proposed to have an important role in 
vasoconstriction whereas EP2 and EP4 are important for vasorelaxation (Bos et 
al., 2004). Moreover, these receptors participate in proliferation and migration of 
vascular cells and depending on the receptor involved both inhibition and 
stimulation of cell proliferation or migration can be found (see below).  
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Thromboxane A2 (TXA2) 
TXA2 is a prothrombotic eicosanoid and a powerful vasoconstrictor and 
derived from PGH2 through the activity of TXAS. TXAS promoter contains 
different binding sites for transcription factors such as AP-1, AP-2, GATA-1, 
CCAAT box, TATA box (Bos et al., 2004). The human TXA2 receptor is the TP 
receptor and is coupled to the heterotrimeric Gq protein. TP activation leads to 
activation of MAPKs via Gq and PLC/PKC being essential for platelet 
aggregation, hypertrophy, VSMC contraction and proliferation (Ko, 1997; Bos et 
al., 2004). Alternatively, TP activation might lead to activation of MAPKs via 
Shc-GRB2-SOS, suggesting the participation of Ras in this activation (Bos et 
al., 2004). In parallel, TXA2 induces PI3K/Akt, and thus, mTOR and p70 S6 
kinase activation, which is involved in the inhibition of apoptosis (Morinelli et al., 
1997) (Figure 19). 
Vascular TXA2 production is increased in several animal models of 
hypertension where it contributes to the increased contractile responses 
(García-Redondo et al., 2009; Martínez-Revelles et al., 2013). However, at 
vascular level, there is a paucity of information about which stimuli induce TXAS 
expression and TXA2 production. Besides its effects on vascular contraction, TP 
activation seems to be linked to endothelial cell migration, survival and 
angiogenesis (Nie et al., 2000), although conflicting results have been found 
(Ashton et al., 1999). Importantly, in VSMC, TP activation mediates the 
proliferative effect of TXA2 through phosphoinositide hydrolysis and ERK1/2 
pathway, leading to DNA synthesis (Ko, 1997), which suggest that TXA2 might 
have a role in vascular remodeling in cardiovascular pathologies.  
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Figure 19. Signaling pathways involved in TP activation by TXA2. TXA2 activates 
MAPK via Gq and PKC. Alternatively, it might lead to activation of this kinase via Shc-
Grb2-SOS, suggesting the activation of Ras. In parallel, TXA2 induces p70 S6 kinase 
activity. Mitogen-activated protein kinase kinase (MEK); Mammalian target of 
rapamycin (mTOR); Rapidly accelerated fibrosarcoma (Raf); Son of sevenless (SOS); 
Src homology 2 domain containing) transforming protein (Shc); Growth factor receptor-
bound protein 2 (Grb2); Ribosomal protein S6 kinase (p70S6K). Modified from Bos et 
al., 2004. 
Prostacyclin (PGI2) 
PGI2 is a vasodilator and antiplatelet aggregator prostanoid with 
vasoprotective functions that is generated by PGIS (Bos et al., 2004). PGIS is 
expressed in many human tissues including VSMC (Camacho et al., 2007). 
PGIS expression can be induced in vascular cells by different stimuli such as 
TNF-α (Murakami et al., 1993), hypoxia (Camacho et al., 2011), AngII (Galán et 
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al., 2011) or IL-1 (Fleisher-Berkovich and Danon, 1999); however, the 
regulatory elements of its promoter are poorly known. PGI2 binds to IP receptor 
and stimulates Gs and activates cAMP/PKA/CREB resulting in elevated levels of 
cAMP which potently inhibit the MAPK pathways including ERK1/2 and p38 
MAPK (Figure 20), as well as Rho kinase. In addition, IP activation can also 
activate Gq and Gi (Bos et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Signaling pathways involved in IP activation by PGI2. PGI2 induces 
inhibition of both ERK1/2 and p38 MAPK via the activation of Gs. Modified from Bos et 
al., 2004. 
Besides inducing vasodilation, IP receptor activation inhibits VSMC proliferation 
and migration (Wang et al., 2011b). Thus, cicaprost, a selective IP agonist, 
inhibits cell cycle progression from G1-to S-phase of cultured mouse aortic 
VSMC by blocking the binding of CREB to the cyclin A promoter CRE and 
blocking cyclin E-cdk2 activity and phosphorylation of retinoblastoma protein 
and p107 (Kothapalli et al., 2003). 
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Role of prostanoids in vascular remodeling 
In vivo studies using selective COX-2 inhibitors and COX-2-/- mice have 
demonstrated that prostanoids downstream of COX-2 participate in the 
pathological vascular remodeling observed in aortic aneurysms (King et al., 
2006) and restenosis observed in the wire-injured (Zhang et al., 2013) and 
balloon-injured (Yang et al., 2004a; Wang et al., 2005) arteries. However, the 
implication of COX-2 in hypertensive vascular remodeling is less clear. Virdis et 
al., (2012) recently proposed that COX-1-derived prostanoids are responsible 
for AngII-mediated vascular damage of resistance arteries. However, we have 
demonstrated that COX-2 blockade prevents AngII-induced decreased aortic 
lumen size and increased media thickness (Martínez-Revelles et al., 2013). Of 
importance is the fact that cardiovascular side effects associated to COX-2-
selective nonsteroidal anti-inflammatory drugs have been reported (reviewed in 
Patrignani and Patrono, 2014). However, there is still a big controversy of 
whether selective and non-selective COX-2 inhibitors provide the same degree 
of cardiovascular risk (Nissen, 2012; Bhala et al., 2013).  
The main COX-derived prostanoids responsible for effects on vascular 
structure seem to be PGE2 and TXA2 with PGI2 having a protective effect. 
Therefore, interest of the scientific community has shifted to the study of 
selective inhibitors of mPGES-1 as a drug target with previsible less 
cardiovascular side effects (Wang and Fitzgerald, 2010; Korotkova and 
Jakobsson, 2014). Unfortunately, to date there are no selective mPGES-1 
inhibitors available for clinical use and some of the more selective and active for 
human mPGES-1 show no activity on rat or mice enzyme (Korotkova and 
Jakobsson, 2014). Preclinical studies using mPGES-1 knockout mice have 
provided promising results. Thus, global mPGES-1 deletion prevents abdominal 
aortic aneurisms development (Wang et al., 2008) and neointimal hyperplasia 
formation and impairs VSMC proliferation and migration after wire injury of the 
femoral artery (Wang et al., 2011b). However, recent studies have established 
that the effects of mPGES-1 on vascular damage might depend on the specific 
cell location of the enzyme being macrophage mPGES-1 a key enzyme in 
promoting neointimal hyperplastic response to injury (Chen et al., 2013a) and 
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atherogenesis (Chen et al., 2014). Interestingly, the role of mPGES-1-derived 
PGE2 in hypertensive vascular remodeling is unknown. 
Blockade of specific prostanoids receptors might provide more specific 
effects than the blockade of prostanoids synthesizing enzymes. However, data 
are still inconclusive and might depend on the stimulus or the specific cell type. 
Thus, in VSMC, PDGF-induced proliferation is mediated by EP4 receptor (Fujino 
et al., 2002) and in injury-induced neointimal hyperplasia and PGE2-induced 
VSMC migration, EP3 seems to be a key player (Zhang et al., 2013). On the 
other hand, neointimal hyperplasia was markedly accelerated in EP2-/- mice and 
PDGF treatment resulted in more significant cell proliferation and migration in 
VSMC of EP2-/- mice (Zhu et al., 2011). In cardiac fibroblasts, PGE2 stimulates 
proliferation via EP1 and/or EP3, ERK1/2 and Akt regulation of cyclin D3 
(Harding et al., 2011). Regarding TP receptors, VSMC-specific TP deletion 
significantly attenuated AngII-induced hypertension and aortic vascular 
remodeling (Sparks et al., 2013). In addition, selective TP receptor blockade 
with the antagonist SQ29548 prevented small resistance arteries hypertrophy 
induced by AngII in mice (Virdis et al., 2012). Similarly, in vitro TP inhibition 
blocked vascular cell migration and proliferation induced by different stimuli 
(Sachinidis et al., 1995; Nie et al., 2000). Finally, as a proof of the protective 
role of PGI2 in vascular structure is the fact that deletion of the IP receptor 
augments intimal hyperplasia in a mouse model of transplant arteriosclerosis or 
flow-induced vascular remodeling (Rudic et al., 2005).  
The effects of prostanoids on vascular structure seem to be mediated by 
ECM proteins such as TN-C. Thus, the increased TN-C expression observed in 
the femoral artery wire injury mouse model is abolished in mPGES-1 knockout 
mice (Wang et al., 2011b) and PGI2 reverses TN-C expression and vascular 
remodeling in rat pulmonary hypertension (Schermuly et al., 2005). Moreover, 
mPGES-1-deleted VSMC generated less PGE2 but more PGI2 and reduced TN-
C expression, VSMC proliferation and migration in vitro compared with wild type 
cells (Wang et al., 2011b). However, whether TN-C is increased in hypertensive 
vascular remodeling and affected by PGE2 is unknown.  
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2.2.2. NADPH oxidase 
NADPH oxidases are the major source of ROS in the vascular wall in 
physiological and pathological conditions (Dikalova et al., 2005; Anrather et al., 
2006; Lassègue et al., 2012; Montezano and Touyz, 2014). ROS are reactive 
derivatives of the oxygen metabolism with superoxide anion (O2•−), hydrogen 
peroxide (H2O2) and peroxynitrite (ONOO-) being of major importance. They are 
produced by almost all cell types including vascular cells. The main catalytic 
function of NADPH oxidases is the generation of ROS, thus differing from the 
rest of the ROS-producing enzymes which produce ROS as a by-product of 
their activity. NADPH oxidase reduces oxygen to superoxide anion (O2•−), being 
NADPH the electron donor; thus, there is an electron transfer from the cytosol 
across biological membranes. There are seven NADPH oxidases isoforms in 
mammals and all of them have a catalytic subunit called NOX (NOX-1-5) or 
DUOX (DUOX-1-2 also called NOX-6-7) and up to seven regulatory subunits 
(Figure 21).  
NOX-1, NOX-2, NOX-4 and NOX-5 are expressed in the cardiovascular 
system. NOX-2 is the classical NOX that was primarily characterized in 
leukocytes. NOX-1, NOX-2 and NOX-3 activities are regulated by cytosolic 
adaptor proteins or “NOX organizers” (p47phox or NOXO1 and p40phox) and 
“NOX activators” (p67phox or NOXA1) that bind GTP-Rac and affect the flow of 
electrons (Figure 21). The p22phox component forms a stable heterodimeric 
complex with NOX core components (NOX-1-4), required for post-translation 
processing or maturation into active oxidases. In NOX-1/NOX-3 systems, 
p22phox also promotes plasma membrane targeting of the oxidases and 
provides a docking site for NOX organizers. However, NOX-4 only depends on 
p22phox in order to be active, is constitutively activated, and ROS production is 
regulated by Poldip2 (Figure 21). NOX-5 and DUOX are Ca2+-responsive 
oxidases that contain Ca2+-binding EF-hands (Figure 21). NOX-1, NOX-2, NOX-
3 and NOX-5 produce O2•− while NOX-4, DUOX-1 and DUOX-2 produce H2O2 
(Guichard et al. 2008; Montezano and Touyz, 2014). 
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Figure 21. Subunit composition of the seven mammalian NADPH oxidase 
isoforms. The catalytic subunits of NADPH oxidase (NOX) 1-5, dual oxidase (DUOX) 
1 and 2 are shown in green. The stabilization subunits are shown in red: p22phox, 
DUOX activator (DUOXA) 1 and 2. Cytosolic organizers are shown in orange: 
p40phox, NOX organizer 1(NOXO1) and p47phox. Cytosolic activators are shown in 
green: p67phox and NOX activator 1 (NOXA1).Small GTPases (RAC1 and RAC2), 
polymerase δ-interacting protein 2 (POLDIP2) and EF hand motifs are shown in blue, 
pink or yellow respectively. Taken from Drummond et al., 2011. 
Within the vascular wall, NOX isoforms locations vary depending on the cell 
type and the cellular compartments (Drummond et al., 2011). Thus, endothelial 
cells express NOX-1, NOX-2, NOX-4 and NOX-5; VSMC mainly express NOX-
1, NOX-4 and NOX-5; and adventitial fibroblasts mainly express NOX-2 and 
NOX-4 (Drummond et al., 2011). It is noteworthy that NOX-5 is only expressed 
in human cells (Drummond et al., 2011). NOX distribution in subcellular 
compartments also varies within the cell. In VSMC, NOX-1 is localized to the 
plasma membrane, caveolae and endosomes while NOX-4 seems to be in focal 
adhesions, ER and nucleus (Drummond et al., 2011; Chen et al., 2012) (Figure 
22). Additionally, NOX-4 seems to be present in the mitochondria of 
cardiomyocytes (Chen et al., 2012).  
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Figure 22. Cellular and subcellular expression of NADPH oxidase isoforms in the 
vessel wall. Schematic diagram showing the subcellular location of the different 
NADPH oxidase isoforms (on the right) and their location in different cell types of the 
vascular wall (on the left). Taken from Drummond et al., 2011. 
NOXs are important in physiological processes including host defense, 
aging, and cellular homeostasis. However, the up-regulation of different NOXs, 
including NOX-1 and NOX-4, has been implicated in several cardiovascular 
diseases such as atherosclerosis, hypertension, diabetes, isquemia/reperfusion, 
restenosis or abdominal aortic aneurisms. Thus, NOX-derived ROS contribute 
to the oxidative stress, vascular inflammation, endothelial dysfunction and 
vascular remodeling observed in these cardiovascular pathologies (Dikalova et 
al., 2005; Anrather et al., 2006; Drummond et al., 2011; Lassègue et al., 2012; 
Montenzano and Touyz 2014; Raaz et al., 2014). The mechanisms whereby 
NOX-derived ROS contribute to altered vessel structure include modulation of 
cell growth, apoptosis, migration, inflammation and ECM production (Xu and 
Touyz, 2006; Drummond et al., 2011). This is based on both in vitro and in vivo 
studies using genetically modified animals and experimental models of 
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hypertension, atherosclerosis, aneurysms and others. However, although a 
causal relationship has clearly been demonstrated in many animal studies, an 
effective ROS-modulating therapy still remains to be established by clinical 
studies. In addition, despite of the amount of literature available on this subject, 
the regulation of specific NOXs in vascular cells is not completely understood.  
Because of their preferential expression in VSMC and their importance in 
vascular remodeling, in the next part of the Introduction we will focus on specific 
aspects of NOX-1 and NOX-4 including available information on regulation, 
function and their role in vascular remodeling. 
2.2.2.1. NOX-1 
NOX-1 is expressed in colon epithelium and also in other tissues including 
the vascular wall where it seems to be up-regulated in pathological conditions 
or after exposure to different agonists important in cardiovascular disease 
(Lassègue et al., 2012). Thus, in VSMC NOX-1 is up-regulated by AngII 
(Lassègue et al., 2001; Briones et al., 2011), PGF2α and PDGF (Katsuyama et 
al., 2005), IFN-γ (Manea et al., 2010a) or IL-1β (Martín et al., 2012). In addition, 
vascular NOX-1 expression is elevated in several in vivo animal models of 
hypertension such as two-kidney two-clip renovascular hypertensive rats, 
DOCA salt hypertensive rats and AngII-infused mice (Wang et al., 2007; 
Nakano et al., 2008; Martínez-Revelles et al., 2013). Moreover, NOX-1 
expression is elevated during restenosis following balloon angioplasty (Szöcs et 
al., 2002). However, the role of NOX-1 in atherogenesis remains controversial 
with NOX-1 being undetected in atherosclerotic rabbit (Paravicini et al., 2002) or 
human lesions (Sorescu et al., 2002; Kalinina et al., 2002) and overexpressed 
in aorta from ApoE-/- mice (Bengtsson et al., 2003).  
NOX-1 promoter has different binding sites for transcription factors 
including a member of CREB/ATF family (ATF-1; Katsuyama et al., 2005), AP-1 
(Cevik et al., 2008), NF-κB (Manea et al., 2010b) or Janus kinase/Signal 
transducers and activators of transcription (JAK/STAT) (Manea et al., 2010a) 
(Figure 23). 
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Figure 23. Structure of human NOX-1 gene promoter. Binding sites for transcription 
factors involved in NOX-1 expression. 
Most of these studies have evaluated transcriptional regulation of NOX-1. 
However, to our knowledge, no studies have demonstrated post-transcriptional 
regulation of NOX-1. In fact, regulation of NOX-1 mRNA through its 3’UTR is 
conceivable because of the presence of AREs which, as mentioned, are 
implicated in mammalian mRNA degradation. Particularly, the role of HuR in 
stabilizing NOX-1 mRNA and whether this might affect NOX-1 activity and its 
functional properties has never been evaluated.  
2.2.2.2. NOX-4 
NOX-4 is very abundant in kidney and it seems ubiquitously expressed 
mainly in differentiated cells. NOX-4 is mostly found in focal adhesions and in 
the ER (Hilenski et al., 2004; Chen et al., 2008; Helmcke et al., 2009). As 
mentioned, its structure differs from NOX-1 and enables the protein to directly 
produce H2O2 (Dikalov et al., 2008; Takac et al., 2011). It has been suggested 
that the predominant factor controlling NOX-4-dependent ROS formation is the 
expression level of the enzyme (Schröder, 2014); therefore, the knowledge of 
the mechanisms responsible of its expression is very important. 
It seems now accepted that NOX-4 is constitutively active (Chen et al., 
2012). However, less clear is whether NOX-4 expression can be modulated and 
variable data regarding NOX-4 induction are found in the literature. Thus, 
hypoxia induces NOX-4 expression in pulmonary artery SMC (Mittal et al., 
2007; Diebold et al., 2010) and TGF-β induces NOX-4 in cardiomyocytes and 
vascular cells (Cucoranu et al., 2005; Sturrock et al., 2006; Sturrock et al., 
2007). However, thrombin, PDGF and peroxisome proliferator-activated 
receptor-γ (PPAR-γ) ligands reduce NOX-4 expression in VSMC and 
endothelial cells, (Lassègue et al., 2001; Ellmark et al., 2005; Hwang et al., 
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2005). Moreover, other stimuli including AngII and IL-1β have demonstrated to 
up-regulate, decrease or no affect  NOX-4 expression in vascular cells 
(Lassègue et al., 2001; Ellmark et al., 2005; Dikalov et al., 2008; Richard et al., 
2009; Briones et al., 2011). Reasons for these differences remain elusive but 
different locations in different cell types or presence of different NOX-4 isoforms 
might contribute to the observed findings (Lassègue et al., 2012). 
In vivo studies have tried to shed light on the role of NOX-4 in 
cardiovascular disease; however, findings are still far from being conclusive. 
Depending on the pathology or the blood vessel studied, increased, decreased 
or unchanged NOX-4 expression can be found (Chen et al., 2012). Thus, in 
SHR, NOX-4 levels have been reported to be decreased in the aorta (Wind et 
al., 2010). In contrast, NOX-4 mRNA expression is higher in basilar arteries 
from SHR compared to normotensive Wistar-Kyoto rats (WKY) and in aortas 
from SHR (Paravicini et al., 2004; Martínez-Revelles et al., 2013). Similarly, 
increased NOX-4 expression has been observed in the renal cortex of 
aldosterone-salt rats and in aorta of AngII-infused mice (Mollnau et al., 2002; 
Nishiyama et al., 2004). In human atherosclerosis, NOX-4 expression is 
increased in intimal lesions of coronary arteries (Sorescu et al., 2002); however, 
in experimental atherosclerosis, NOX-4 expression is unchanged in the aorta of 
ApoE-/- mice or in primate models (Judkins et al., 2010; Stanic et al., 2012).   
NOX-4 regulation seems to be mostly transcriptional (Figure 24). NOX-4 
has been proposed to be a housekeeping gene because its promoter region 
contains many GC bases (Katsuyama et al., 2012). E2F1 transcription factor is 
involved in the basal NOX-4 expression in rodent VSMC (Zhang et al., 2008). 
Sp3 and three GC-boxes containing putative Sp/Klf binding sites are also 
essential for the basal expression of the NOX-4 gene (Katsuyama et al., 2011). 
Furthermore, in human endothelial cells, NOX-4 basal transcription is 
dependent of the deacetylation of transcription factor(s) and polymerase(s) 
(Siuda et al., 2012). Regarding the inducible expression of NOX-4, JAK/STAT 
and NF-κB seem to be involved in NOX-4 expression in response to IFN-γ or 
TNF-α (Manea et al., 2010a; Manea et al., 2010b). In addition, hypoxia induces 
NOX-4 through a hypoxia-inducible factor-1α (HIF-1α) dependent mechanism 
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contributing to maintain ROS levels in smooth muscle cells from pulmonary 
artery (Diebold et al., 2010). However, the mechanisms whereby NOX-4 is 
down-regulated are poorly understood. To date, it has been demonstrated that 
a PPAR-γ agonist inhibits hypoxia-mediated NOX-4 increase in smooth muscle 
cells from pulmonary artery (Lu et al., 2010). Additionally, JunD knockdown 
decreases NOX-4 expression in endothelial cells (Paneni et al., 2013). 
However, additional mechanisms might contribute to NOX-4 down-regulation in 
response to different stimuli.  
 
Figure 24. Structure of human NOX-4 gene promoter. Binding sites for transcription 
factors involved in NOX-4 expression. Retinoid X receptor (RXR). 
In the last few years, NOX-4 post-transcriptional regulation has also been 
described. In cholesterol-fed rats, hypercholesterolemia down-regulates 
myocardial microRNA-25 expression and consequently increases NOX-4 
expression and oxidative/nitrative stress in the heart (Varga et al., 2013).  In 
addition, in cultured endothelial cells, serum stimulation decreases NOX-4 
mRNA level due to a translation-initiated mRNA destabilization program 
(Peshavariya et al., 2009). Despite these evidences, there are very few studies 
focused on NOX-4 post-transcriptional regulation.   
2.2.2.3. Reactive oxygen species 
As mentioned, O2•−, H2O2 and ONOO- are signaling molecules of major 
importance that are produced by almost all cell types including vascular cells. 
Besides NADPH oxidase, other sources of ROS in the vascular wall include 
mitochondria, xanthine oxidase (XO), uncoupled endothelial nitric oxide 
synthase (eNOS), ER, COX, cytochrome P450 and lipoxygenase (Frazziano et 
al., 2012; Hernanz et al., 2014). Mitochondria are a major cellular source of 
ROS. There are several sites in the electron-transport chain where oxygen can 
be reduced to O2•−, with complexes I and III being the sites with the greatest 
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capacity (Dikalov, 2011). XO catalyzes the sequential oxidation of hypoxanthine 
to xanthine and xanthine to urate and can generate O2•− and H2O2 (Lacy et al., 
1998). XO is mainly expressed in the endothelium and both its protein 
expression and O2•− production can be activated by AngII (Landmesser et al., 
2007). eNOS uses L-arginine as substrate and tetrahydrobiopterin (BH4) as 
cofactor to generate NO. However, under pathological conditions, L-arginine or 
BH4 deficiency induce eNOS uncoupling resulting in O2•− production (Schulz et 
al., 2008).  
O2•− is highly reactive, has a short half-life and is unable to diffuse across 
biological membranes except possibly via ion channels (Touyz and Briones, 
2011). O2•− can dismute to H2O2, both spontaneously and enzymatically via any 
of the three isoforms of the superoxide dismutase (SOD): cytosolic Cu/Zn-SOD 
or SOD1, mitochondrial Mn-SOD or SOD2 and extracellular EC-SOD or SOD3 
(Figure 25). As mentioned, H2O2 can also be formed directly by some types of 
NOX such as NOX-4, DUOX-1 and -2 (Drummond et al., 2011). H2O2 is more 
stable than O2•− and crosses membranes through some members of the 
aquaporin family (Al Ghouleh et al., 2013). H2O2 is rapidly metabolized to water 
and oxygen by several enzymatic systems such as glutathione peroxidase, 
catalase and the thioredoxin system (Ebrahimian and Touyz, 2008) (Figure 25). 
In the presence of transition metals (such as Fe2+) H2O2 can be converted to 
hydroxyl radicals (HO•), which are highly reactive and can cause damage to 
lipids, proteins and DNA. In addition, NO which has a very short half-life, can 
react with O2•− to form ONOO- that is capable of modifying the structure and 
function of proteins. Thus, ROS regulation is important to maintain redox 
environment of the cell. When there is an imbalance between oxidants and 
antioxidant systems increased ROS steady-state levels start multiple 
pathologies including inflammation and cardiovascular disease (Drummond et 
al., 2011; Frazziano et al., 2012). At low intracellular concentrations, ROS have 
a key role in the physiological regulation of vascular tone, cell growth, adhesion, 
differentiation, senescence and apoptosis (Drummond et al., 2011; Schröder, 
2014). However, an increase in the amount of ROS leads to pathological 
processes such as endothelial dysfunction, inflammation and proliferation or 
migration of VSMC leading to vascular remodeling.  
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Figure 25. Schematic illustration of reactive oxygen and nitrogen species 
synthesis. O2•− and H2O2 are synthesized by different enzymes and its reaction with 
NO generate the reactive nitrogen species ONOO− that could be converted into NO2−, 
which reacts with protein tyrosine residues to generate NO2-Tyr. Modified from 
Frazziano et al., 2012. 
ROS can act as second messengers activating different intracellular 
signaling pathways. Particularly, H2O2 induces post-translational oxidative 
modifications on sulfur containing amino acid of proteins such as methionine 
and cysteine residues. Thus, ROS react with the sulfur atom of cysteine side 
chains of different proteins including proteins implicated in cell migration. 
Depending on the environmental oxidative state these reactions are reversible 
or irreversible, causing protein oxidative damage. It is also well established, that 
redox-dependent signaling pathways in VSMC include modifications in the 
activity of protein tyrosine kinases such as Src, Ras, JAK2, Pyk2, PI3K and 
EGFR, as well as MAPK, particularly p38 MAPK, ERK1/2 and ERK5 which have 
a key role in cell migration and proliferation and hence in pathological vascular 
remodeling (Briones and Touyz, 2010, Figure 26). These processes probably 
occur through oxidation/reduction of protein tyrosine phosphatases (PTP), 
which are susceptible to oxidation and inactivation by ROS. Increased 
intracellular ROS also induces an increase in intracellular free Ca2+ 
Nox-4
Thioredoxin System
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concentration ([Ca2+]i) and an increase in intracellular pH (pHi) that also 
contribute to altered contraction and remodeling observed in pathological 
situations where ROS have a prominent role (Briones and Touyz, 2010, Figure 
26). Rho GTPases and actin are also sensitive to these modifications leading to 
actin cytoskeleton reorganization (Briones and Touyz, 2010; Son et al., 2011; 
Stanley et al., 2014). Thus, ROS are able to induce VSMC proliferation and 
migration by a number of different intracellular signaling pathways.  
 
Figure 26. Intracellular mechanisms activated by ROS that participate in 
cardiovascular disease. NOX-derived ROS activate different signaling pathways as 
well as increase in pH and Ca2+. These processes lead to different cellular responses 
that will end in cardiovascular disease. Taken from Briones and Touyz, 2010. 
To date, a number of studies have demonstrated that important stimuli for 
cardiovascular diseases induce VSMC migration and/or proliferation via ROS 
(Amanso and Griendling, 2012). For example, AngII regulates FAT atypical 
cadherin 1 (Fat1) expression and activity and induces Fat1-dependent VSMC 
migration via activation of AT1R, ERK1/2, and NOX-1-derived ROS (Bruder-
Nascimento et al., 2014). Similarly, PDGF-induced VSMC migration is ROS 
dependent and the Src/PDK1/PAK1 signaling pathway is important as a ROS-
sensitive mediator of migration (Weber et al., 2004). Moreover, in VSMC H2O2 
induces cell migration by inducing the expression of a cytoskeleton protein, 
ARPC2, through a p38 MAPK-dependent mechanism (Al Ghouleh et al., 2013).  
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Role of reactive oxygen species in vascular remodeling 
Many in vitro studies have demonstrated the role of oxidative stress as 
facilitator of different processes leading to vascular remodeling in 
cardiovascular diseases (Valente et al., 2012; Al Ghouleh et al., 2013; Bruder-
Nascimento et al., 2014). In addition, several studies in different animal models 
including the SHR or the AngII-infused mice, have demonstrated that 
pharmacological treatment with different antioxidants such as tempol a SOD 
analogue, apocyinin, a non-specific NADPH oxidase inhibitor, or mito-TEMPO, 
a mitochondria targeted SOD mimetic, attenuated vascular remodeling (Park et 
al., 2002; Virdis et al., 2004; Chen et al., 2013b; Martínez-Revelles et al., 2013), 
demonstrating the key role of ROS from different origins in vascular disease.  
Regarding the specific NOX isoform involved in vascular remodeling, 
transgenic knockout or overexpressing mice have yielded additional although 
not conclusive results. In the wire injury-induced neointima formation model, 
both proliferation and apoptosis were reduced in NOX-1-/- mice but there was 
little difference in mice overexpressing NOX-1 compared with wild type mice 
(Lee et al., 2009). Accordingly, proliferation and migration were reduced in 
response to PDGF in cultured NOX-1-/- VSMC and increased in cells 
overexpressing NOX-1 compared with wild type VSMC (Lee et al., 2009), 
suggesting that NOX-1 is required for the neointima formation. Several studies 
have evaluated the role of NOX-1 in vascular remodeling in response to AngII. 
AngII induces VSMC proliferation and migration as well as carotid artery 
hyperplasia in rats via AT1R interaction with NOX-1 (Valente et al., 2012). 
Interestingly, NOX-1-/- mice showed a marked reduction in aortic media 
hypertrophy in response to AngII (Gavazzi et al., 2006; Schröder et al., 2012), 
but this reduction was due to a marked decrease in extracellular matrix 
accumulation and not in the number of VSMC (Gavazzi et al., 2006). On the 
other hand, Matsuno et al., (2005) demonstrated that AngII did elicit similar 
hypertrophic response in the thoracic aorta of NOX-1-/- and NOX-1+/+ mice. 
Finally, transgenic mice overexpressing NOX-1 in SMC showed markedly 
greater aortic hypertrophy in response to AngII than their littermate controls 
(Dikalova et al., 2005). Altogether, these findings suggest that cell specific 
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location of NOX-1 might be the key to modulate hypertrophic vascular 
remodeling being VSMC NOX-1 of fundamental importance. Regarding 
mechanisms activated by NOX-1-derived ROS, it has been demonstrated that 
in the presence of some stimuli, NOX-1 activates different proteins involved in 
cell adhesion and migration such as paxilin, Rac, RhoA and cofilin (Schröder, 
2014). Moreover, recently NOX-1 has been shown to be involved in matrix 
metalloproteinase-9 expression, a metalloproteinase essential in cell migration 
(Schröder, 2014). 
The functional role of NOX-4 in vascular cells is under debate (Chen et al., 
2012; Lassègue et al., 2012). It is thought that NOX-4 contributes to the 
maintenance of a differentiated state of the cell preventing cell activation or 
proliferation (Clempus et al., 2007; Schröder et al., 2009; Lassègue et al., 2012; 
Schröder, 2014), suggesting a protective effect of NOX-4. However, transgenic 
mice with cardiac specific overexpression of NOX-4 showed decreased left 
ventricular function with enhanced O2•−, production in the heart, which was 
accompanied by increased apoptosis and fibrosis, suggesting a deleterious role 
for NOX-4 (Ago et al., 2010). Interestingly, NOX-4-/- mice developed 
exaggerated contractile dysfunction, hypertrophy and cardiac dilatation during 
exposure to chronic overload, whereas mice with cardiomyocyte-targeted 
overexpression of NOX-4 were protected (Zhang et al., 2010). The different 
functions of NOX-4 might also depend on the disease model or stimulus to be 
studied (Chen et al., 2012). In the AngII-infused mouse model, aortas from 
NOX-4-deficient animals developed increased inflammation, and media 
hypertrophy compared to their wild type littermates (Schröder et al., 2012) 
suggesting that NOX-4 might indeed act as a protective enzyme. Besides acting 
on differentiation, proliferation and migration, NOX-4 has a role on other 
processes involved in vascular remodeling such as apoptosis, senescence and 
cell cycle (Lassègue et al., 2012) and it has been suggested that NOX-4 might 
regulate fundamental cellular processes that contribute to each of these 
responses (Lassègue et al., 2012).  
Reasons for so different roles for NOX-1 and NOX-4 in vascular biology are 
far for being clarified. As mentioned, NOX-4 is a special NOX because it has a 
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high constitutive activity, is highly expressed in some cells such as endothelial 
cells and its subcellular location is different to other NOXs (Chen et al., 2012). 
Moreover, different from NOX-1 and NOX-2, NOX-4 releases predominantly 
H2O2. Although not extensively studied, H2O2 in the media and endothelial 
layers may have different functions. Thus, smooth muscle-specific catalase 
overexpression blocks the H2O2-mediated angiotensin II-induced vascular 
hypertrophy (Zhang et al., 2005) whereas endothelial-specific catalase 
overexpression prevents exercise-stimulated induction of eNOS (Lauer et al., 
2005). Future studies with improved tools will reveal the true nature of the role 
of NOX-4 in both health and disease (Chen et al., 2012).    
2.2.3. Reciprocal relationship between reactive oxygen species and 
prostanoids 
ROS and prostanoids share many stimuli and intracellular signaling 
pathways. Therefore, it is not surprising that both mediators could act in concert 
to induce their biological effects (Hernanz et al., 2014). Different studies have 
demonstrated that ROS from different sources can affect both the activity and 
expression of COX isoforms in vessels (Karaa et al., 2006; García-Redondo et 
al., 2009; Barbieri et al., 2011; Li et al., 2011; Martín et al., 2012; Martínez-
Revelles et al., 2013). On the other hand, COX can produce directly ROS in 
part due to its ability to co-oxidize substances such as NADPH (Tang et al., 
2007; Félétou et al., 2011). In addition, COX-derived products may function as 
autocrine stimulators of ROS (Hernanz et al., 2014). Selective COX-2 inhibitors 
and COX-2 deletion decrease vascular oxidative stress (Stichtenoth et al., 
2005; Wu et al., 2005; Wu et al., 2011; Martínez-Revelles et al., 2013). 
However, it is unclear whether this effect is mediated by inhibition of COX-2-
associated ROS production or by inhibition of the synthesis of downstream 
prostanoids that can directly regulate the expression and activity of several 
sources of ROS. Our group and others have reported a reciprocal relationship 
between COX-2 and NOX. Thus, in human liver cells phorbol 12-myristate 13-
acetate initiates a pathway in which NOX-1 activation controls COX-2 
expression and activity, which in turn induces NOX-4 expression by activation of 
EP4 receptors (Sancho et al., 2011). At vascular level, antioxidants treatments 
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decreased COX-2 expression and activity in hypertensive animal models; 
conversely, selective COX-2 blockade decreased the increased oxidative stress 
associated to hypertension (Martínez-Revelles et al., 2013). More importantly, 
this reciprocal relationship had a role in the altered vascular function and 
hypertension (Martínez-Revelles et al., 2013). However, the impact of this 
relationship in vascular remodeling is unknown.   
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It is now accepted that inflammation is common for different cardiovascular 
diseases. This inflammatory process observed in both experimental animal 
models and in humans is associated with the increased expression and/or 
activation of different pro-inflammatory enzymes such as COX-2 and NADPH 
oxidase leading to the production of prostanoids and ROS. AngII and cytokines 
like IL-1β, promote a pro-inflammatory environment associated with increased 
COX-2 and NOX expression and/or activity in the vascular wall. As a result, 
VSMC undergo proliferation and migration contributing to vascular structural 
alterations observed in cardiovascular pathologies. Transcriptional and post-
transcriptional mechanisms regulate COX-2 and NOX expression in response to 
inflammatory stimuli in different cell types. HuR, which is a RNA binding protein 
implicated in different cell processes, seems to have a key role in the 
stabilization of different mRNAs. However, whether HuR is involved in the 
stabilization of COX-2 and NOX mRNAs in VSMC is unknown. More 
importantly, whether this regulating mechanism has a functional role in VSMC is 
also unknown.  
The aim of this PhD Thesis was to investigate transcriptional and post-
transcriptional mechanisms implicated in the regulation of COX-2, NOX-1 and 
NOX-4 expression in VSMC stimulated with AngII and IL-1β. In addition, the 
role of this regulation in vascular remodeling was evaluated. The specific aims 
were as follows: 
1. To analyze the contribution of HuR upon COX-2 expression induced by 
AngII and IL-1β and its consequences on VSMC migration and vascular 
remodeling. 
2. To investigate transcriptional and post-transcriptional mechanisms 
involved in the effects of AngII and IL-1β on NOX-1 and NOX-4 
expressions in VSMC and their implications in cell migration.  
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1. ETHICAL ASPECTS 
All experimental procedures were approved by the Ethical Committees of 
Research of the Universidad Autónoma de Madrid and University of Kansas 
Medical Center and by the Reviewer Institutional Committee on Human 
Research of the Hospital de la Santa Creu i Sant Pau, conforms to the 
Declaration of Helsinki. These studies were conducted in accordance with the 
National Institutes of Health (NIH) Guide for the Care and Use of Laboratory 
Animals (NIH Publication No. 85-23, revised 1996) and with guidelines for 
ethical care of experimental animals of the European Community and the 
current Spanish and European laws (RD 223/88 MAPA and 609/86). 
2. CELL CULTURE 
Primary cultures of aortic VSMC were obtained from aortas of 3 months-old 
Sprague-Dawley male rats. Aortas were isolated and immediately submerged in 
DMEM-F12 medium supplemented with 0.1% BSA, 2 mmol/L L-glutamine and 
antibiotics (200 U/mL of penicillin and 200 μg/mL streptomycin). Aortas were 
cleaned in a cell hood (NuAIRE, Plymouth, MN, USA) and then treated with 2 
mg/mL of collagenase type II (Worthington, Lakewood, USA) for 30 min at 37 
ºC. After that, adventitia was removed with tweezers and the media layer was 
chopped and put into a well with DMEM-F12 medium supplemented with 10% 
FBS, containing 100 U/mL of penicillin, and 100 µg/mL of streptomycin. 
Explants were incubated in a 6-well plate with complete medium at 37 ºC, 5% 
CO2 and 95% air. Three times a week, the medium was replaced with fresh 
medium. 10-13 days later, confluent cells were rinsed with phosphate-buffered 
saline (PBS), split with trypsin-EDTA and seeded at a density of 30% in DMEM-
F12 medium. Cells were identified as smooth cells by their spindle shape, by 
the “hills and valleys” organization and by immunocytochemical staining with 
specific monoclonal anti-α actin antibody (1:200; Sigma-Aldrich, St. Louis, MO, 
USA) (Figure 27). Rat cell cultures were used between passages 2 and 4.  
 
Materials and Methods 
98 Andrea Aguado Martínez PhD Thesis 
 
Figure 27. Vascular smooth muscle cells characterization. Phase contrast (A) and 
α-actin staining (in red) (B) pictures of VSMC. Pictures were taken with a microscope 
Nikon with  10X objective or confocal microscope Leica TCS SP2 with 63X objective. 
Human VSMC were obtained from coronary arteries of hearts (removed in 
transplant operations) by using a modification of the explant technique (Orriols 
et al., 2014). Human VSMC were growth in M199 supplemented with 20% FBS, 
1% human serum, 2 mmol/L of L-glutamine, 100 U/mL of penicillin and 100 
µg/mL of streptomycin. Human cell cultures were used between passages 3 
and 6.  
Cells were starved in serum free media for 24 h prior to stimulation. All cell 
culture products were purchased to Sigma-Aldrich (St. Louis, MO, USA).  
Cells were stimulated with vehicle, AngII (0.1 μmol/L), IL-1β (10 ng/mL), 
AngII+IL-1β, 16,16-dimethyl PGE2 (0.1-10 μmol/L) or U46619 (0.01-1 μmol/L) at 
the times and concentrations indicated in the results section. The effects of the 
following inhibitors were analyzed by its addition 30 min (or 4 h in the case of 
MS-444) before and throughout stimulation: actinomycin D, celecoxib, 
chelerythrine, cycloheximide, furegrelate, KN93, L798106, LY294002, ML171, 
MS-444, ozagrel, PD98059, suberoylanilide hydroxamic acid (SAHA), 
SB203580, SC19220, SP600125, SQ29548, trichostatin, tyrphostin AG 1478, 
U0126, W7, W12 and 5-aza-2’-deoxycytidine (5-aza-dC) (Table 1). Compounds 
used for stimuli and ozagrel were dissolved in distilled water; remaining 
compounds were dissolved in DMSO. All compounds were prepared in a stock 
solution and in the day of the experiment they were diluted using DMEM-F12 
medium.  
A B
Materials and Methods 
Andrea Aguado Martínez PhD Thesis  99 
INHIBITOR CONCENTRATION  TARGET 
Actinomycin D 5 μg/mL DNA*a 
Celecoxib 10 μmol/L COX-2 
Chelerythrine 20 μmol/L  PKC 
Cycloheximide 25 μg/mL *b 
Furegrelate 10 μmol/L TXAS 
KN93 20 μmol/L 
Ca2+/calmodulin-
dependent protein 
kinase II (pCaMKII) 
L798106 1 μmol/L EP3 receptor 
LY294002 10 μmol/L PI3K 
ML171 0.5 μmol/L NOX-1 
MS-444 8 μmol/L HuR 
Ozagrel 10 μmol/L TXAS 
PD98059 20 μmol/L MEK*c 
SAHA 5 μmol/L Histone deacetylase 
(HDAC) class I and II 
SB203580 10 μmol/L p38 MAPK 
SC19220 10 μmol/L EP1 receptor 
SP600125 20 μmol/L JNK 
SQ29548 3 μmol/L TP receptor 
Trichostatin 0.5 μmol/L HDAC class I and II 
Tyrphostin AG 
1478 
10 μmol/L EGFR 
U0126 10 μmol/L MEK*c 
W7 10 μmol/L Calmodulin (CaM) 
W12 10 μmol/L CaM 
5-aza-dC 2 μmol/L DNA 
methyltransferase 
Table 1. Inhibitors, final concentration and target. 
*a. Actinomycin D inhibits transcription through its binding to DNA at the transcription 
initiation complex and preventing elongation of RNA chain by RNA polymerase. 
*b. Cycloheximide exerts its effect by interfering with the translocation step in protein 
synthesis (movement of two tRNA molecules and mRNA in relation to the ribosome) 
thus blocking translational elongation. 
*c. PD98059 and U0126 block selectively the activation of MEK, thereby inhibiting the 
phosphorylation and the activation of ERK1/2. 
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3. ANIMAL MODELS  
The following animal models were used:  
1) Model of left carotid artery ligation. C57BL6 male 4-month-old mice with 
were used. Mice were not allowed to eat 4h before the surgery. An 
anesthetic cocktail (ketamine 45 mg/kg plus medetomidine 0.6 mg/kg) and 
analgesic (buprenorphine 0.1 mg/kg) were administered intraperitoneally. 
The decrease of the corporal temperature was prevented with an electric 
blanket and eyes were protected from desiccation with an ophthalmic 
solution. The ventral neck region was shaved and disinfected with povidone-
iododine solution. Once the animals were sedated to a surgical level of 
anesthesia (verified by toe or tail pinch), 1-cm incision was made in the neck 
(0.5 cm below the neck) and skin, glands and underlying muscular layer were 
separated with a retractor. Then, the left carotid was dissected and ligated 
with a 7-0 silk suture just proximal to its bifurcation of the left common carotid 
artery (Figure 28A). The ligation was performed in the left carotid in order to 
obtain an injured area of 9-mm length subjected to hemodynamic stress 
since the blood cannot escape. The right carotid was not used because 
blood could escape through the right subclavian artery thus the injury size 
would be smaller (Figure 28B). Mice were sutured with a 5-0 silk and 
atipamezol was administered intraperitoneally to recovery the animals of the 
anesthesia. During two days post-surgery buprenorphine (1.5 mg/L) was 
added in the drinking water. 
 
Figure 28. Left common carotid artery ligation surgery. A, Left common carotid 
artery ligated. B, Scheme of the aortic arch, carotid arteries and the ligation site. 
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2) Model of AngII infusion. C57BL6 male 4-month-old mice were infused with 
saline, AngII (1.44 mg/Kg/day, 2 weeks, subcutaneously by osmotic 
minipumps, Alza Corp., Cupertino, CA, USA) or with AngII plus celecoxib (25 
mg/Kg/day intraperitoneal started 24 h before AngII-infusion). Mice were 
sedated with inhalational anesthesia (breathing concentrations of 2.5% 
isoflurane with oxygen) to a surgical level of anesthesia, verified by toe or tail 
pinch. After that, mid-scapular incision was made (Figure 29A), hemostat 
was inserted into the incision and, by opening and closing the jaws of the 
hemostat, the subcutaneous tissue was spread to create a pocket for the 
pump. The AngII filled pump was inserted into the pocket (Figure 29B). The 
wound was closed with 2-0 silk suture. 
 
 
Figure 29. Osmotic mini-pump subcutaneous implantation. Mid-scapular incision 
(A) and pump implantation (B) procedures. 
mPGES-1 wild-type and mPGES-1-deficient (mPGES-1-/-) mice infused with 
saline or with AngII were also used. Wild type and mPGES-1-/- mice were 
maintained in a DBA/1 genetic background and were generated by 
corresponding heterozygous breeders derived from mPGES-1+/− embryo, which 
were a kind gift from Pfizer Inc (Groton, CT, USA) (Figure 30).  
 
 
Figure 30. Genotyping of mPGES-1-/- (KO), wild type (WT) and heterozygous (HT) 
by PCR analysis. The lower band (412 bp) is amplified from the wild type alleles and 
the upper band (720 bp) is from the mPGES-1-/-alleles. 
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4. RNA ANALYSIS 
For VSMC mRNA extraction, cells were rinsed with cold PBS and then 
harvested in 1 mL of Tri Reagent (Sigma-Aldrich) and transferred to a 1.5 mL 
tube. For aorta mRNA extraction, mouse aortas were homogenized on ice in 1 
mL of Tri Reagent using a Polytron PT-20 (Kinematica AG, Lucerna, 
Switzerland). Samples were centrifuged 5 min 12,000 g to remove the debris of 
tissue, supernatants were transferred to a fresh tube and total RNA was 
obtained according to the manufacturer’s recommendations. Total RNA 
absorbance was determined using a spectrophotometer Nanodrop (Thermo 
Fisher Scientific Inc, Wilmington, DE, USA) at 260 nm (1 unit  A260 de ssRNA = 
40 µg/mL). Sample absorbances at 280 and 230 nm were also determined in 
order to check RNA quality. 1 µg of total RNA was reverse transcribed using 
High Capacity cDNA Archive Kit (Life Technologies Inc., Gaithersburg, MD, 
USA) with random hexamers in a final volume of 10 µL according to 
manufacturer’s recommendations. The reverse transcription PCR protocol was 
10 min at 25 ºC, 2 h at 37 ºC and 5 min at 85 ºC.   
Quantitative PCR (qPCR) was performed in a 7500 Fast ABI System (Life 
Technologies). Depending on the gene, primers for SyBR Green or TaqMan 
Probes were used. The final volume of the reaction was 10 µL composed by 5 
µL of sample (50 ng), 4 µL of iTaq FAST SyBRGreen Supermix or 4.5 µL of 
iTaq Universal Probes Supermix (Bio-Rad, Hercules, CA, USA) and 1 μL of 
forward and reverse primers or 0.5 µL of each probe. SyBRGreen primers 
concentrations were tested with a standard curve to obtain efficiency between 
90-110%. We used Taqman Gene Expression Assays for human COX-2 
(Hs00153133_m1), mPGES-1 (Hs00610420_m1), NOX-1 (Hs00246589_m1), 
NOX-4 (Hs00418356_m1), PGIS (Hs00168766_m1), TXAS (Hs01022706_m1), 
18S (Hs99999901_s1), rat PPAR-γ (Rn00440945_m1), TXAS 
(Rn00562160_m1) and mouse TXAS (Mm00495553_m1) (Life Technologies).  
SYBR green primers sequence information is listed on Table 2. 
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Gene Specie FW RV 
Concentration 
(nmol/L) 
COX-2 rat AAGGGAGTCTGGAACATTGTGAAC CAAATGTGATCTGGACGTCAACA 1.300 
Egr-1 rat CAGCGCTTTCAATCCTCAAG GCGATGTCAGAAAAGGACTCTGT 500 
Elf-3 rat CTGAGCAAAGAATACTGGGACTGTC CCATAGTTGGGCCACAGCCTCTGAAC 500 
Elk-1 rat GCTCCCCACACATACCTTGA CGCGGTGCAATTGGACTCAGA 500 
HuR rat TGTACATCAGTGGGCTTCCA CTGCTTCAGACCGTTTGTCA 500 
mPGES-1 rat AGGAGTGACCCAGATGTG ATGTATCCAGGCGATGAGA 340 
NOX-1 rat CGGCAGAAGGTCGTGATTA TGGAGCAGAGGTCAGAGT 500 
NOX-4 rat GCCTCCATCAAGCCAAGA CCAGTCATCCAGTAGAGTGTT 500 
PGIS rat CCATCAACAGCATCAAACAGTTT CAAAGCCATATCTGCTAAGGTCAA 500 
TN-C rat ACCTCTCTGGAATTGCTCCCA CATCTGAAACTAGAAGGTTGTC 500 
B2M rat ACCGTGATCTTTCTGGTGCTT TAGCAGTTGAGGAAGTTGGGC 110 
COX-2 mouse TTCGGGAGCACAACAGAGT TAACCGCTCAGGTGTTGCAC 500 
HuR mouse ATGAAGACCACATGGCGGAAGAC AGTTCACAAAACCGTAGCCCAAGC 700 
mPGES-1 mouse AGGATGCGCTGAAACGTGGAG CCGAGGAAGAGGAAAGGATAG 800 
B2M mouse ACCCTGGTCTTTCTGGTGCTT TAGCAGTTCAGTATGTTCGGCTT 200 
Table 2. SyBR Green primer sequences with the name of the target gene, the specie 
and the final concentration. β2-microglobulin (B2M). 
PCR cycles proceeded as follows: initial denaturation for 30 s at 95°C followed 
by 40 cycles at 95°C for 5 s and 60°C for 30 s. Melting curve analysis was 
performed in SYBR green reactions to show PCR product specificity. Relative 
expression was determined using 2-ΔΔCt method (where Ct is threshold cycle) 
(Livak y Schmittgen, 2001), using β2-microglobulin or 18S rRNA as the internal 
control. Variations of mRNA levels were calculated as fold increase over 
controls or over controls with the corresponding inhibitor. 
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Determination of COX-2, NOX-1 and NOX-4 mRNA stability in stimulated 
cells was initiated by adding 5 µg/mL actinomycin D, an inhibitor of 
transcription, to the growth medium at specified times. Then, total RNA was 
isolated at indicated times and COX-2, NOX-1, NOX-4 and β2-microglobulin 
mRNA expression levels were measured by qPCR as indicated above.  
5. WESTERN BLOT ANALYSIS 
After appropriate treatments, cells were washed once in ice-cold PBS, 
scraped and whole-cell lysates were prepared in RIPA buffer containing 50 
mmol/L Tris pH 7.5, 150 mmol/L NaCl, 1 mmol/L MgCl2, 1 mmol/L EDTA, 1% 
Nonidet-P40 (NP-40), 0.5% sodium deoxicolate and 1% sodium dodecyl sulfate 
(SDS). RIPA buffer was supplemented with a protease inhibitor cocktail (Roche 
Applied Science, Barcelona, Spain) and a mix of phosphatase inhibitors (1 
mmol/L orthovanadate, 20 mmol/L β-glycerophosphate, 10 mmol/L NaF). Cell 
lysates were centrifuged 10 min 14.000 rpm and supernatants were transferred 
to a fresh tube.  
For cellular fractionation, cells were lysed in hypotonic lysis buffer (10 
mmol/L HEPES pH 8, 3 mmol/L MgCl2, 40 mmol/L KCl, 0.2% NP-40, 10% 
glycerol, 0.1 mmol/L dithiothreitol (DTT) with protease and phosphatase 
inhibitors) for 15 min at 4 ºC. Samples were centrifuged 2 min at 10,000 rpm to 
separate cytoplasmic supernatant from nuclei. Nuclei were washed four times in 
hypotonic buffer and lysed in RIPA buffer. Samples were then centrifuged 10 
min at 10,000 rpm to obtain the nuclear fraction.  
Protein concentration was determined with Lowry (Bio-Rad) or BCA protein 
assay reagent (Pierce, Rockford, IL, USA), using bovine serum albumin (BSA) 
as standard. 20-40 µg of protein were mixed with Laemli 5X buffer (300 mmol/L 
Tris-HCl pH 6.8, 10% SDS, 25% β-mercaptoethanol, 0.5% bromophenol blue, 
50% glycerol) and boiled 5 min. Proteins were separated in a 10% or 12% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
submerged in running buffer (25 mmol/L Tris, 200 mmol/L glycine, 1% SDS). 
Then, gels were electrophoretically transferred to polyvinylidene difluoride or 
nitrocellulose membranes (Amersham, GE Healthcare, Buckinghamshire, UK) 
in Tris-Glycine transfer buffer (25 mmol/L Tris, 190 mmol/L glycine, 0.05% SDS, 
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20% methanol) in a Trans-Blot Cell (Bio-Rad). Membranes were blocked with 
5% skim milk or 5% BSA in wash buffer (TBS-T: 10 mmol/L Tris-HCl pH 7.5, 
100 mmol/L NaCl, 0.1% Tween-20) 30 min at room temperature. After that, 
membranes were probed with antibodies against HuR (1:1000; Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA), NOX-1 and NOX-4 (1:200; Santa 
Cruz Biotechnology, Inc.), Nucleoporin p62 (1:5,000; BD Bioscience, San Jose, 
CA, USA), COX-2 and mPGES-1 (1:200; Cayman Chemical, Ann Arbor, MI, 
USA), PGIS (1:1,000; Cayman Chemical), p-myosin light chain (MLC) and MLC, 
p-ERK1/2 and ERK1/2, p-p38 MAPK and p38 MAPK, p-JNK and JNK, p-Akt 
and Akt (1:1,000; Cell Signaling, Boston, MA, USA). Detection was 
accomplished using horseradish peroxidase-coupled anti-rabbit (1:2,000; Bio-
Rad) or anti-mouse (1:5,000; Stressgen, Victoria, Canada) IgG antibodies for 1 
h at room temperature. Blots were stripped and then probed with antibodies 
against β-actin (1:50,000; Sigma-Aldrich) or tubulin (1:10,000; Sigma-Aldrich). 
Signal was detected using the Luminata Forte (Millipore Corporation, Billerica, 
MA, USA) detection system. Immunoblot signals were quantified using NIH 
ImageJ using β-actin or tubulin expressions as loading controls. Nucleoporin 
and tubulin were used to discard nuclear or cytoplasmic contamination in 
cytoplasmic or nuclear fractions, respectively. Variations of protein expressions 
were calculated as fold increase over controls. 
6. RIBONUCLEOPROTEIN COMPLEX IMMUNOPRECIPITATION 
Ribonucleoprotein complex immunoprecipitation was performed as 
described (Lal et al., 2004). Cells were lysed in polysome lysis buffer (20 
mmol/L Tris-HCl pH 7.5, 150 mmol/L NaCl, 5 mmol/L MgCl2, 1 mmol/L DTT, 
0.5% NP-40, 1 mmol /L PMSF, protease inhibitors, 100 U RNAse inhibitor). 200 
μg of cytoplasmic lysate were incubated with anti-HuR antibody or control IgG 
precoated to protein A/G PLUS agarose (Santa Cruz Biotechnology) overnight 
at 4°C in NT2 buffer (50 mmol/L Tris-HCl pH 7.5, 150 mmol/L NaCl, 1 mmol/L 
MgCl2, 0.05% NP-40) adding 0.1 mmol/L DTT, 40 U RNAse inhibitor, 5 mmol/L 
EDTA and 100 μg/mL tRNA. Immunoprecipitates were collected by 
centrifugation and washed 4 times with NT2 buffer. Total RNA was isolated 
from immunoprecipitates using 1 mL TRIzol reagent and then used for cDNA 
synthesis and qPCR as described above. 
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7. PLASMID CONSTRUCTS 
Constructs included in Figure 31 were performed in our laboratory or kindly 
provided by other groups.  
The 537 bp of NOX-4 3’UTR DNA fragment was obtained by a nested PCR 
using human VSMC gDNA as a template and the following sets of primers, first 
primer set: FW: CATACTTCTTGTCATGTTCTGC, RV: 
TTTGAGGAAGGTTCAGTTAGC and XbaI-containing second primer set: FW: 
GCTCTAGAAAACTGAGTAACCAGAACAAC, RV: 
GCTCTAGATTTGCCTGGAGTGCTTGC. 1% agarose gel was used to separate 
the second PCR product and gel-purified (Qiagen, Valencia, CA, USA). The 
product was ligated overnight at 16 ºC to 100 ng of pGEM-T (Promega 
Corporation, Madison, WI, USA) in a ratio 1:3 (vector:insert) with T4 DNA ligase 
(New England Biolabs, Beverly, MA, USA), transformed in competent XL1-Blue 
bacteria (Stratagene, La Jolla, CA, USA) and plated on Petri dishes containing 
agar. Clones were selected 16 h with ampicillin as well as X-Gal and IPTG at 
37ºC (blue-white screening). White colonies were picked up using a toothpick 
and allowed to expand (20 h, 37ºC, 250 rpm) in LB medium with 100 µg/mL of 
ampicillin. Plasmid DNA were isolated from each colony using a miniprep kit 
(Qiagen) and submitted to automated sequencing. 1.3 µg of positive colony 
DNA were digested with XbaI restriction enzyme (Roche Applied Science) at 37 
ºC for 2 h. and the DNA fragment gel-purified. pGL3 control vector (Promega 
Corporation, Madison, WI, USA) was digested by XbaI, dephosphorylated with 
alkaline phosphatase (SEAP, Roche Applied Science), gel-purified and 100 ng 
were ligated in a ratio 1:3 (vector:insert) to the XbaI insert. After bacterial 
transformation and plasmid DNA isolation, correct insert orientation was verified 
by restriction using BamHI and NdeI restriction enzymes (Roche Applied 
Science). 
The Elf-3 dominant negative mutant was obtained by subcloning Elf-3 DNA 
binding domain (Elf-3-DBD) into the pGEM-T as follows: the Elf-3-DBD (450 bp) 
fragment was obtained by PCR using Taq polymerase (AmpliTaq Gold, Life 
Technologies), piRES-puro-Elf-3 (Addgene, www.addgene.org) as a template 
and EcoRI-containing forward primer: GGGAATCGATGGTTTTCGTGACTGC, 
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and XbaI-containing reverse primer:  GGTCTAGATCAGTTCCGACTCTGGAG. 
Positive clones were analyzed by restriction. pGEM-T Elf-3-DBD was digested 
with EcoRI and XbaI, cloned into the pEGFP-C2 plasmid (Clontech 
Laboratories, Palo Alto CA, USA) carrying a kanamycin resistance and verified 
by automated sequencing. During the cloning steps a punctual missense 
mutation was introduced. This mutation was reverted to the wild type sequence 
by site-directed mutagenesis (QuikChange, Stratagene) using the following 
primers: CGTGACTGCAAGaAGGGGGATCCCAAGC and 
GCTTGGGATCCCCCTtCTTGCAGTCACG and verified by automated 
sequencing. 
 The luciferase reporter vector containing the human 3.9 kb of COX-2 
promoter (pGL3-COX-2P) and the human 3’-UTR of COX-2 (from 3074 to 3236) 
(pGL3P-UTR2) were kindly provided by Dr. W. Eberhardt (Klinikum der Johann 
Wolfgang Goethe-Universitat Frankfurt am Main, Germany, Doller et al., 2008)  
2,700 bp of the rat NOX-1 promoter (-2547 +125) called pGL3/3 were kindly 
provided by Dr. J. Pfeilschifter (University of Frankfurt Medical School, 
Germany) and cloned as described previously (Plesková et al., 2006). 
The luciferase reporter vector containing NOX-4 promoter and the deletion 
mutants of human NOX-4 promoter were kindly provided by Dr. A. Manea 
(Institute of Cellular Biology and Pathology “Nicolae Simionescu”, Romania, 
Manea et al., 2010a). 
630 bp of human NOX-1 3’UTR pGL3 control was purchased from Genewiz 
Inc. (South Plainfield, NJ, USA). Briefly, NOX-1 3’UTR was cloned in the XbaI 
site of the pGL3 control checking the orientation. 
Human NOX-4/EGFP were kindly provided by Dr. L. Terada (University of 
Texas Southwestern Medical Center, Dallas, Texas, USA) and cloned as 
described previously (Wu et al., 2010). 
Egr-1 expression was accomplished using Flag-tagged Egr-1 cDNA cloned 
in pcDNA3.1/Zeo+. 
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Figure 31. Scheme of the constructs. The sequences of interest cloned in the 
vectors are shown in pink. Nucleotide number is also indicated. Luciferase gene (Luc) 
(orange), SV40 promoter (blue), cytomegalovirus (CMV) promoter (purple) and EGFP 
(green) are also shown.  
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8. DNA AND siRNA TRANSFECTIONS 
Cells were seeded in 12-well culture plates at a density of 6×104 cells per 
well and incubated overnight. Next day, the medium was replaced with DMEM-
F12 with 10% FBS and glutamine without antibiotics because of their toxicity in 
the presence of liposomes. Then cells were transiently transfected with 0.5 μg 
luciferase reporter gene construct per well using the Lipofectamine LTX Plus 
reagent prepared in Opti-Mem (Life Technologies) in a ratio Plus:LTX 1:2.5. 
After 6 h, media was changed and cells were transferred to depletion medium 
overnight. After stimulation, cells were washed with PBS and harvested in 80 μL 
of reporter lysis buffer. Luciferase activities of 20 µL of cell lysate were 
measured using a luminometer (Orion I, Berthold detection systems, Oak 
Ridge, TN, USA) according to the manufacturer’s instructions. Relative 
luciferase activities were normalized to total protein. Variations of activity were 
calculated as fold increase over controls or over controls with the corresponding 
inhibitor. 
Cells seeded in 6-well plates or transwells at a density of 1.2×105 or 3×104 
cells per well, respectively, were transfected with a predesigned siRNA against 
HuR or a negative control siRNA (Life Technologies) using the Lipofectamine 
LTX Plus reagent (Life Technologies) as described above. Cells were 
transfected for 48 h with 20 nmol/L siRNA and silencing efficiency was 
determined by qPCR or western blot. 
9. CELL VIABILITY ASSAY 
Cell viability was assessed using the CellTiter 96 Non-Radioactive Cell 
Proliferation Assay MTT (Promega). This assay is a colorimetric method based 
on the reduction of a tetrazolium salt in formazan using the cellular NADPH or 
NADH. The formazan product is insoluble in culture medium and precipitates, 
and it is directly proportional to the number of living cells in culture. 
8×103 cells were seeded on 96-well plates in DMEM-F12 medium and were 
allowed to attach for 24-48 h. After stimulation, cell survival was quantified by 
adding MTT tetrazolium solution (10 μL per well). After 4 hours of incubation at 
37 ºC, medium was removed and 50 μL of 0.1 N HCl in isopropanol were added 
and mixed to dissolve the salts. Absorbance was measured at 540 nm in an 
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ELx800 Absorbance Microplate Reader (BioTek Instruments, Inc., Winooski, 
VT, USA). The experiments were performed in duplicates. Blank was 
subtracted. Variations of viability were calculated as fold increase over controls. 
10. CELL MIGRATION ASSAYS  
VSMC migration was examined using a 6.5 mm Transwell chamber with an 
8 μm pore size (Corning Costar Inc., Corning, New York, NY, USA). 3×104 cells 
were resuspended in 100 µL of medium with 10% FBS and were seeded in the 
upper compartment. The lower compartment of the transwell was ﬁlled with 600 
µL of the same medium. Next day, medium were removed and changed by 
serum free medium in both compartments maintaining the same volumes 
(Figure 32). 
 
Figure 32. Transwell Assay. Cells are seeded on a porous membrane and the 
chemoattractant solution is placed in the lower compartment where it diffuses into the 
upper compartment forming a gradient across the membrane. Cells respond by 
migrating through the membrane to the bottom surface where they can be 
subsequently fixed, stained and counted. Taken from Keenan and Folch, 2008. 
24 h later cells were pretreated or transfected in the upper compartment 
and then stimuli were added in the bottom compartment. Cells were allowed to 
migrate 5 or 24 h. Afterwards, cells of the upper membrane surface were 
removed with a cotton swab and the membrane was washed with PBS, fixed in 
4% paraformaldehyde (PFA) during 10 min and washed twice in PBS. Hoechst 
33342 (10 μg/mL) was used to stain the nuclei of the migrating cells. 
Membranes were cut and put over a slide with anti-fading mounting medium 
and sealed with nail polish. Migration values were determined by counting three 
fields per chamber in a confocal Leica TCS SP2 with a 40X objective and 
calculated as fold increase over controls. 
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Cell migration in response to physical damage was determined using a 
wound healing assay. Cells were seeded in a 24-well plate and when they 
reached 90% of confluence, they were starved 24 h. VSMC monolayers were 
wounded using a sterile 10 μL pipette tip. Phase contrast images were taken 
immediately (0 h) and 24 h after wounding using a Nikon microscope (Tokyo, 
Japan) connected to a video camera (Sony Corporation, Tokyo, Japan). To 
measure migration, wound area was quantified using Adobe Photoshop and 
expressed as percentage of wound closure over controls or over controls with 
the corresponding inhibitor. 
11. IMMUNOFLUORESCENCE MICROSCOPY 
Cells were seeded in coverslips in the well. At 60% of confluence, cells 
were serum starved overnight and then stimulated 24 h. Cells were rinsed with 
PBS, fixed with 4% paraformaldehyde (10 min), permeabilized with 0.2% Triton-
PBS, blocked with 3% BSA in PBS (1 h) and incubated overnight at 4°C with 
anti-HuR monoclonal primary antibody diluted 1:200 in blocking solution. The 
fluorescein isothiocyanate–conjugated secondary IgG antibody was incubated 2 
h at room temperature (1:200; Jackson ImmunoResearch, West Grove, PA, 
USA). After washing, coverslips were incubated 10 min with Hoechst 33342 
(Life Technologies) mounted on slides and examined using an Evos XL Cell 
Imaging System with a 40X objective. A negative control using only the 
secondary antibody was used to adjust the fluorescence. Images were 
processed using Adobe Photoshop CS3 software (Adobe Systems Inc., San 
Jose, CA). 
For tissue immunofluorescence, aortic segments of control and AngII-
infused mice were fixed with 4% PFA for 1 h. After three washes of 10 min with 
PBS, arteries were incubated 30 min in a sucrose solution (0.1 M PBS and 30% 
sucrose), immersed in OCT tissue-tek mounting medium (Sakura finetek 
Europe B. V, Flemingweg, Netherland), frozen in liquid nitrogen and stored at -
80 ºC. Fixed aortas were cut in cross sections of 14 μm in a cryostat and 
mounted in gelatinized slides. Then, slides were air-dried 90 min, blocked 1 h at 
37 ºC in 0.1 M PBS containing 5% BSA and 0.4 % Triton X100  and incubated 2 
h with a mouse anti-HuR (Santa Cruz Biotechnology Inc) diluted 1:100 in 0.1 M 
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PBS containing 0.3 % Triton X100 and 2% BSA. After washing, slides were 
incubated with a mouse CyTM3-conjugated secondary IgG (1:200; Jackson 
ImmunoResearch). All incubations were done in a humid chamber. Pictures 
were taken in a Leica TCS SP2 with a 63X objective. The specificity of the 
immunostaining was evaluated by omission of the primary antibody and 
processed as above. 
12. HISTOLOGICAL ANALYSIS 
14-µm cross sections from fixed aortas were stained with hematoxylin-
eosin. All images were acquired at room temperature using a microscope 
(DM2000; Leica) with 10X objective. Morphometric determinations of the lumen 
and vessel areas were performed by using Metamorph image analysis software 
(Molecular Devices, Downington, PA, USA). All microscopic images of the 
sections were traced for the calculations of the areas. To determine the luminal 
area, the cross-sectional area enclosed by the internal elastic lamina was 
corrected to a circle by applying the form factor l2/4π to the measurement of the 
internal elastic lamina, where l is the length of the lamina. Vessel area was 
determined by the cross-sectional area enclosed by the external elastic lamina 
corrected to a circle, applying the same form factor (l2/4π) to the measurement 
of the external elastic lamina. The media area was calculated as the difference 
between the corrected vessel and luminal areas. Internal and external 
diameters were calculated from luminal and vessel areas, respectively. This 
method avoids miscalculations of areas caused by eventual collapse of the 
immersion-fixed arteries. 
13. IMMUNOHISTOCHEMISTRY 
Mouse aortas were perfused with PBS and fixed in 4% PFA for 24 h, 
embedded in paraffin and prepared in 5-14 μm cross sections with a microtome 
(Jung RM 2055, Leica). Sections from aorta were deparaffinized in xylene and 
rehydrated in graded ethanol solutions. Slides were then rinsed in distilled water 
and treated with 10% hydrogen peroxide in methanol for 30 min to remove 
endogenous peroxidase activity. Sections were blocked with a 10% of normal 
serum in PBS-Tween 0.1% for 30 min and incubated with anti-HuR (1/100), 
anti-COX-2 (1/100), anti-mPGES-1 (1/100), and anti-TXAS (1/50) antibodies 
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overnight at 4°C. After washing 3 times in PBS-Tween 0.1%, samples were 
incubated for 1 h with a biotinylated secondary antibody (Vector Laboratories). 
After rinsing 3 times in PBS, standard Vectastain (ABC) avidin-biotin peroxidase 
complex (Vector Laboratories, Burlingame, CA, USA) was applied, and the 
slides were incubated for 30 min. Color was developed using 3,3’-
diaminobenzidine and sections were counterstained with haematoxylin before 
dehydration, clearing, and mounting. Negative controls in which the primary 
antibody was omitted were included to test for non-specific binding. 
14. NADPH OXIDASE ACTIVITY 
The O2•− production generated by NADPH oxidase activity was determined 
by a chemiluminescence assay using lucigenin. Lucigenin is an aromatic 
compound, which can be reduced by O2•− producing light. This light is read by a 
luminometer. 
Cells were rinsed with PBS and harvested in phosphate buffer pH 7.4 (50 
mmol/L KH2PO4, 1 mmol/L EGTA, 150 mmol/L sucrose). The O2•− production 
generated by NADPH oxidase activity was determined by a chemiluminescence 
assay using lucigenin (5 μmol/L; Sigma-Aldrich) and NADPH (100 μmol/L; 
Sigma-Aldrich). The reaction was started by the addition of a lucigenin/NADPH 
mixture to the protein sample in a final volume of 250 μL. Chemiluminescence 
was determined every 2.4 seconds for 5 min in a plate luminometer (Berthold 
Detection System, Sirius, Pforzheim, Germany). Basal activity was subtracted 
from each reading. Luminescence was normalized by protein concentration 
measured by the Lowry assay and data were expressed as fold increase over 
the control or over controls with the corresponding inhibitor.  
15. DETECTION OF REACTIVE OXYGEN SPECIES BY FLUORESCENCE 
MICROSCOPY 
The oxidative fluorescent dye dihydroethidium (DHE) was used to evaluate 
ROS production in situ in VSMC. Hydroethidine freely permeates cells and is 
oxidized in the presence of ROS to ethidium bromide, which is retained in the 
nucleus by intercalation with DNA. Ethidium bromide is excited at 535 nm and 
emitted at 610 nm.  
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VSMC were plated onto glass coverslips inserted into 6-well plates and 
cultured. When the cells reached 60-80% they were stimulated. Afterwards, 
cells were loaded with DHE (10 µmol/L; Sigma-Aldrich) in cell culture medium 
for 30 min at 37ºC and then rinsed with serum-free medium. Coverslips were 
mounted on a slide and visualized with a confocal microscope (Leica TCS SP2 
with a 40X objective) using the same imaging settings in all experimental 
conditions. Fluorescence intensity was measured using Metamorph image 
analysis software (Molecular Devices). Variations of fluorescence intensity were 
calculated as fold increase over controls or over controls with the corresponding 
inhibitor. 
16. H2O2 RELEASE 
The Amplex Red reagent in combination with horseradish peroxidase 
(HRP), has been used to detect H2O2 released from biological samples. In the 
presence of peroxidase, the Amplex Red reagent reacts with H2O2 in a 1:1 
stoichiometry to produce the red-fluorescent oxidation product, resorufin. 
Resorufin has excitation and emission maxima of approximately 571 nm and 
585 nm respectively and the signal can be measured fluorometrically or 
spectrophotometrically.  
Cells were seeded in 12-well plate, transfected with NOX-4/EGFP, EGFP 
alone or without transfection and then stimulated 24 h. In order to prevent 
interference with the resorufin measurement, we used phenol red-free medium. 
Supernatants were used to determine H2O2 release and cell lysates to measure 
total protein content. Amplex Red (100 µmol/L; Sigma-Aldrich) and horseradish 
peroxidase type II (0.2 U/mL; Sigma-Aldrich) were added to 50 µL of 
supernatants. Fluorescence readings were made in duplicate in a 96-well plate 
at Ex/Em = 530/580 nm. H2O2 concentration was estimated using a standard 
curve between 0-4.8 μmol/L of H2O2. Total protein of cell lysates as well as the 
volume of the supernatants was measured in order to normalize H2O2 values.  
17. REAGENTS 
Acrylamide (N,N’-Methylenebisacrylamide) (Bio-Rad) 
Actinomycin D (Sigma-Aldrich) 
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Agarose (Bio-Rad) 
Angiotensin II human acetate (Sigma-Aldrich) 
BSA (Bovine serum albumin) (Sigma-Aldrich) 
Celecoxib (generously provided by Pfizer Inc) 
Chelerytrhine (Tocris, Biogen Científica, Spain) 
Chloroform (Merck) 
Cycloheximide (4-[(2R)-2-[(1S,3S,5S)-3,5-Dimethyl-2-oxocyclohexyl]-2-
hydroxyethyl]piperidine-2,6-dione) (Sigma-Aldrich) 
DEPC (Diethylpyrocarbonate) (Sigma-Aldrich) 
DMSO (Dimethyl sulfoxide) (Merck) 
DTT (Dithiothreitol) (Promega) 
EDTA (Ethylenediaminetetraacetic acid) (Sigma-Aldrich) 
EGTA (ethylene glycol tetraacetic acid) (Sigma-Aldrich) 
Ethanol (Merck)  
Furegrelate 5-(3-pyridinylmethyl)-2-benzofurancarboxylic acid, sodium salt) 
(Cayman Chemical) 
Glycine (Sigma-Aldrich) 
Glycerol (Panreac, Castellar del Vallés, Barcelona, España) 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (Sigma-Aldrich) 
Interleukin 1β mouse (Sigma-Aldrich) 
Isopropanol (Merck) 
KN93 (N-[2-[N-(4-Chlorocinnamyl)-N-methylaminomethyl]phenyl]-N-(2-
hydroxyethyl)-4-methoxybenzenesulfonamide phosphate salt ) (Calbiochem, 
Darmstadt, Germany) 
L798106 (N-[(5-Bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-
naphthalenylmethyl)phenyl]-2-propenamide) (Sigma-Aldrich)  
LY294002 (2-Morpholin-4-yl-8-phenylchromen-4-one) (Calbiochem) 
Magnesium chloride (Panreac) 
ML171 (2-Acetylphenothiazine) (Sigma-Aldrich) 
MS-444 (generously provided by Novartis, Basil, Switzerland) 
NP-40 (Igepal) (Octylphenoxy)polyethoxyethanol) (Sigma-Aldrich) 
Ozagrel ((2E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]acrylic acid) (generously 
provided by Kissei Pharmaceutical CO, Matsumoto, Japan) 
Paraformaldehyde (Panreac) 
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PD98059 (2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one) 
(AlomoneLabs) 
PMSF (phenylmethanesulfonyl fluoride) (Sigma-Aldrich) 
Potassium Chloride (Panreac) 
Potassium hydrogen phosphate (Panreac) 
RNAase inhibitor (Promega, Mannheim, Germany) 
Rofecoxib (4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one) (LKT 
Laboratories Inc. St Paul, MN, USA) 
SB203580 (4-(4’-Fluorophenyl)-2-(4’-methylsulfinylphenyl)-5-(4’-pyridyl)-
imidazole) (Calbiochem) 
SC19220 (2-Acetylhydrazide 10(11H)-carboxylic acid) (Sigma-Aldrich) 
Sodium chloride (Panreac) 
Sodium deoxicholate (Sigma-Aldrich) 
Sodium fluoride (Sigma-Aldrich) 
Sodium orthovanadate (Sigma-Aldrich) 
SP600125 (1,9-Pyrazoloanthrone, Anthrapyrazolone) (Calbiochem)  
SQ29548 ([1S-[1α,2α(Z),3α,4α]]-7-[3-[[2-
[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-
heptenoic acid) (ICN Iberica, Barcelona, Spain) 
Suberoylanilide hydroxamic acid (N-hydroxy-N’-phenyl-octanediamide) (Sigma-
Aldrich) 
Sucrose (Merck) 
SDS (sodium dodecyl sulfate) (Bio-Rad) 
Tris (tris(hydroxymethyl)aminomethane) (Bio-Rad) 
Triton X100 (Sigma-Aldrich) 
tRNA (Promega) 
Tyrphostin AG1478 (N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine) 
(AlomoneLabs, Jerusalem, Israel) 
Trichostatin (7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-
2,4-dienamide) (Sigma-Aldrich) 
Tween-20 (Bio-Rad) 
U0126 (1,4-diamino-2,3-dicyano-1,4-bis 
(2-aminophenylthio)butadiene) (Calbiochem, Darmstadt, Germany) 
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U46619 ((Z)-7-[(1S,4R,5R,6S)-5-[(E,3S)-3-hydroxyoct-1-enyl]-3-
oxabicyclo[2.2.1]heptan-6-yl]hept-5-enoic acid) (Cayman Chemical) 
W7 (N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide) (Calbiochem) 
W12 (N-(4-aminobutyl)-1-naphthalenesulfonamide) (Calbiochem) 
β-glycerophosphate (Sigma-Aldrich) 
β-mercaptoethanol (Bio-Rad) 
5-aza-2’-deoxycytidine (2′-Deoxy-5-azacytidine, 4-Amino-1-(2-deoxy-β-D-
ribofuranosyl)-1,3,5-triazin-2(1H)-one) (Sigma-Aldrich) 
16,16-dimethyl Prostaglandin E2) (Calbiochem) 
General reagents of the laboratory were purchased from different providers 
such as Sigma-Aldrich or Merck. 
18. DATA ANALYSIS AND STATISTICS 
Data analysis was performed using GraphPad Prism software (GraphPad 
Software, San Diego, CA, USA). All values are expressed as mean ± SEM of 
the animals used in each experiment or independent cell culture-based 
experiments. Statistical analysis was done by Student’s t test, Mann-Whitney 
test or by one-way ANOVA followed by a Bonferroni test. Values were 
considered to be significant when P<0.05. 
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1. HuR MEDIATES THE SYNERGISTIC EFFECTS OF ANGII AND IL-1β ON 
VASCULAR COX-2 EXPRESSION AND CELL MIGRATION 
1.1. ANGII AND IL-1β SYNERGISTICALLY INDUCE COX-2 EXPRESSION 
IN VSMC THROUGH ERK1/2 PATHWAY 
In basal conditions, rat VSMC express low-to-undetectable COX-2 mRNA 
and protein levels and after 24 h stimulation with either AngII (0.1 μmol/L) or IL-
1β (10 ng/mL), a modest increase in COX-2 expression was observed (Figure 
33). However, co-stimulation of rat VSMC with AngII and IL-1β led to a 
synergistic increase in COX-2 mRNA and protein levels (Figure 33). 
 
Figure 33. AngII potentiates IL-1β-induced COX-2 expression in rat VSMC. Effect 
of AngII, IL-1β and AngII+IL-1β (24 h) on COX-2 mRNA levels (A) and protein 
expression (B) in rat VSMC. Data are expressed as mean ± SEM. *p<0.05, **P<0.01 vs 
Control; †P<0.05, ††P<0.01 vs AngII or IL-1β. n=4-9.  
The exacerbated induction of COX-2 mRNA in the presence of AngII+IL-1β was 
observed to occur as early as 1 h after stimulation and persisted out to 24 h with 
enhanced COX-2 protein expression being observed at 24 h (Figure 34). 
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Figure 34. Effect of AngII, IL-1β and AngII+IL-1β on COX-2 expression. Time 
course of COX-2 mRNA levels (A) and protein expression (B) in rat VSMC. Data are 
expressed as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 vs unstimulated cells. n=5-7. 
Similar effects of AngII, IL-1β and AngII+IL-1β on COX-2 expression were 
observed in human VSMC indicating that this effect is conserved and adding to 
this finding an additional relevance (Figure 35). 
 
 
 
 
 
 
Figure 35. AngII potentiates IL-1β-induced COX-2 expression in human VSMC. 
Effect of AngII, IL-1β or AngII+IL-1β (24 h) on COX-2 mRNA levels in human VSMC. 
Data are expressed as mean ± SEM. *P<0.05, **P<0.01; †P<0.05 vs AngII or IL-1β. 
n=6-7. 
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MAPK pathways are involved in COX-2 expression induced by AngII in 
different cell types (Ohnaka et al., 2000; Pham et al., 2008; Galán et al., 2011). 
AngII also activates Akt pathway in VSMC (Takahashi et al., 1999). Therefore, 
we analyzed the involvement of these signaling pathways in the synergistic 
effect of AngII and IL-1β on COX-2 expression. As expected, AngII, IL-1β and 
AngII+IL-1β promoted rapid phosphorylation of ERK1/2, JNK, p38 MAPK and 
Akt (Figure 36).  
 
Figure 36. Effect of AngII, IL-1β and AngII+IL-1β on ERK1/2, JNK, p38 MAPK and 
Akt activation. Quantification of the time course activation of ERK1/2 (A), JNK (B) and 
p38 (C) MAPK and Akt (D) in response to AngII, IL-1β and AngII+IL-1β in rat VSMC.  
(E) representative blots of MAPK and Akt activation in response to AngII+IL-1β. Data 
are expressed as mean ± SEM. *P<0.05 vs unstimulated cells. n=4-9. 
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Interestingly, the ERK1/2 inhibitor (U0126, 10 μmol/L) decreased the AngII+IL-
1β-induced COX-2 mRNA expression, whereas the JNK (SP600125, 20 
μmol/L), p38 MAPK (SB203580, 10 μmol/L) and PI3K (LY294002, 10 μmol/L) 
inhibitors did not (Figure 37). These results suggest that ERK1/2 is implicated in 
AngII+IL-1β-induced COX-2 expression.  
 
 
 
 
 
 
 
Figure 37. AngII potentiates IL-1β-induced COX-2 expression in VSMC through 
ERK1/2. Effect of MAPKs inhibitors (U: U0126; SP: SP600125; SB: SB203580) and 
PI3K inhibitor (LY: LY294002) on COX-2 mRNA levels induced by AngII+IL-1β (4 h). 
Data are expressed as mean ± SEM. ***P<0.001 vs Control; ‡‡‡P<0.001 vs AngII+IL-1β. 
n=4-9.  
1.2. HuR IS INVOLVED IN THE COX-2 mRNA STABILIZATION INDUCED 
BY ANGII IN VSMC 
COX-2 expression is regulated by both transcriptional and post-
transcriptional mechanisms (Harper and Tyson-Capper, 2008). Previous studies 
in intestinal epithelial cells, human mesangial cells and adventitial fibroblasts 
demonstrated transcriptional activation of COX-2 expression and changes in 
COX-2 mRNA stability in response to AngII (Pham et al., 2008; Doller et al., 
2008; Galán et al., 2011). To determine whether the effect of AngII on IL-1β-
induced COX-2 expression was due to changes in transcription, COX-2 
transcriptional activity was measured in VSMC transfected with a reporter 
plasmid containing the human COX-2 promoter fused to luciferase cDNA. As 
expected, IL-1β increased COX-2 promoter activity but the combination of 
AngII+IL-1β resulted in a similar transcriptional activity (Figure 38).  
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Figure 38. IL-1β and AngII+IL-1β increases COX-2 promoter activity. Rat VSMC 
were transiently transfected with the luciferase reporter construct containing COX-2 
promoter. Luciferase activity was assayed in untreated (control) VSMC and after 
incubation with AngII+IL-1β (4 h). Data are expressed as mean ± SEM. *P<0.05, 
***P<0.001 vs Control. n=5-7. 
These results suggested post-transcriptional regulatory mechanisms to be the 
primary effector of the synergistic induction of COX-2 expression in response to 
AngII+IL-1β. To test this hypothesis, we performed mRNA stability assays. 
Figure 39A shows that AngII stabilized COX-2 mRNA in IL-1β-triggered VSMC. 
Accordingly, mRNA stability in AngII+IL-1β treated cells was greater than in 
control cells (Figure 39A). We also performed transfections of VSMC using a 
luciferase reporter plasmid containing a 150 bp 3’UTR from COX-2 mRNA, 
which included the binding site for HuR. Figure 39B shows that both stimuli 
were needed to increase COX-2 3’UTR luciferase activity.  
 
 
 
 
 
Figure 39. The synergistic effect of AngII and IL-1β on COX-2 expression in 
VSMC is due to an increase of COX-2 mRNA stability mediated by HuR. A, Effect 
of U0126 and MS-444 on COX-2 mRNA stability in cells stimulated with AngII+IL-1β for 
24 h. Effect of IL-1β is also shown. Actinomycin D was added for the indicated times 
and COX-2 mRNA levels were measured by qPCR. B, Rat VSMC were transfected 
with a luciferase reporter construct containing the COX-2 3’-UTR. Luciferase activity 
was assayed in untreated (control) VSMC and after incubation with IL-1β and AngII+IL-
1β (24 h). Data are expressed as mean ± SEM. **P<0.01, ***P<0.001 vs Control; 
†††P<0.001 vs IL-1β; ‡‡P<0.01, ‡‡‡P<0.001 vs AngII+IL-1β. n=4-8. 
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In unstressed cells, the mRNA binding protein HuR is predominantly 
localized to the nucleus (>90%) and can be exported to the cytoplasm to 
stabilize different mRNAs including COX-2 mRNA (Dixon et al., 2001; Young et 
al., 2012). We explored the role of HuR on COX-2 expression induced by 
AngII+Il-1β. As shown in Figure 40, treatment of VSMC with AngII+IL-1β 
increased HuR cytoplasmic localization and this effect was abolished by 
ERK1/2 (+PD98059, 20 μmol/L) or HuR (+MS-444, 8 µmol/L) inhibition. 
 
Figure 40. HuR is translocated to the cytoplasm in the presence of AngII+IL-1β. 
A, Effect of PD98059 and MS-444 on HuR subcellular localization assayed by HuR 
immunofluorescence. B, Western blotting of cellular fractions from VSMC unstimulated 
(control) or stimulated with AngII+IL-1β (24 h). n=4-8. 
Consistent with these observations on HuR trafficking, another ERK1/2 inhibitor 
(U0126, 10 μmol/L) and MS-444 also abolished the increased stability of COX-2 
mRNA observed in AngII+IL-1β-stimulated VSMC (Figure 39A). Moreover, MS-
444 or HuR knockdown by siRNA (Figure 41A) reduced COX-2 mRNA levels 
induced by AngII+IL-1β (Figures 41B and 41C).  
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Figure 41. HuR blockade decreases COX-2 expression induced by AngII+IL-1β. A, 
HuR expression in cells transfected with control or HuR siRNA. Effects of MS-444 (B) 
and HuR siRNA (C) on COX-2 mRNA levels in VSMC stimulated with AngII+IL-1β (24 
h). Data are expressed as mean ± SEM. **P<0.01, ***P<0.001 vs Control; ‡‡P<0.01 vs 
AngII+IL-1β. n=4-8. 
MS-444 was originally characterized as MLC kinase (MLCK) inhibitor in the 
µmol/L-range (Aotani et al., 1995). However, the concentration used in these 
experiments did not affect MLC phosphorylation induced by AngII+IL-1β (Figure 
42A) or cell viability (Figure 42B).  
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Figure 42. MS-444 does not affect myosin light chain kinase activity or cell 
viability of VSMC. A, Quantification and representative blots of the effect of MS-444 
on p-MLC and MLC expression in VSMC treated with AngII+IL-1β (24 h). B, 
Concentration-dependent effect of MS-444 on cell viability in control or AngII+IL-1β-
treated VSMC. Data are expressed as mean ± SEM. *P<0.05 vs Control. n=5-7. 
To determine if AngII+IL-1β signaling promotes increased cytoplasmic HuR 
binding to COX-2 mRNA, ribonucleoprotein immunoprecipitation was done. 
Cytoplasmic lysates of VSMC unstimulated or stimulated 24 h with AngII+IL-1β 
were immunoprecipitated using an antibody against HuR or control IgG. The 
association of COX-2 mRNA with HuR was assayed by qPCR of COX-2 mRNA 
in immunoprecipitates. We observed an enrichment in COX-2 mRNA in anti-
HuR precipitates from cells treated with AngII+IL-1β, but not in unstimulated 
cells or in anti-IgG precipitates (Figure 43A). GAPDH mRNA co-precipitation 
was used as control to assess the nonspecific background (Figure 43B).  
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Figure 43. HuR binds to COX-2 mRNA. Ribonucleoprotein immunoprecipitation of 
HuR or control IgG was done to isolate COX-2 mRNA (A) or GAPDH (B) bound to HuR 
in VSMC unstimulated (control) or stimulated with AngII+IL-1β (24 h). Data are 
expressed as mean ± SEM. *P<0.05 vs Control. n=4. 
All together, these findings suggest that AngII+IL-1β induce an ERK1/2-
dependent activation of HuR that is responsible for increased COX-2 mRNA 
stability and COX-2 levels in VSMC.  
1.3. EFFECT OF ANGII AND IL-1β ON mPGES-1, PGIS AND TXAS 
EXPRESSION IN RAT AND HUMAN VSMC 
To assess whether prostanoid synthases were also regulated by AngII, IL-
1β or the combination of both, we measured mPGES-1, PGIS and TXAS mRNA 
and protein levels. Rat VSMC express low-to-undetectable mPGES-1 mRNA 
and protein levels (Figure 44). IL-1β treatment led to a time-dependent increase 
in mPGES-1 mRNA levels, whereas AngII treatment decreased mPGES-1 
mRNA; accordingly, AngII+IL-1β increased mPGES-1 mRNA levels less than 
IL-1β alone (Figures 44A). Similar results were observed when mPGES-1 
mRNA and protein levels were examined only at 24 h stimulation (Figure 44B 
and 44C).  
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Figure 44. Effect of AngII, IL-1β and AngII+IL-1β on mPGES-1 expression. A, Time 
course of mPGES-1 mRNA levels in rat VSMC stimulated with AngII, IL-1β or AngII+IL-
1β. Effect of AngII, IL-1β or AngII+IL-1β (24 h) on mPGES-1 mRNA levels (B) and 
protein expression (C). Representative blots are also shown. Data are expressed as 
mean ± SEM. *P<0.05, ***P<0.001 vs unstimulated (control) cells; †P<0.05 vs AngII or 
IL-1β. n=4-8. 
In contrast to mPGES-1 expression, PGIS mRNA and protein levels were 
significantly induced by AngII and not affected by IL-1β (Figure 45); the effects 
of AngII+IL-1β on PGIS mRNA and protein were similar to those produced by 
AngII alone (Figure 45).  
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Figure 45. Effect of AngII, IL-1β and AngII+IL-1β on PGIS expression. A, Time 
course of PGIS mRNA levels in rat VSMC stimulated with AngII, IL-1β or AngII+IL-1β. 
Effect of AngII, IL-1β or AngII+IL-1β (24 h) on PGIS mRNA levels (B) and protein 
expression (C). Representative blots are also shown. Data are expressed as mean ± 
SEM. *P<0.05, **P<0.01, ***P<0.001 vs unstimulated (Control) cells. n=4-7. 
TXAS mRNA levels were increased in a time-dependent manner by IL-1β, AngII 
and AngII+IL-1β (Figures 46A and 46B). At protein level, all stimuli slightly but 
significantly increased TXAS levels (Figure 46C).  
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Figure 46. Effect of AngII, IL-1β and AngII+IL-1β on TXAS expression. A, Time 
course of TXAS mRNA levels in rat VSMC stimulated with AngII, IL-1β or AngII+IL-1β. 
Effect of AngII, IL-1β or AngII+IL-1β (24 h) on TXAS mRNA levels (B) and protein 
expression (C). Representative blots are also shown. Data are expressed as mean ± 
SEM. *P<0.05, **P<0.01 vs unstimulated (Control) cells. n=4-7. 
When exposed during 24 h to AngII and/or IL-1β, human VSMC showed a 
similar pattern that rat VSMC in mPGES-1, PGIS and TXAS mRNA levels 
except PGIS which was also induced by IL-1β in human cells (Figure 47). 
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Figure 47. AngII and IL-1β regulate differentially mPGES-1, PGIS and TXAS 
expressions in human VSMC. Effect of AngII, IL-1β or AngII+IL-1β (24 h) on mPGES-
1 (A), PGIS (B) and TXAS (C) mRNA levels in human VSMC. Data are expressed as 
mean ± SEM. *P<0.05, ***P<0.01 vs Control; †P<0.05 vs AngII or IL-1β. n=6-7. 
The increased mPGES-1 mRNA levels observed after 24 h stimulation with 
AngII+IL-1β were blocked with ERK1/2 (U0126), JNK (SP600125), p38 MAPK 
(SB203580) and PI3K (LY294002) inhibitors (Figure 48A). However, PGIS 
mRNA levels were diminished only by the ERK1/2 inhibitor (Figure 48B). TXAS 
mRNA levels were reduced by ERK1/2, p38 MAPK and PI3K inhibitors (Figure 
48C). These results indicate that different signaling pathways are involved in 
the regulation of mPGES-1, PGIS and TXAS expression. 
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Figure 48. Different signaling pathways are involved in mPGES-1, PGIS and 
TXAS expression. Effect of ERK1/2 (U0126, U), JNK (SP600125, SP), p38 MAPK 
(SB203580, SB) and PI3K (LY294002, LY) inhibitors on mPGES-1 (A), PGIS (B) and 
TXAS (C) mRNA levels in rat VSMC stimulated with AngII+IL-1β (4 h). Data are 
expressed as mean ± SEM. **P<0.01 vs Control; ‡P<0.05, ‡‡P<0.01 vs AngII+IL-1β. 
n=5-8.  
1.4. COX-2-DERIVED PROSTANOIDS MEDIATE THE SYNERGISTIC 
EFFECT OF ANGII AND IL-1β ON CELL MIGRATION 
Transwell and wound healing assays were used to study cell migration in 
VSMC. Both AngII and IL-1β induced VSMC migration that was synergistically 
increased in the presence of both stimuli (Figure 49).Thus, the effect of the 
combination of AngII and IL-1β was greater than the sum of the effects of each 
stimulus alone. 
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Figure 49. AngII+IL-1β potentiates cell migration. Transwell (5 h) (A) and wound 
healing (24 h) (B) migration assays were performed in rat VSMC unstimulated (control) 
or stimulated with AngII, IL-1β or AngII+IL-1β. Data are expressed as mean ± SEM. 
**P<0.01, ***P<0.001 vs Control; †P<0.05, ††P<0.01 vs AngII or IL-1β. n=3-6.  
The effect of AngII+IL-1β on cell migration was reduced by U0126 and by 
inhibitors of COX-2 (celecoxib, 10 μmol/L), TXAS (furegrelate, 10 μmol/L and 
ozagrel, 10 μmol/L), TP receptor (SQ29548, 3 μmol/L), EP1 receptor (SC19220, 
10 μmol/L) and EP3 receptor (L798106, 1 μmol/L) (Figure 50).  
0
5
10
15
20
Control    AngII IL-1β AngII
C
el
lm
ig
ra
tio
n
(fo
ld
in
cr
ea
se
)
** **
**
†
+
IL-1β
0
1
2
3
4
Control     AngII IL-1β AngII
C
el
lm
ig
ra
tio
n
(fo
ld
in
cr
ea
se
)
*** **
***
††
+
IL-1β
A B
Results 
136 Andrea Aguado Martínez PhD Thesis 
 
Figure 50. AngII+IL-1β potentiates cell migration through COX-2-derived PGE2 
and TXA2. Transwell (A) and wound healing (B) migration assays were performed in 
rat VSMC unstimulated (control) or stimulated with AngII+IL-1β with or without U0126 
(U), celecoxib (Cele), MS-444 (MS), furegrelate (F), ozagrel (Oza), SQ29548 (SQ), 
SC19220 (SC) or L798106 (L7). Data are expressed as mean ± SEM. ***P<0.001 vs 
Control; ‡P<0.05, ‡‡P<0.01, ‡‡‡P<0.01 vs AngII+IL-1β. n=3-6.  
Since COX-2 is under the control of HuR, we investigated whether HuR 
blockade also affects VSMC migration. As shown in Figures 50 and 51, 
AngII+IL-1β-induced VSMC migration was inhibited by MS-444 and by HuR 
siRNA.  
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Figure 51. HuR is involved in AngII+IL-1β-induced cell migration. Transwell 
migration assays were performed in cells transfected with control or HuR siRNA and 
stimulated or not with AngII+IL-1β. Data are expressed as mean ± SEM. ***P<0.001 vs 
Control; ‡‡P<0.01 vs AngII+IL-1β. n=3-6.  
All together these results indicate that ERK1/2, HuR and PGE2 and TXA2 
derived presumably from COX-2 are involved in cell migration induced by 
AngII+IL-1β. In agreement, cell migration was induced by 16,16-dimethyl PGE2 
or by the TP agonist U46619 in a concentration dependent manner (Figure 52). 
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Figure 52. PGE2 and TXA2 induce cell migration. Concentration dependent effect of 
U46619 (A) or PGE2 (B) on VSMC migration measured by wound healing. Effects of 
single dose of U46619 or PGE2 on VSMC migration measured by transwell (C) or 
would healing (D). Data are expressed as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 
vs Control. n=3-17. 
To understand the signaling whereby TXA2 and PGE2 mediate cell 
migration, we performed wound healing assays in cells stimulated with the TP 
agonist U46619 (0.1 μmol/L) and 16,16-dimethyl PGE2 (1 μmol/L) and 
pretreated with inhibitors of ERK (U0126) JNK (SP600125), p38 MAPK 
(SB203580), pI3K (LY294002), PKC (chelerythrine, 20 μmol/L), calmodulin 
(CaM) (W7, 10 μmol/L), pCaMKII (KN93, 20 μmol/L) and EGFR (AG1478, 10 
μmol/L); a CaM less potent inhibitor (W12, 10 μmol/L) was also used as a 
negative control. As shown in Figure 53, only U0126, SP600125, W7, KN93 
and AG1478 inhibited 16,16-dimethyl PGE2- and U46619-induced cell migration 
indicating the participation of ERK1/2, JNK, CaM, pCaMKII and EGFR in such 
effects. As expected, cell migration induced by U46619 and 16,16-dimethyl 
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PGE2 was also abolished by TP (SQ29548) and EP1 (SC19220) and EP3 
(L798106) receptor antagonists, respectively (Figure 53). 
 
Figure 53. Signaling pathways involved in TXA2- and PGE2-dependent cell 
migration. Wound healing migration assay in VSMC stimulated with U46619 (A) or 
16,16-dimethyl PGE2 (PGE2) (B) with and without SQ29548 (SQ), SC19220 (SC), 
L798106 (L7), U0126 (U), SP600125 (SP), SB203580 (SB), LY294002 (LY), 
chelerythrine (Ch), W7, W12, KN93 (KN) or AG1478 (AG). Data are expressed as 
mean ± SEM. ***P<0.001 vs Control; ‡P<0.05, ‡‡P<0.01, ‡‡‡P<0.001 vs U46619 or 
PGE2. n=3-6.  
TN-C is expressed predominantly in pathological conditions and it is 
involved in cell migration (Wang et al., 2011b; Yu et al., 2013). In addition, 
PGE2 induces its expression both in vitro and in vivo (Wang et al., 2011b). As 
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shown in Figure 54A, TN-C mRNA levels were increased by AngII or IL-1β and 
this effect was potentiated in the presence of both stimuli. The effect of 
AngII+IL-1β on TN-C mRNA levels was abolished by celecoxib, U0126, 
SC19220, L798106 and furegrelate (Figure 54B). 
 
Figure 54. AngII+IL-1β potentiates TN-C expression through COX-2, ERK1/2, 
PGE2 and TXA2 dependent mechanisms. A, Effect of AngII, IL-1β or AngII+IL-1β (24 
h) on TN-C mRNA levels. B, Effect of U0126, celecoxib, SC19220, L798106 or 
furegrelate on TN-C mRNA levels in VSMC stimulated with AngII+IL-1β (24 h). Data 
are expressed as mean ± SEM. **P<0.01 vs Control; †P<0.05 vs AngII or IL-1β; 
‡‡P<0.01, ‡‡‡P<0.001 vs AngII+IL-1β. n=6.  
All together our results demonstrate that PGE2 and TXA2 presumably 
derived from the ERK1/2/HuR/COX-2 pathway participate of the effects induced 
by AngII and IL-1β on cell migration by mechanisms involving TN-C and 
different signaling pathways.  
1.5. IMPLICATION OF COX-2-DERIVED PROSTANOIDS IN VASCULAR 
REMODELING 
To study the potential involvement of the results obtained in cultured 
VSMC, we used two models of vascular remodeling characterized by thickening 
of the vascular wall influenced by VSMC migration and inflammation.  
As shown in Figure 55, increased expression of COX-2, mPGES-1, TXAS 
and HuR was observed in ligated carotid arteries compared with non-ligated 
controls.  
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Figure 55. COX-2, mPGES-1, TXAS and HuR expression are up-regulated in 
carotid ligated arteries. Representative immunohistochemical staining of COX-2, 
mPGES-1, TXAS and HuR in non-ligated and ligated carotids. Representative images 
of 3 independent animals. 
Similar results were obtained in aorta from AngII-infused mice since COX-2, 
mPGES-1, TXAS and HuR mRNA levels were increased in this model (Figure 
56). Moreover, AngII-infused mice showed increased aortic TN-C mRNA levels 
Figure 56B). Celecoxib treatment did not modify HuR mRNA levels 
demonstrating that COX-2-derived prostanoids do not affect HuR expression in 
this model. However, the increased aortic TN-C mRNA levels were reduced by 
pharmacological COX-2 blockade with celecoxib and by mPGES-1 deletion 
(Figure 56B).  
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Figure 56. COX-2, mPGES-1, TXAS, HuR and TN-C levels are up-regulated in 
AngII infused mice. A, COX-2, mPGES-1 and TXAS mRNA levels in aorta from 
untreated or AngII-treated mice. B, HuR (mRNA and immunofluorescence) and TN-C 
mRNA levels in aorta from mice untreated or treated with AngII or AngII plus celecoxib. 
Aortic TN-C expression in mPGES-1+/+ (wild type, WT) and mPGES-1-/- mice infused or 
not with AngII is also shown. Data are expressed as mean ± SEM. *P<0.05, **P<0.01 vs 
Untreated; ‡P<0.05, ‡‡P<0.01 vs AngII. n=3-7. 
Aorta from AngII-infused mice also showed increased media:lumen ratio and 
cross sectional area (markers or hypertrophic remodeling) that was reduced by 
celecoxib treatment and mPGES-1 deletion (Figure 57). 
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Figure 57. COX-2 and mPGES-1-derived PGE2 participate in vascular remodeling.  
Representative photographs of hematoxylin-eosin aortic sections and media/lumen 
ratio and cross-sectional-area (CSA) from mice untreated or treated with AngII or AngII 
plus celecoxib (A) and from mPGES-1+/+ (wild type, WT) and mPGES-1-/- mice infused 
or not with AngII (B). Data are expressed as mean ± SEM. *P<0.05, **P<0.01 vs 
Untreated; ‡P<0.05 vs AngII. n=3-7. 
All together these results suggest that the increased expression of COX-2 
and mPGES-1 could participate in vascular damage/remodeling by modulating 
TN-C expression.  
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2. HuR IS REQUIRED FOR NOX-1 BUT NOT NOX-4 REGULATION BY 
INFLAMMATORY STIMULI IN VASCULAR SMOOTH MUSCLE CELLS  
2.1. ANGII AND IL-1β SYNERGISTICALLY INDUCE NOX-1 EXPRESSION 
AND DECREASE NOX-4 EXPRESSION IN VSMC 
Stimulation of the cells with AngII (0.1 μmol/L) or IL-1β (10 ng/mL) led to a 
modest increase in NOX-1 mRNA and protein expression (Figure 58). Co-
stimulation of cells with AngII+IL-1β led to a synergistic increase in NOX-1 
mRNA and protein that become evident after 8 h stimulation and persisted out 
to 24 h (Figure 58).  
Figure 58. AngII+IL-1β potentiates NOX-1 expression in VSMC. (A) Time course of 
NOX-1 mRNA levels in rat VSMC stimulated with AngII, IL-1β or AngII+IL-1β. Effect of 
AngII, IL-1β or AngII+IL-1β (24 h) on NOX-1 mRNA levels (B) and protein expression 
(C). Representative blots are also shown. Data are expressed as mean ± SEM. *P 
<0.05, **P<0.01, ***P<0.001 vs Control; †P<0.05, ††P<0.01 vs AngII or IL-1β. n=4-13.  
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In contrast, AngII modestly reduced NOX-4 mRNA levels without modifying 
protein expression and IL-1β robustly decreased NOX-4 mRNA and protein 
levels (Figure 59). The combination of AngII+IL-1β did not produce further 
decrease in NOX-4 expression at any time analyzed (Figure 59).  
 
Figure 59. AngII and IL-1β decrease NOX-4 expression in VSMC. (A) Time course 
of NOX-4 mRNA levels in rat VSMC stimulated with AngII, IL-1β or AngII+IL-1β. Effect 
of AngII, IL-1β or AngII+IL-1β (24 h) on NOX-4 mRNA levels (B) and protein 
expression (C). Representative blots are also shown. Data are expressed as mean ± 
SEM. *P <0.05, **P<0.01, ***P<0.001 vs Control. n=4-13.  
In human VSMC stimulated for 24 h, the effects of AngII, IL-1β or AngII+IL-1β 
on NOX-1 and NOX-4 mRNA levels were similar (Figure 60) indicating an 
interspecies conserved effect.  
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Figure 60. AngII+IL-1β potentiates NOX-1 expression and decreases NOX-4 
expression in human VSMC. Effect of AngII, IL-1β or AngII+IL-1β (24 h) on NOX-1 
(A) or NOX-4 (B) mRNA levels in human VSMC. Data are expressed as mean ± SEM. 
*P<0.05, **P<0.01, ***P<0.01 vs Control; ††P<0.01 vs AngII or IL-1β.  n=7-10. 
Based on these findings, we aimed to analyze the molecular mechanisms 
responsible for the synergistic effect of AngII+IL-1β on NOX-1 expression and 
the IL-1β-induced NOX-4 down-regulation in rat VSMC. Pre-treatment with 
specific inhibitors of ERK1/2 (U0126), JNK (SP600125) and p38 MAPK 
(SB203580) but not with a PI3K inhibitor (LY294002) reduced the AngII+IL-1β-
induced NOX-1 mRNA levels at 24 h (Figure 61A). On the other hand, U0126, 
SP600125 and LY294002 but not SB203580 partially blocked the IL-1β-
dependent NOX-4 down-regulation (Figure 61B).  
 
Figure 61. Signaling pathways involved in the effects of AngII and/or IL-1β on 
NOX-1 and NOX-4 expression. Effect of inhibitors of ERK1/2 (U, U0126), JNK (SP, 
SP600125) and p38 MAPK (SB, SB203580) and PI3K (LY, LY294002) on NOX-1 (A) 
and NOX-4 (B) mRNA levels induced by AngII and/or IL-1β (24 h). ***P<0.01 vs Control; 
‡P<0.05, ‡‡P<0.01 vs AngII+IL-1β or IL-1β. n=7-11. 
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2.2. ANGII INDUCES HuR-DEPENDENT NOX-1 mRNA STABILIZATION 
Previous studies in VSMC demonstrate that NOX-1 expression is regulated 
by transcriptional mechanisms (Katsuyama et al., 2005; Cevik et al., 2008; 
Manea et al., 2010a; 2010b). However, there is a paucity of information on 
whether post-transcriptional mechanisms are also involved. NOX-1 
transcriptional activity was measured in VSMC transfected with a reporter 
plasmid containing the human NOX-1 promoter fused to luciferase cDNA. As 
shown in Figure 62, NOX-1 promoter activity increased in the presence of AngII 
and IL-1β being higher in the presence of both stimuli (Figure 62), confirming 
that transcriptional regulatory mechanisms are involved in NOX-1 expression 
induced by AngII+IL-1β. 
 
Figure 62. AngII+IL-1β potentiates NOX-1 promoter activity in VSMC. Luciferase 
activity of NOX-1 promoter in rat VSMC stimulated with AngII, IL-1β or AngII+IL-1β (24 
h). Data are expressed as mean ± SEM. ***P<0.001 vs Control; ††P<0.01 vs AngII or IL-
1β. n=6. 
A time-course mRNA decay analysis evidenced that NOX-1 mRNA was 
stabilized in the presence of AngII+Il-1β (Figure 63A). We also performed 
transfections of VSMC using a luciferase reporter plasmid containing the 3'UTR 
from NOX-1 mRNA. Figure 63B shows that AngII+Il-1β increased NOX-1 3’UTR 
luciferase activity. Together, these results suggest that post-transcriptional 
regulatory mechanisms are also involved in NOX-1 expression induced by 
AngII+IL-1β.  
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Figure 63. The AngII+IL-1β-induced NOX-1 expression in VSMC is due to an 
increase of NOX-1 mRNA stability mediated by HuR. A, Effect of MS-444 on NOX-1 
mRNA stability in cells stimulated with AngII+IL-1β (24 h). Actinomycin D was added 
for the indicated times and NOX-1 mRNA levels were measured by qPCR. B, Rat 
VSMC were transfected with a luciferase reporter construct containing the NOX-1 3’-
UTR. Luciferase activity was assayed in untreated (control) VSMC and after incubation 
with AngII+IL-1β (24 h). Data are expressed as mean ± SEM. **P<0.01, ***P<0.001 vs 
Control; ‡‡P<0.01 vs AngII+IL-1β. n=4-7. 
As mentioned, HuR is a RNA-binding protein that stabilizes different 
mRNAs by binding to AREs found in 3’UTR (Meisner and Filipowicz, 2011). To 
test whether HuR was responsible for NOX-1 mRNA stabilization, we performed 
the mRNA stability assay in the presence of the HuR inhibitor MS-444. As 
shown in Figure 63A, MS-444 abolished the AngII+IL-1β-dependent NOX-1 
mRNA stabilization. Furthermore, HuR blockade with MS-444 (Figure 64A) or 
with HuR siRNA (Figures 64B and 41A) reduced the AngII+IL-1β-induced NOX-
1 mRNA levels.  
 
Figure 64. HuR blockade decreases NOX-1 expression induced by AngII+IL-1β. 
Effects of MS-444 (A) and HuR siRNA (B) on NOX-1 mRNA levels in VSMC stimulated 
with AngII+IL-1β (24 h). Data are expressed as mean ± SEM. **P<0.01 vs Control; 
‡‡P<0.01 vs AngII+IL-1β. n=4-7. 
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To determine whether AngII+IL-1β signaling promotes HuR binding to NOX-1 
mRNA, ribonucleoprotein immunoprecipitation assays were done. VSMC were 
stimulated for 24 h with AngII+IL-1β and immunoprecipitation of cytoplasmic 
lysates was performed using an antibody against HuR or a control IgG. We 
observed enrichment in NOX-1 mRNA in anti-HuR precipitates from cells 
treated with AngII+IL-1β but not in control cells or in anti-IgG precipitates 
(Figure 65).  
  
Figure 65. HuR binds to NOX-1 mRNA. NOX-1 mRNA binding to HuR by 
ribonucleoprotein immunoprecipitation in VSMC stimulated with AngII+IL-1β (24 h). 
Data are expressed as mean ± SEM. *P<0.05 vs Control. n=4. 
Altogether, these findings suggest that AngII+IL-1β induce HuR binding to NOX-
1 mRNA which is responsible for increased NOX-1 mRNA stability.  
2.3. A TRANSCRIPTIONAL MECHANISM IS INVOLVED IN NOX-4 DOWN-
REGULATION INDUCED BY IL-1β 
In order to elucidate the mechanisms by which IL-1β decreased NOX-4 
expression, we first studied whether a post-transcriptional mechanism was 
involved by performing a NOX-4 mRNA stability assay. In VSMC, IL-1β did not 
modify NOX-4 mRNA decay (Figure 66A) supporting the involvement of a 
transcriptional mechanism. Accordingly, transient transfection assays with a 
luciferase reporter construct containing NOX-4 promoter, evidenced that IL-1β 
reduced NOX-4 transcriptional activity (Figure 66B). Interestingly, the decrease 
in NOX-4 promoter activity triggered by IL-1β was partially reversed with U0126, 
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SP600125 and LY294002 (Figure 66B) which were the same inhibitors that 
partially restored the IL-1β-mediated NOX-4 mRNA decrease (Figure 61B).  
 
 
 
 
 
Figure 66. A transcriptional mechanism is involved in NOX-4 down-regulation 
induced by IL-1β in VSMC. A, NOX-4 mRNA stability after 24 h stimulation with IL-1β. 
NOX-4 mRNA levels were measured by qPCR at indicated times after actinomycin D 
addition. B, Effect of MAPKs (U: U0126; SP: SP600125) and PI3K (LY: LY294002) 
inhibitors on luciferase activity of NOX-4 promoter in cells incubated with IL-1β (24 h). 
Data are expressed as mean ± SEM. *P<0.05 vs Control; †P<0.05 vs IL-1β. n=5-12. 
To study which region of the promoter was involved in the NOX-4 transcriptional 
down-regulation, cells were transfected with different promoter constructs 
ranging from ∼1,200 to 200 bp and stimulated with IL-1β. Luciferase activities of 
all constructs were decreased in IL-1β-treated cells, suggesting that the 
sequence responsible for NOX-4 down-regulation was within the proximal 192 
bp of NOX-4 promoter (Figure 67).  
 
 
 
 
 
 
 
Figure 67. NOX-4 promoter of 192 bp is involved in NOX-4 down-regulation 
induced by IL-1β in VSMC. Luciferase activity of rat VSMC transfected with luciferase 
reporter constructs containing different lengths of the human NOX-4 promoter and 
stimulated with IL-1β (24 h). Scheme of the constructs is also shown. Data are 
expressed as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 vs Control. n=5-12. 
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Epigenetic modifications are mechanisms involved in gene expression. 
These mechanisms are reversible and involve DNA methylation and histone 
deacetylation leading to a major compaction of the chromatin and thus inhibition 
of gene expression. Very few is known about epigenetic modifications and 
NOX-4 expression; for example in cancer cells, NOX-4 expression is regulated 
by DNA methylation (De Carvalho et al., 2012). We used the inhibitors of DNA 
methyltransferase 5-aza-dC, and of HDAC trichostatin and SAHA, to determine 
whether epigenetic modifications were involved in the observed NOX-4 
transcriptional repression induced by IL-1β. As shown in Figure 68, 5-aza-dC (2 
µmol/L) did not affect basal or IL-1β-mediated NOX-4 mRNA decrease; 
however, trichostatin (0.5 µmol/L) or SAHA (5 µmol/L) greatly decreased basal 
NOX-4 mRNA levels and no further effect was observed with IL-1β, probably 
because no further diminution can be achieved.  
 
Figure 68. HDAC participates in NOX-4 basal expression. Effects of 5-aza-2’-
deoxycytidine (5-aza-dC), trichostatin and suberoylanilide hydroxamic acid (SAHA) on 
NOX-4 mRNA levels in VSMC unstimulated (control) or stimulated with IL-1β (8 h). 
Data are expressed as mean ± SEM. **P<0.01; ***P<0.001 vs Control; ###P<0.001 vs 
Control in the absence of inhibitors. n=5-12. 
In VSMC transfected with the 192 bp NOX-4 promoter, trichostatin and SAHA 
greatly repressed NOX-4 basal transcriptional rate without affecting IL-1β 
effects (Figure 69). This suggests that deacetylation is needed for the basal 
expression of NOX-4. 
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Figure 69. HDAC participates in NOX-4 basal promoter activity. Effects of 
trichostatin and suberoylanilide hydroxamic acid (SAHA) on luciferase activity of NOX-
4 promoter in VSMC transfected with the NOX-4 192 promoter construct and 
stimulated or not with IL-1β (8 h). Data are expressed as mean ± SEM. ***P<0.001 vs 
unstimulated (control); #P<0.05, ###P<0.001 vs control in the absence of inhibitors. n=5-
12. 
To gain further insights into the mechanisms involved in the IL-1β-mediated 
NOX-4 decrease, VSMC were treated with the protein synthesis inhibitor 
cycloheximide (25 µg/mL) before stimulation. As shown in Figure 70, 
cycloheximide abolished the effect of IL-1β on NOX-4 expression suggesting 
that the new synthesis of a repressor is needed for the IL-1β-induced NOX-4 
decrease.  
 
 
 
 
 
 
Figure 70. New synthesis of a repressor is required for NOX-4 down-regulation 
induced by IL-1β in VSMC. Effect of cycloheximide on NOX-4 mRNA levels in VSMC 
stimulated with IL-1β (8 h). Data are expressed as mean ± SEM. ***P<0.001 vs Control; 
†P<0.05 vs IL-1β. n=9-12. 
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Thereafter, we studied the expression of some transcription factors that could 
act as repressors that bind to the 192 bp proximal promoter. Elk-1 and PPAR-γ 
mRNA levels were unchanged and decreased, respectively, after IL-1β 
stimulation (Figure 71).  
 
 
 
 
 
Figure 71. Elk-1 and PPAR-γ transcription factors are unaffected and decreased 
by IL-1β. Effects of IL-1β (24 h) on Elk-1 (A) and PPAR-γ (B) mRNA levels in rat 
VSMC. Data are expressed as mean ± SEM. ***P<0.001 vs Control. n=6-11.  
However, Elf-3 and Egr-1 mRNA levels were increased in the presence of IL-1β 
(Figure 72A and 72B). The Elf-3 dominant negative mutant did not affect IL-1β-
mediated NOX-4 mRNA down-regulation (Figure 72C) and Egr-1 
overexpression increased NOX-4 expression (Figure 72D), suggesting no 
implication of these transcription factors in the IL-1β-dependent NOX-4 
decrease. 
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Figure 72. Elf-3 and Egr-1 transcription factors are not involved in IL-1β-mediated 
NOX4 down-regulation. Effects of IL-1β (24 h) on Elf-3 (A) and Egr-1 (B) mRNA 
levels in rat VSMC. (C) NOX-4 mRNA levels in VSMC transfected with EGFP or Elf-3 
dominant negative mutant (Elf-3 DN) and stimulated or not with IL-1β. (D) NOX-4 
mRNA levels in VSMC transfected with pcDNA3.1 (Control) or Egr-1. Data are 
expressed as mean ± SEM. **P<0.01, ***P<0.001 vs Control. n=6-11. 
2.4. NOX-1-DERIVED ROS AND NOX-4-DERIVED H2O2 PARTICIPATE IN 
CELL MIGRATION 
We next studied whether the regulatory mechanisms observed in NOX-1 
and NOX-4 expression have a functional role on NOXs activity and their 
presumed effects on cell migration.   
NOX-1 has been described to produce O2•− while H2O2 is produced, at least 
in part, by NOX-4 (Dikalov et al., 2008). AngII or IL-1β induced NADPH oxidase 
activity and ROS production that were further increased by the combination of 
both stimuli (Figure 73A and 73B). AngII+IL-1β-induced NADPH oxidase 
activation and ROS production were blocked by a NOX-1 inhibitor (ML171, 0.5 
μmol/L) and by NOX-1 siRNA (Figure 73).  
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Figure 73. NOX-1 is responsible for AngII+IL-1β-induced ROS production. Effect 
of ML171 (A,B) and NOX-1 siRNA (C-E) on NADPH oxidase activity and ROS 
production induced by AngII, IL-1β and AngII+IL-1β in rat VSMC (24 h). C, NOX-1 
mRNA levels in cells transfected with control or NOX-1 siRNA stimulated or not with 
AngII+IL-1β (24 h). Data are expressed as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 
vs Control; ‡P<0.05, ‡‡P<0.01, ‡‡‡P<0.001 vs AngII+IL-1β. n=3-7.  
We have previously demonstrated that HuR is involved in AngII+IL-1β-
induced NOX-1 expression. The role of HuR on NOX activity was confirmed by 
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the fact that HuR knockdown by siRNA partially decreased NADPH oxidase 
activity and ROS production induced by AngII+IL-1β (Figure 74). 
 
Figure 74. HuR participates in AngII+IL-1β-induced ROS production. Effects of 
control or HuR siRNA on NADPH oxidase activity (A) and ROS production (B) in 
VSMC stimulated with AngII+IL-1β. Data are expressed as mean ± SEM. *P<0.05, 
***P<0.001 vs Control; ‡‡P<0.01 vs AngII+IL-1β. n=3-7.  
We next evaluated whether effects of AngII and/or IL-1β on NOX-4 expression 
were paralleled by changes in H2O2 production. As shown in Figure 75A, H2O2 
production was decreased in the presence of AngII being this effect more 
exacerbated in the presence of IL-1β or AngII+IL-1β suggesting that NOX-4 
might be the responsible for H2O2 production. In agreement, NOX-4 over-
expression abolished the decrease induced by IL-1β in H2O2 production, (Figure 
75B). 
 
 
 
 
 
Figure 75. NOX-4 participates in IL-1β-dependent H2O2 production. H2O2 
production in VSMC stimulated with AngII, IL-1β or AngII+IL-1β (A) or transfected with 
EGFP or NOX-4/EGFP and stimulated with IL-1β (B). Data are expressed as mean ± 
SEM. *P<0.05, **P<0.01, ***P<0.001 vs Control; ‡‡P<0.01 vs IL-1β. n=3-7.  
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Transwell and wound healing assays were used to study the implication of 
ROS in VSMC migration. We previously observed that 5 h stimulation with AngII 
and/or IL-1β induced VSMC migration (Figure 49). This was confirmed herein 
after 24 h stimulation (Figure 76).   
 
Figure 76. AngII+IL-1β potentiates cell migration. Transwell assay performed in rat 
VSMC unstimulated and stimulated with AngII, IL-1β or AngII+IL-1β for 24 h. Data are 
expressed as mean ± SEM. *P<0.05, **P<0.01 vs Control; †P<0.05 vs AngII or IL-1β. 
n=3.  
We previously showed that HuR was involved in AngII+IL-1β-induced cell 
migration (Figure 51). We now compared the effects of NOX-1 and HuR 
blockade on cell migration induced by AngII+IL-1β. As expected, MS-444 and 
HuR siRNA inhibited AngII+IL-1β-induced VSMC migration (Figure 77) and 
these effects were mimicked by ML171 and NOX-1 siRNA (Figure 77) 
suggesting that NOX-1 which is under the control of HuR, is involved in VSMC 
migration.   
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Figure 77. NOX-1 and HuR participate in cell migration induced by AngII+IL-1β. 
Effect of ML171 and MS-444 on cell migration induced by AngII+IL-1β measured by 
wound healing (A) and transwell (B) assays. Effect of NOX-1 (C) or HuR (D) siRNAs 
on cell migration induced by AngII+IL-1β measured by transwell assays. Data are 
expressed as mean ± SEM. **P<0.01 vs Control; ‡P<0.05, ‡‡P<0.01 vs AngII+IL-1β. 
n=3-5.  
In order to study the participation of NOX-4 in cell migration, we overexpressed 
NOX-4 in the presence of IL-1β. As shown in Figure 78, overexpression of 
NOX-4 increased IL-1β-induced cell migration.  
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Figure 78. NOX-4 participates in cell migration. Effect of NOX-4/EGFP over-
expression on cell migration induced by IL-1β measured by transwell assays. Data are 
expressed as mean ± SEM. ***P<0.001 vs Control; ‡‡P<0.01 vs IL-1β. n=3-5.  
Altogether these results suggest the implication of the HuR/NOX-1 axis and 
NOX-4 on VSMC migration in response to inflammatory stimuli.  
2.5. LACK OF RECIPROCAL RELATIONSHIP BETWEEN COX-2 AND NOX-1 
A reciprocal relationship between COX-2 and NADPH oxidase has been 
described in liver cells (Sancho et al., 2011) and arteries from hypertensive 
animals (Martínez-Revelles et al., 2013). We evaluated whether this reciprocal 
relationship was part of the mechanisms responsible of the effects of AngII+IL-
1β on COX-2 and NOX-1 expression. COX-2 and NOX-1 mRNA levels and 
NADPH oxidase activity were analyzed in VSMC stimulated with AngII+IL-1β in 
the presence or absence of ML171 or celecoxib. As shown in Figure 79A, COX-
2 expression was not affected by ML171. Conversely, although NOX-1 
expression was slightly inhibited by celecoxib (Figure 79B) the NADPH oxidase 
activity was not modified by this compound (Figure 79C). These results 
demonstrate that in these particular experimental conditions, COX-2 and NOX-1 
pathways seem to be independently activated by AngII+IL-1β. 
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Figure 79. Lack of reciprocal relationship between COX-2 and NOX-1. A, Effect of 
ML171 on COX-2 mRNA levels. Effect of celecoxib (Cele) on NOX-1 mRNA levels (B) 
and NADPH oxidase activity (C) in VSMC stimulated with AngII+IL-1β (24 h). Data are 
expressed as mean ± SEM. ***P<0.001 vs Control; ‡P<0.05 vs AngII+IL-1β. n=6. 
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1. HuR MEDIATES THE SYNERGISTIC EFFECTS OF ANGII AND IL-1β ON 
VASCULAR COX-2 EXPRESSION AND CELL MIGRATION 
In this part of the PhD Thesis, we present evidences that the combination 
of two inflammatory stimuli, AngII and IL-1β, synergistically induce COX-2 
expression and cell migration in VSMC via a HuR-mediated increase of mRNA 
stability. We propose that this mechanism might be implicated in the vascular 
remodeling associated to cardiovascular diseases.  
It is well known that AngII and cytokines have been implicated in several 
cardiovascular pathologies through their inflammatory actions in the vascular 
wall (Marchesi et al., 2008). COX-2 is an early response gene overexpressed in 
pathological conditions associated with inflammatory processes, such as cancer 
(Dixon et al., 2001; Young et al., 2012), atherosclerosis (Cipollone and Fazia, 
2006) and hypertension (Martínez-Revelles et al., 2013; Virdis et al., 2013). We 
found that AngII and IL-1β time-dependently increased COX-2 protein levels in 
VSMC, as described in this and other cell types (Ohnaka et al., 2000; Slice et 
al., 2005; Martín et al., 2012). However, the temporal pattern of COX-2 up-
regulation by these stimuli was different. IL-1β induced a sustained long-term 
COX-2 up-regulation, whereas AngII induced an earlier response that was 
attenuated after prolonged stimulation times. Importantly, the combination of 
AngII+IL-1β leads to an exacerbated and more sustained COX-2 induction 
suggesting that amplifying mechanisms of COX-2 regulation might take place to 
increase the inflammatory response. In agreement, in intestinal epithelial cells 
(Pham et al., 2008), mesangial cells (Doller et al., 2008) or adventitial 
fibroblasts (Galán et al., 2011), AngII potentiated COX-2 expression induced by 
growth factors or pro-inflammatory cytokines. One of the main consequences of 
vascular inflammation relates to the effects of pro-inflammatory mediators in 
vascular structure. In fact, COX-2-derived prostanoids are known to promote 
VSMC migration as demonstrated by both in vitro and in vitro studies (Wang et 
al., 2005; Zhang et al., 2013). In agreement, we observed that the effects of 
AngII+IL-1β on COX-2 expression in VSMC had a functional consequence 
since the combination of both stimuli synergistically induced VSMC migration by 
a mechanism dependent on COX-2-derived prostanoids.  
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COX-2 expression is tightly regulated by both transcriptional and post-
transcriptional mechanisms (Dixon et al., 2000; Harper and Tyson-Capper, 
2008; Young et al., 2012). Pham et al., (2008) described that the synergistic up-
regulation of COX-2 induced by AngII and epidermal growth factor in intestinal 
epithelial cells was due to an increase of its transcriptional rate and its mRNA 
stability. Our results in VSMC demonstrate that the effect of AngII on IL-1β-
induced COX-2 expression was mainly due to a mRNA stabilization 
mechanism, as previously described in adventitial fibroblasts (Galán et al., 
2011). RNA stability is regulated by different mRNA binding proteins such as 
HuR, which is most noted to play a role in cancer through stabilization of 
various target genes such as COX-2 (Dixon et al., 2001; Abdelmohsen and 
Gorospe, 2010). HuR is mainly located in the nucleus and shuttles between the 
nucleus and the cytoplasm. The presence of cytoplasmic HuR contribute to 
promote cell growth, proliferation, angiogenesis and survival (Abdelmohsen and 
Gorospe, 2010), through its capacity to stabilize ARE-containing mRNAs such 
as cyclins, TNF-α, vascular endothelial growth factor, and COX-2 
(Abdelmohsen and Gorospe, 2010). This is evident in colorectal and other 
tumor types, where HuR is overexpressed and present within the cytoplasm 
leading to ARE-mRNA stabilization and increased of COX-2 expression (Dixon 
et al., 2001; Young et al., 2012). Post-translational modifications of HuR 
including serine and threonine phosphorylation by several kinases such as 
Chk2, PKCα or PKCδ can modify HuR subcellular location (Meisner and 
Filipowicz, 2011). Additionally, ERK1/2 can participate in HuR phosphorylation, 
modifying its activity as described in a lung cancer cell line (Yang et al., 2004b) 
or modifying HuR cytoplasmic location as shown in hepatic stellate cells 
(Woodhoo et al., 2012). Herein, we demonstrate for the first time in VSMC that 
ERK1/2-mediated HuR activation is involved in the synergistic effect of AngII 
and IL-1β on COX-2 expression and cell migration. This is supported by the 
following findings: 1) AngII+IL-1β interfered with rapid decay of COX-2 mRNA 
resulting in increased 3’UTR reporter activity in VSMC. This effect was 
accompanied with HuR translocation to the cytoplasm and its binding to COX-2 
mRNA; 2) HuR silencing and/or treatment with the HuR inhibitor MS-444 
reduced COX-2 mRNA stability, COX-2 mRNA levels and cell migration induced 
by AngII+IL-1β; 3) ERK1/2 phosphorylation was increased by AngII+IL-1β and 
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ERK1/2 inhibition reduced COX-2 mRNA stability, COX-2 mRNA levels, HuR 
cytoplasmic translocation and cell migration. All together, these results suggest 
that HuR cytoplasmic trafficking could be a central node implicated in vascular 
remodeling associated to cardiovascular pathologies by modulating COX-2 
expression and cell migration. In agreement, we observed increased vascular 
expression of HuR in AngII-infused mice and in the carotid ligation mouse 
model, as described in different vascular injuries such as intimal hyperplasia, 
arterialized saphenous vein or atherosclerotic plaque (Pullmann et al., 2005).  
During the last few years, the involvement of COX-2 downstream 
prostanoids in vascular remodeling has gained growing attention (Wang et al., 
2011b; Zhang et al., 2013; Sparks et al., 2013). Our results demonstrate that 
PGE2 and TXA2 most likely derived from COX-2, are involved in cell migration 
induced by the combination of AngII+IL-1β. Thus, we found that not only COX-2 
but also mPGES-1 and TXAS expressions were increased in VSMC treated 
with AngII+IL-1β. In addition, although we have no determined PGES and TXAS 
activities, we observed that cell migration induced by AngII+IL-1β was blocked 
by pharmacological inhibitors of COX-2 and the TXA2 and PGE2 pathways. The 
effects of both PGE2 and TXA2 on VSMC migration were further confirmed by 
the fact that a PGE2 analogue and a TP agonist mimicked AngII+IL-1β effects 
on cell migration, effects that were blocked by EP1 and EP3 and TP blockade, 
respectively. Our results are in agreement with previous findings demonstrating 
that PGE2 and TXA2 induce cell migration in VSMC (through EP3 receptor) or in 
endothelial cells (through TP receptor) (Zhang et al., 2013; Bos et al., 2004). 
The effects of prostanoids on cell migration might be mediated by TN-C, an 
ECM protein that participates in cell proliferation and migration (Wang et al., 
2011b; Yu et al., 2013) and that it is regulated by PGI2 or PGE2 (Wang et al., 
2011b). Our results demonstrate that not only EP1 and EP3 receptors but also 
TXA2 participate in the AngII+IL-1β-mediated TN-C induction. An additional 
relevant finding arising from our study is the fact that the effects of AngII+IL-1β 
on COX-2, mPGES-1, TXAS and TN-C expression were recapitulated in two 
animal models of vascular remodeling associated with inflammation and 
increased cell migration/proliferation (the carotid artery ligation model and the 
AngII infusion model). Moreover, the vascular remodeling and the increased 
Discussion 
166 Andrea Aguado Martínez PhD Thesis 
TN-C expression induced by AngII were reversed by celecoxib treatment and 
genetic mPGES-1 deletion, demonstrating that COX-2/mPGES-1/TXAS-derived 
prostanoids are key mediators of vascular damage/remodeling. Supporting 
these findings, other authors have demonstrated a role for COX-2, PGE2 and 
TXA2 in animal models of restenosis or hypertension (Wang et al., 2011b; 
Zhang et al., 2013; Sparks et al., 2013). 
Different intracellular signaling pathways are responsible for cell migration. 
Among the most extensively studied are ERK1/2 and JNK. Both are able to 
phosphorylate different proteins such as MLCK, focal adhesion kinase or paxilin 
leading to cytoskeleton reorganization and cell migration (Huang et al., 2004). 
CaM and pCaMKII are also important mediators of VSMC migration (Scott et 
al., 2012). CaM/pCaMKII is activated by Gq proteins which are associated to 
EP1, EP3 and TP receptors (Bos et al., 2004; Yamaoka et al., 2009). The 
participation of EGFR in VSMC migration has been suggested in response to 
AngII (Mugabe et al., 2010). Interestingly EGFR can be activated directly by TN-
C or transactived by EP and TP receptors (Han et al., 2006; Uchiyama et al., 
2009). Herein, we demonstrate that ERK1/2, JNK, CaM and pCaMKII and 
EGFR are key mediators responsible for PGE2 and TXA2-dependent VSMC 
migration. 
The results obtained in the first part of this PhD Thesis are summarized in 
Figure 80. We demonstrate in VSMC a post-transcriptional regulation mediated 
by ERK1/2-dependent HuR shuttling that underlies the synergistic effect of 
AngII and IL-1β on COX-2 expression. COX-2-derived TXA2 and PGE2 acting 
on TP and EP1 and EP3 respectively, induce TN-C expression and promote cell 
migration. In addition, increased COX-2, mPGES-1, TXAS, TN-C and HuR 
expressions were observed in animal models of vascular damage and blockade 
of COX-2 and mPGES-1 protects the vessel against TN-C expression and 
altered vessels structure.  
Discussion 
Andrea Aguado Martínez PhD Thesis  167 
 
Figure 80. Scheme showing the role of HuR in AngII and IL-1β effects on 
vascular COX-2 expression and cell migration. In VSMC AngII and IL-1β 
synergistically induces COX-2 expression through ERK1/2 pathway. ERK1/2 activation 
leads to HuR binding to COX-2 3’UTR mRNA and exportation to the cytoplasm where 
HuR increases COX-2 mRNA stability. COX-2 is translated to protein and converts 
arachidonic acid in PGH2 and TXAS and mPGES-1 will transform it in PGE2 and TXA2. 
Both prostanoids through TP and EP1/EP3 increase TN-C expression and would 
activate EGFR (EGFR transactivation) that will lead to ERK1/2, JNK, CaM/pCaMKII 
activation ending in cell migration and vascular remodeling. Inhibitors used in the 
experiments are showed in the scheme with their protein targets marked with bar-
headed lines. Dashed lines indicate non-investigated mechanisms. 
In conclusion, these results suggest that HuR and COX-2/mPGES-1/TXAS 
pathway could be targets to prevent or regress vascular remodeling associated 
to cardiovascular diseases. However, an intriguing finding that deserves further 
discussion is the fact that COX-2-selective nonsteroidal anti-inflammatory drugs 
seem to be associated with an increase of cardiovascular risk through the 
reduced biosynthesis of endothelial COX-2-dependent PGI2 (Patrignani and 
Patrono, 2014). There are a number of reasons that might explain the 
apparently contradictory effects of blockade of prostanoids pathways between 
experimental and human studies, but very probably relate to the different animal 
models, duration or type of the pathology studied or particular inhibitor assayed 
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in these studies. To overcome the cardiovascular problems of coxibs, in the last 
few years selective inhibitors of mPGES-1 or specific prostanoids receptors as 
drug targets with previsible less cardiovascular side effects are being developed 
(Wang and Fitzgerald, 2010; Korotkova and Jakobsson, 2014). However, the 
results are far for being conclusive. Interestingly, rediversion of the excess of 
PGH2 towards PGI2 synthase thereby enhancing PGI2 biosynthesis has been 
described in mPGES-1 knockout mice (Wang et al., 2006; Wang et al., 2011b), 
which might provide additional cardiovascular safety compared to COX-2 
blockade. Another important consideration is the fact that recent evidences 
support different and opposing contributions of COX-2 in different 
cardiovascular compartments (i.e endothelial cells vs macrophages) and 
suggest that targeted blockade of COX-2 to macrophages may conserve their 
efficacy while limiting cardiovascular risk (Tang et al., 2014). Finally, there is 
currently some controversy of whether selective and non-selective COX-2 
inhibitors provide the same degree of cardiovascular risk (Bhala et al., 2013; 
Patrignani and Patrono, 2014). In this sense, results of the PRECISION study, 
an ongoing cardiovascular outcome trial comparing celecoxib, ibuprofen and 
naproxen, will hopefully shed light on this issue. There is no doubt that results 
from animals- and cell-based studies similar to the ones presented here are part 
of a proof of concept and that future clinical trials will definitively address the 
cardiovascular consequences of selective and non-selective COX-2 blockade in 
the context of different cardiovascular diseases. 
 
2. HuR IS REQUIRED FOR NOX-1 BUT NOT NOX-4 REGULATION BY 
INFLAMMATORY STIMULI IN VASCULAR SMOOTH MUSCLE CELLS  
Besides COX-2 derived prostanoids, it is well known that NADPH oxidase-
derived ROS are implicated in vascular remodeling associated with several 
cardiovascular pathologies (Xu and Touyz, 2006; Lassègue and Griendling, 
2010). The second part of this PhD Thesis provides evidences that in VSMC 
AngII and IL-1β synergistically induce NOX-1 expression, at least in part, 
through a HuR-mediated increase in NOX-1 mRNA stability subsequently 
leading to increased NADPH oxidase activity and ROS production. In contrast, 
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IL-1β decreases NOX-4 expression and NOX-4-derived H2O2 through a 
transcriptional mechanism involving response elements located in the 192 
proximal promoter. Both effects contribute to cell migration triggered by 
inflammatory mediators and could be implicated in the vascular remodeling 
associated with cardiovascular diseases.  
We observed that IL-1β and AngII induced NOX-1 expression in VSMC, 
which is in agreement with previous studies performed in the same cell type 
(Lassègue et al., 2001; Briones et al., 2011; Martín et al., 2012). We also found 
that the combination of AngII and IL-1β lead to a potentiated NOX-1 induction 
suggesting that, similarly to COX-2, amplifying mechanisms occur to modulate 
NOX-1 expression in the presence of several pro-inflammatory stimuli. This 
effect was dependent, at least in part, on MAPK signaling (ERK1/2, JNK and 
p38 MAPK) and we also observed that transcriptional and post-transcriptional 
mechanisms are involved. Specifically, we demonstrate that a post-
transcriptional regulatory mechanism mediated by the RNA binding protein HuR 
participates in the exacerbated NOX-1 induction in VSMC. This is based in the 
following findings: 1) AngII+IL-1β interfered with the decay of NOX-1 mRNA; 2) 
AngII+IL-1β increased HuR binding to NOX-1 mRNA; 3) HuR silencing and 
treatment with the HuR inhibitor MS-444 reduced NOX-1 mRNA stability and 
AngII+IL-1β-induced NOX-1 mRNA levels. HuR-dependent mRNA stabilization 
has been suggested to be involved in the post-transcriptional regulation of 
various pro-inflammatory genes (Meisner and Filipowicz, 2011). However, to 
our knowledge this is the first report demonstrating that HuR is involved in NOX-
1 expression. More importantly, this regulation has a functional role on enzyme 
activity, since we demonstrate that the synergistically increased NADPH 
oxidase activity and ROS production induced by AngII+IL-1β, were abolished by 
NOX-1 and HuR blockade using pharmacological and knockdown approaches. 
Since NOX-1 has been described to be responsible for O2•− production and 
redox signaling in pathological conditions including atherosclerosis, diabetes, 
and hypertension (Matsuno et al., 2005; Gray et al., 2013), future studies are 
warranted to determine the potential role of HuR/NOX-1 regulation in vivo.  
 Previous studies suggested that NOX-4 might be a housekeeping gene 
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due to the presence of GC rich regions in its promoter (Katsuyama et al., 2012). 
However, modulation of NOX-4 by different stimuli has been described (Chen et 
al., 2012). TGF-β and IFN-γ induce NOX-4 expression in VSMC (Cucoranu et 
al., 2005; Manea et al., 2010a), while the effects of AngII and IL-1β on NOX-4 
expression are controversial with NOX-4 being up- and down-regulated by 
these agents in vascular cells (Lassègue et al., 2001; Ellmark et al., 2005; 
Richard et al., 2009; Briones et al., 2011). We found that IL-1β significantly 
reduced NOX-4 gene expression with AngII having no additional effect. Our 
results indicate that IL-1β-mediated NOX-4 decrease is due to a transcriptional 
repression, involving ERK1/2, JNK and PI3K and the 200-bp region of NOX-4 
proximal promoter. Epigenetic mechanisms including DNA methylation or 
histone deacetylation might explain NOX-4 down-regulation. Our results 
excluded DNA methylation mechanisms since 5-aza-dC did not modify NOX-4 
in VSMC. To our knowledge, very few studies have evaluated the role of HDAC 
in NOX-4 expression in vascular cells. Sp3 deacetylation has been implicated in 
basal expression of NOX-4 in endothelial cells (Katsuyama et al., 2011). In 
VSMC, we observed that HDAC inhibitors decreased NOX-4 mRNA levels and 
luciferase activity of the NOX-4 proximal promoter in unstimulated cells 
supporting the role of deacetylation in basal NOX-4 expression. We do not 
know the exact mechanism but deacetylation of a chromatin region of a 
repressor or deacetylation of a transcription factor binding to the proximal 
promoter might  be involved. Interestingly, no effect on these inhibitors was 
observed in IL-1β-treated cells. The fact that basal NOX-4 expression is almost 
abolished by both trichostatin and SAHA probably prevents further effects of IL-
1β. Future investigations are needed to more accurately evaluate the role of 
HDAC in NOX-4 expression. 
 We then focused on other mechanisms possibly involved in NOX-4 
repression. Thus, we found that cycloheximide, a protein synthesis inhibitor 
abolished IL-1β-dependent NOX-4 mRNA decrease. In addition, serial deletion 
analysis of NOX-4 promoter region enclosed IL-1β-dependent down-regulation 
to the 192 bp proximal region. In silico analysis of this promoter region using 
MatInspector software indicated some candidate repressors (PPAR-γ, Elk-1, 
Egr-1, Elf-3) that may be contributing to IL-1β-dependent NOX-4 down-
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regulation. However, our data exclude the contribution of these transcription 
factors to the down-regulation of NOX-4 expression induced by IL-1β. Very few 
studies have examined transcriptional mechanisms involved in NOX-4 down-
regulation. Recently, JunD a member of the AP-1 family of transcription factors, 
has been described as a repressor of NOX-4 expression at vascular level 
(Paneni et al., 2013); however, the 192 bp proximal region lacks an AP-1 
binding site. Further examination is needed to identify and characterize which 
factor is responsible for this effect. Of interest is the fact that the effects of IL-1β 
on NOX-4 expression have a functional consequence in ROS production. Thus, 
IL-1β decreased H2O2 production and this effect was reversed by NOX-4 over-
expression suggesting that NOX-4 might function as a H2O2 generating enzyme 
as has been previously suggested by other authors (Dikalov et al., 2008; Takac 
et al., 2013).  
 Both O2•− and H2O2 are able to induce cell migration (Velarde et al., 2004; 
Yoo et al., 2011; Al Ghouleh et al., 2013; Schröder, 2014) through actin 
cytoskeleton reorganization (Stanley et al., 2014). We demonstrate that NOX-1-
derived ROS presumably under the influence of HuR, participates in cell 
migration since the potentiation induced by AngII+IL-1β on VSMC migration 
was inhibited by pharmacological inhibition and knockdown of both NOX-1 and 
HuR. Moreover, NOX-4 overexpression further increased IL-1β-induced VSMC 
migration, suggesting that both NOX-1 and NOX-4 participate in cell migration 
in inflammatory conditions. Interestingly, as discussed above, we observed that 
IL-1β decreased NOX-4 expression in VSMC suggesting that NOX-4 might not 
significantly contribute to IL-1β induced vascular damage. Alternatively, NOX4 
down-regulation might favor a dedifferentiated VSMC phenotype which is an 
important process involved in cell migration (Clempus et al., 2007; Rzucidlo et 
al., 2007). The role of NOX-1 in vascular remodeling has been previously 
demonstrated since NOX-1 knockout mice were protected against vascular 
remodeling induced by wire injury (Lee et al., 2009). However, the role of NOX-
4 in vascular damage is controversial. Thus, depending on the pathology or the 
vascular bed studied, increased, decreased or unchanged NOX-4 expression 
can be found and some studies suggest NOX-4 as a deleterious protein 
whereas others demonstrate that NOX-4 is a vascular protective enzyme (Chen 
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et al., 2012; Touyz and Montezano, 2012; Schröder et al., 2012). Future studies 
are warranted to further clarify the role of NOX-4 in vascular diseases.  
 Our study has some limitations and deserves further considerations. We 
have focused on NOX-1 and NOX-4 because these isoforms appear to be the 
key vascular NOXs involved in VSMC migration (Lassègue et al., 2012). 
However, it is well known that activation of other NOXs (NOX-2 and NOX-5) 
also contribute to O2•− production in rodent and/or human VSMC (Làssegue et 
al., 2012). As such, we cannot exclude the possibility that these NOXs may also 
play a role in the results observed here. In depth studies to further study NOX-2 
and NOX-5 regulation, particularly in human VSMC, will elucidate whether these 
isoforms also play a role in AngII and/or IL-1β-mediated ROS-dependent 
migration of VSMC. Exact reasons for the differential regulation of NOX-1 and 
NOX-4 that we observed remain unclear but may relate to localization of 
different NOXs in distinct intracellular regions (Làssegue et al., 2012). For 
example, NOX-1 appears to localize primarily in caveolae whereas NOX-4 
localizes to the nucleus and focal adhesions (Hilenski et al., 2004). In VSMC, 
both NOX-1 and NOX-4 participate in cell migration, although via different 
mechanisms (Làssegue et al., 2012). 
The results obtained in the second part of this PhD Thesis are summarized 
in Figures 81 and 82. We demonstrate that transcriptional and post-
transcriptional mechanisms dependent on HuR-mediated mRNA stabilization 
are responsible for AngII+IL-1β-dependent NOX-1 expression in VSMC (Figure 
81). We also demonstrate that IL-1β decreases NOX-4 expression in VSMC 
through transcriptional mechanisms involving the proximal promoter (Figure 82). 
Regulation of NOXs is important since NOX-1-derived ROS and NOX-4-derived 
H2O2 participate in cell migration.  
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Figure 81. Scheme showing the role of HuR in AngII and IL-1β effects on 
vascular NOX-1 expression and cell migration. In VSMC AngII and IL-1β 
synergistically induces NOX-1 expression through ERK1/2, JNK and p38 MAPK 
pathways. HuR binds to NOX-1 3’UTR mRNA, increasing NOX-1 mRNA stability. NOX-
1 is translated to protein and converts O2 in O2•− using NADPH as a cofactor. NOX-1 
derived  O2•− is involved in cell migration and possibly in vascular remodeling. Inhibitors 
used in the experiments are showed in the scheme with their protein targets marked 
with bar-headed lines. Dashed lines indicate non-investigated mechanisms. 
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Figure 82. Scheme showing how IL-1β decreases vascular NOX-4 expression and 
cell migration. In VSMC IL-1β increases a NOX-4 repressor through ERK1/2, JNK 
and PI3K pathways. This repressor binds to the proximal promoter (200 bp) and 
inhibits NOX-4 transcription thus decreasing NOX-4 protein levels. NOX-4 converts O2 
in H2O2 using NADPH as a cofactor; this H2O2 participate cell migration and possibly to 
vascular remodeling. Inhibitors used in the experiments are showed in the scheme with 
their protein targets marked with bar-headed lines and NOX-4/EGFP over-expression 
is shown with an arrow. Dashed lines indicate non-investigated mechanisms. 
In conclusion, our study further elucidates mechanisms regulating NOX-1 
and NOX-4 and indicates how this impacts on functional responses of VSMC. 
Targeting such mechanisms may provide new approaches to regulating 
abnormal VSMC migration in vascular injury associated with cardiovascular 
disease. It is important to highlight that similarly to findings related to the COX-2 
pathway, the role of oxidative stress in the clinical context is still unclear. 
Despite of the extensive literature suggesting the key role of oxidative stress in 
different aspects of cardiovascular diseases, clinical trials with antioxidants 
have no provided conclusive and direct evidences between ROS and 
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cardiovascular diseases. Possible reasons are multiple and relate among other 
factors with pharmacological, methodological and molecular aspects of ROS 
biology. Thus, after the clinical failure of most antioxidant trials, NOX inhibitors 
are the most promising therapeutic option for diseases associated with oxidative 
stress; unfortunately to date, the selectivity or the pharmacokinetic properties of 
these compounds is still limited (Altenhöfer et al., 2014). A variety of methods 
have been developed for ROS detection; however, many of these methods are 
not exempted of selectivity problems and more research is needed to develop 
sensitive, specific and reliable biomarkers and assays to assess the redox 
status of humans in health and disease (Dikalov and Harrison, 2014; Violi and 
Pignatelli, 2014). Finally, despite of growing information regarding the different 
NOX isoforms present in human vascular cells, there is still a paucity of 
information on molecular mechanisms of ROS biology in human tissue 
(Montezano and Touyz, 2014). Hopefully, future advances in these aspects will 
provide definitive evidences of the role of oxidative stress in cardiovascular 
diseases.  
3. FINAL CONSIDERATIONS 
An increasing body of evidence supports the notion that inflammation plays an 
important role in the development and progression of cardiovascular diseases. 
In this context, activation of local RAAS and elevated levels of pro-inflammatory 
cytokines such as IL-1β play a key role in the structural and functional 
alterations of the vasculature. HuR is a member of the Hu family of RNA-binding 
proteins and its activity and function is associated with its subcellular 
distribution, transcriptional regulation and translational and post-translational 
modifications. HuR is able to regulate target mRNAs through its interaction with 
AREs in the untranslated region of target mRNAs. These effects have been 
extensively investigated in cancer research (Wang et al., 2013)  and within this 
context, this protein is involved in different processes including inflammation, 
cell proliferation and angiogenesis through the mRNA stabilization of different 
ILs, TNF-α, cyclins and VEGF (Wang et al., 2013). The role of HuR in 
cardiovascular diseases is very unknown. Under mechanical and biochemical 
stresses HuR increases adhesion of monocytes and ICAM-1 and VCAM-1 
expression in endothelial cells (Rhee et al., 2010). In this PhD Thesis, we 
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demonstrate that HuR is involved vascular inflammation and VSMC migration 
through the regulation of COX-2 and NOX-1 mRNAs, two enzymes involved in 
inflammation and altered vascular structure. COX-2-derived prostanoids and 
NOX-1-derived ROS are implicated in vascular remodeling in different 
cardiovascular pathologies (Wang et al., 2011b; Zhang et al., 2013; Sparks et 
al., 2013; Lee et al., 2009; Gavazzi et al., 2006; Matsuno et al., 2005). The 
participation of these enzymes in vascular structure relies on the reported 
effects of TXA2, PGE2 and ROS in promoting cell proliferation and migration 
(Sachinidis et al., 1995; Nie et al., 2000; Stanic et al., 2010; Wang et al., 2011b; 
Valente et al., 2012; Al Ghouleh et al., 2013). We provide in vitro and in vivo 
data demonstrating that the HuR/COX-2/PGE2 and TXA2 pathway is 
responsible for VSMC migration. Similarly, HuR/NOX-1/ROS also promote cell 
migration. We have previously demonstrated a reciprocal relationship between 
COX-2 and NOX which is responsible for hypertension and for hypertension-
associated vascular alterations (Martínez-Revelles et al., 2013). Since COX-2 
and NOX-1 seems to have shared mechanisms of regulation, the reciprocal 
regulation of these mediators might have a critical role in several pathologies 
through a harmful self-perpetuating cascade. However, we did not clearly 
observe this association in our experimental conditions and a more exhaustive 
analysis of this reciprocal relationship should be carried out in order to 
definitively exclude a COX-2/NOX-1 interaction in this context.  
Growing evidences suggest that NOX-4 regulation might be different to 
other NOX and in fact, no a clear line exist between the protective and 
damaging effects of NOX-4-derived ROS (Lassègue et al., 2012; Konior et al., 
2014). NOX-4 has been described as a housekeeping and as an inducible gene 
(Sturrock et al., 2006; Mittal et al., 2007; Katsuyama et al., 2012). However, it 
has also been described that NOX-4 expression is reduced by pro-inflammatory 
stimuli in vascular cells (Ellmark et al., 2005). Our results show that NOX-4 
regulation differs radically from NOX-1 regulation; while IL-1β induces NOX-1 
expression, NOX-4 expression is reduced. Moreover, IL-1β-induced NOX-4 
decrease is mediated by transcriptional repression, demonstrating completely 
different regulation of both NOXs. Our results also show that NOX-4-derived 
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H2O2 can promote VSMC migration suggesting that alterations in NOX-4 gene 
regulation might impact on the vasculature.  
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In this PhD Thesis, we demonstrate that the combination of two 
inflammatory stimuli AngII and IL-1β which are important for cardiovascular 
diseases, synergistically induce the expression of two major pro-inflammatory 
proteins COX-2 and NOX-1. This effect leads to the production of PGE2, TXA2 
and ROS that have a key role in VSMC migration and hence in vascular 
remodeling in cardiovascular diseases. We also demonstrate that the RNA 
binding protein, HuR, is key to increase the mRNA stability of both COX-2 and 
NOX-1 thus participating in cell migration induced by inflammatory stimuli. 
Finally, we detected differential regulation of NOX-1 and NOX-4 being the latter 
decreased by IL-1β through transcriptional mechanisms involving the proximal 
promoter. The partial conclusions are as follows: 
1. In VSMC AngII and IL-1β synergistically induce COX-2 and TN-C 
expression and cell migration. 
2. ERK1/2-mediated HuR activation is involved in the synergistic effect of 
AngII and IL-1β on COX-2 expression and cell migration. 
3. PGE2 and TXA2 derived from COX-2 participate in cell migration induced 
by AngII and IL-1β. 
4. Animal models of vascular remodeling display increased HuR, COX-2, 
mPGES-1, TXAS and TN-C expression. COX-2 and mPGES-1 blockade 
reverse vascular hypertrophy and TN-C expression.  
5. AngII and IL-1β synergistically induce NOX-1 expression and activity 
through an increase of NOX-1 mRNA stability mediated by HuR.  
6.  NOX-1-derived-ROS participate in AngII+IL-1β induced cell migration. 
7. IL-1β-induced NOX-4 down-regulation is mediated by an inducible 
repressor which binds to the 200 bp proximal promoter. 
8. All these effects could contribute to the vascular damage induce by AngII 
and IL-1β in the vascular wall.   
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Our study further elucidates mechanisms regulating COX-2 and NOXs and 
indicates how this impacts on functional responses of VSMC. Specifically, HuR-
dependent regulation of COX-2 and NOX-1 in VSMC is a novel mechanism that 
might contribute to vascular remodeling in different cardiovascular diseases. We 
believe that targeting the HuR/COX-2/NOX-1 pathways may provide new 
approaches to regulating abnormal VSMC migration in vascular injury 
associated with cardiovascular disease. 
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En esta Tesis Doctoral demostramos que la combinación de dos estímulos 
inflamatorios, AngII e IL-1β, los cuales son importantes en enfermedades 
cardiovasculares, induce la expresión sinérgica de dos de las principales 
proteínas pro-inflamatorias, COX-2 y NOX-1. Este efecto da lugar a la 
producción de PGE2, TXA2 y especies reactivas de oxígeno, las cuales tienen 
un papel fundamental en la migración de las CMLV y, por tanto, en el 
remodelado vascular en enfermedades cardiovasculares. También 
demostramos que la proteína de unión a RNA, HuR, es clave en el incremento 
de la estabilidad de los mRNAs de COX-2 y NOX-1, participando así en la 
migración celular inducida por estímulos inflamatorios. Finalmente, 
demostramos una regulación diferente de NOX-1 y NOX-4 siendo ésta última 
disminuida por IL-1β a través de mecanismos transcripcionales asociados al 
promotor proximal. Las conclusiones parciales son las siguientes: 
1. En CMLV, AngII e IL-1β inducen sinérgicamente la expresión de COX-2 
y TN-C así como migración celular. 
2. La activación de HuR mediada por ERK1/2 está implicada en el efecto 
sinérgico de AngII e IL-1β sobre la expresión de COX-2 y la migración 
celular. 
3. PGE2 y TXA2 derivados de COX-2 participan en la migración celular 
inducida por AngII e IL-1β. 
4. Modelos animales de remodelado vascular muestran un incremento en 
la expresión de HuR, COX-2, mPGES-1, TXAS  y TN-C. El bloqueo de 
COX-2 y de mPGES-1 revierte la hipertrofia vascular y la expresión de 
TN-C. 
5. AngII e IL-1β inducen sinérgicamente la expresión y actividad de NOX-1 
a través de un incremento en la estabilidad del mRNA de NOX-1 
mediado por HuR. 
6. Las especies reactivas de oxígeno derivadas de NOX-1 participan en la 
migración celular inducida por AngII e IL-1β. 
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7. La disminución de NOX-4 inducida por IL-1β está mediada por un 
represor inducible que se une en las 200 bp del promotor proximal.  
8. Todos estos efectos podrían contribuir al daño vascular inducido por 
AngII e IL-1β en la pared vascular. 
Nuestros estudios elucidan algunos de los mecanismos reguladores de 
COX-2 y NOXs y muestran el impacto que éstos tienen sobre las respuestas 
funcionales de las CMLV. Específicamente, la regulación de COX-2 y NOX-1 
dependiente de HuR en CMLV es un nuevo mecanismo que contribuiría al 
remodelado vascular en diferentes enfermedades cardiovasculares. Creemos 
que las rutas HuR/COX-2/NOX-1 podrían ser dianas terapéuticas para el 
desarrollo de nuevas aproximaciones que controlen la migración anormal de 
las CMLV en daño vascular asociado con enfermedades cardiovasculares. 
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